{
    "ProgramID": 11757,
    "ProgramName": "Dupixent MyWay Copay Card",
    "TherapeuticAreas": [
      "Asthma",
      "Chronic Obstructive Pulmonary Disease (COPD)",
      "Dermatology - Dermatitis / Eczema / Rosacea",
      "Severe Asthma",
      "Dermatology - Atopic Dermatitis",
      "Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)",
      "Eosinophilic Esophagitis",
      "Dermatology - Prurigo Nodularis (PN)"
    ],
    "Drugs": [
      "Dupixent",
      "Dupixent Pen"
    ],
    "CoverageEligibilities": [
      "Commercially insured"
    ],
    "FundLevels": [],
    "Manufacturers": [
      "Sanofi-Aventis"
    ],
    "ProgramURL": "https://www.dupixent.com/support-savings/copay-card",
    "HelpLine": "844-387-4936",
    "EnrollmentReq": true,
    "EnrollmentURL": "https://www.dupixent.com/support-savings/copay-card",
    "ExpirationDate": "Expires at end of calendar year",
    "EstAppTime": "Data Not Available",
    "EligibilityDetails": "- Patient must have commercial insurance, including health insurance exchanges, federal employee plans, or state employee plans\n- Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs\n- Program offer is not valid for cash-paying patients\n- Patient must be prescribed the Program Product for an FDA-approved indication\n- Patient must be a legal resident of the US or a US territory\n- Patients residing in or receiving treatment in certain states may not be eligible",
    "IncomeReq": false,
    "IncomeDetails": "Data Not Available",
    "AnnualMax": "$13,000",
    "MaximumBenefit": null,
    "OfferRenewable": true,
    "RenewalMethod": "Automatically Re-enrolled",
    "AddRenewalDetails": "Patient will be automatically re-enrolled every January 1st provided that their card has been used within 18 months",
    "ProgramDetails": "-  Eligible patients may pay as little as $0 for every month of Dupixent\n-  The maximum annual patient benefit under the Dupixent MyWay Copay Card Program is $13,000\n-  Patient will receive copay card information via email following online enrollment & eligibility questions\n-  Ongoing follow-up and education are provided by the Nurse Educator to help patients stay on track with DUPIXENT\n-  Patient will be automatically re-enrolled every January 1st provided that their card has been used within 18 months\n-  For assistance or additional information, call 844-387-4936, option 1, Monday-Friday, 8 am-9 pm ET\n-  Pharmacists: for questions, call the LoyaltyScript program at 855-520-3765 (8am-8pm EST, Monday-Friday)",
    "MADetails": "Data Not Available",
    "AddOnProgram": false,
    "AddOnDetails": null,
    "BridgeProgram": false,
    "BridgeDetails": null,
    "FreeTrialOffer": false,
    "CouponVehicle": "Physical/Electronic Coupon Card",
    "ProcessingVendor": "McKesson",
    "BinNum": "610524",
    "PCNNum": "Loyalty",
    "GroupNum": "50778036",
    "MaxNumberUses": "Data Not Available",
    "ActivationReq": true,
    "ActivationMethod": "Any Method",
    "ActivationNum": "Data Not Available",
    "ClicknPrint": false,
    "FundLevelType": null,
    "RestrictionDetails": null,
    "AssistanceType": "Coupon",
    "LastUpdated": "01/07/2025",
    "AssociatedCoupons": null,
    "AssociatedPAPs": [],
    "AssociatedFoundations": [
      {
        "ProgramID": 30683,
        "ProgramName": "Accessia Health: Alpha-1 Antitrypsin Deficiency - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Alpha-1 Antitrypsin Deficiency (Alpha-1)"
        ],
        "Drugs": [
          "Glassia",
          "Prolastin-C",
          "Zemaira",
          "Aralast NP"
        ]
      },
      {
        "ProgramID": 30778,
        "ProgramName": "Accessia Health: Alpha-1 Antitrypsin Deficiency - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Alpha-1 Antitrypsin Deficiency (Alpha-1)"
        ],
        "Drugs": [
          "Glassia",
          "Prolastin-C",
          "Zemaira",
          "Aralast NP"
        ]
      },
      {
        "ProgramID": 31027,
        "ProgramName": "Accessia Health: Asthma - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Asthma",
          "Severe Asthma",
          "Severe Eosinophilic Asthma"
        ],
        "Drugs": [
          "Rayos",
          "Xolair",
          "Nucala",
          "Cinqair",
          "Dupixent",
          "Fasenra",
          "Tezspire",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Zyflo",
          "Dupixent Pen",
          "Fasenra Pen",
          "Airsupra"
        ]
      },
      {
        "ProgramID": 31029,
        "ProgramName": "Accessia Health: Asthma - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Asthma",
          "Severe Asthma",
          "Severe Eosinophilic Asthma"
        ],
        "Drugs": [
          "Rayos",
          "Xolair",
          "Nucala",
          "Cinqair",
          "Dupixent",
          "Fasenra",
          "Tezspire",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Zyflo",
          "Dupixent Pen",
          "Fasenra Pen",
          "Airsupra"
        ]
      },
      {
        "ProgramID": 31030,
        "ProgramName": "Accessia Health: Chronic Myeloid Leukemia (C.M.L.) - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Myeloid Leukemia (CML)"
        ],
        "Drugs": [
          "Bosulif",
          "Gleevec",
          "Iclusig",
          "Sprycel",
          "Tasigna",
          "Cytarabine",
          "Cyclophosphamide",
          "Busulfex",
          "Myleran",
          "Imatinib",
          "Scemblix"
        ]
      },
      {
        "ProgramID": 30675,
        "ProgramName": "Accessia Health: Chronic Myeloid Leukemia (C.M.L.) - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Myeloid Leukemia (CML)"
        ],
        "Drugs": [
          "Bosulif",
          "Gleevec",
          "Iclusig",
          "Sprycel",
          "Tasigna",
          "Cytarabine",
          "Cyclophosphamide",
          "Busulfex",
          "Myleran",
          "Imatinib",
          "Scemblix"
        ]
      },
      {
        "ProgramID": 30383,
        "ProgramName": "Accessia Health: Circadian Rhythm Disorders - Public Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Non-24-Hour Sleep-Wake Disorder"
        ],
        "Drugs": [
          "Hetlioz",
          "Tasimelteon"
        ]
      },
      {
        "ProgramID": 30677,
        "ProgramName": "Accessia Health: Fabry Disease - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 30370,
        "ProgramName": "Accessia Health: Fabry Disease - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 30676,
        "ProgramName": "Accessia Health: Gastrointestinal Stromal Tumors (GIST) - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Gastrointestinal Stromal Tumor (GIST)"
        ],
        "Drugs": [
          "Gleevec",
          "Mekinist",
          "Stivarga",
          "Sutent",
          "Tafinlar",
          "Imatinib",
          "Ayvakit",
          "Qinlock",
          "Sunitinib Malate",
          "Tafinlar & Mekinist"
        ]
      },
      {
        "ProgramID": 30978,
        "ProgramName": "Accessia Health: Gaucher Disease - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat",
          "Yargesa"
        ]
      },
      {
        "ProgramID": 30371,
        "ProgramName": "Accessia Health: Gaucher Disease - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat",
          "Yargesa"
        ]
      },
      {
        "ProgramID": 30543,
        "ProgramName": "Accessia Health: Hereditary Angioedema - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hereditary Angioedema"
        ],
        "Drugs": [
          "Berinert",
          "Cinryze",
          "Firazyr",
          "Kalbitor",
          "Ruconest",
          "Haegarda",
          "Takhzyro",
          "Icatibant Acetate",
          "Orladeyo",
          "Sajazir"
        ]
      },
      {
        "ProgramID": 30979,
        "ProgramName": "Accessia Health: Hereditary Angioedema - Public Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hereditary Angioedema"
        ],
        "Drugs": [
          "Berinert",
          "Cinryze",
          "Firazyr",
          "Kalbitor",
          "Ruconest",
          "Haegarda",
          "Takhzyro",
          "Icatibant Acetate",
          "Orladeyo",
          "Sajazir"
        ]
      },
      {
        "ProgramID": 30372,
        "ProgramName": "Accessia Health: Hypoparathyroidism - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hypoparathyroidism"
        ],
        "Drugs": [
          "Natpara",
          "Yorvipath"
        ]
      },
      {
        "ProgramID": 30680,
        "ProgramName": "Accessia Health: Hypoparathyroidism - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hypoparathyroidism"
        ],
        "Drugs": [
          "Natpara",
          "Yorvipath"
        ]
      },
      {
        "ProgramID": 30982,
        "ProgramName": "Accessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hemophilia",
          "Von Willebrand Disease",
          "Congenital Fibrinogen Deficiency",
          "Thrombocythemia",
          "Pediatric Congenital Fibrinogen Deficiency (PCFD)"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Corifact",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Tretten",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Coagadex",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "RiaSTAP",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Fibryga",
          "Hemgenix",
          "Altuviiio",
          "Roctavian",
          "Beqvez",
          "Vonvendi"
        ]
      },
      {
        "ProgramID": 30968,
        "ProgramName": "Accessia Health: Inherited and Acquired Factor Deficiencies - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hemophilia",
          "Von Willebrand Disease",
          "Congenital Fibrinogen Deficiency",
          "Thrombocythemia",
          "Pediatric Congenital Fibrinogen Deficiency (PCFD)"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Corifact",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Tretten",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Coagadex",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "RiaSTAP",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Fibryga",
          "Hemgenix",
          "Altuviiio",
          "Roctavian",
          "Beqvez",
          "Vonvendi"
        ]
      },
      {
        "ProgramID": 30969,
        "ProgramName": "Accessia Health: Inherited Retinal Diseases - Public Insurance",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD",
          "Ophthalmic - Macular Edema",
          "Ophthalmic - Inherited Retinal Disease",
          "Ophthalmic - RPE65 Mutation-Associated Retinal Dystrophy",
          "Ophthalmic - Myopic Choroidal Neovascularization",
          "Ophthalmic - Geographic Atrophy (GA)"
        ],
        "Drugs": [
          "Lucentis",
          "Ozurdex",
          "Triesence",
          "Iluvien",
          "Retisert",
          "Visudyne",
          "Eylea",
          "Luxturna",
          "Yutiq",
          "Beovu",
          "Susvimo",
          "Vabysmo",
          "Xipere",
          "Syfovre",
          "Izervay",
          "Eylea HD"
        ]
      },
      {
        "ProgramID": 30365,
        "ProgramName": "Accessia Health: Kidney Stones - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Kidney Stones",
          "Homocystinuria",
          "Cystinuria"
        ],
        "Drugs": [
          "Cystadane",
          "Cuprimine",
          "Depen",
          "Thiola EC",
          "Penicillamine",
          "Thiola",
          "Tiopronin"
        ]
      },
      {
        "ProgramID": 30983,
        "ProgramName": "Accessia Health: Kidney Stones - Public Insurance",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Kidney Stones",
          "Homocystinuria",
          "Cystinuria"
        ],
        "Drugs": [
          "Cystadane",
          "Cuprimine",
          "Depen",
          "Thiola EC",
          "Penicillamine",
          "Thiola",
          "Tiopronin"
        ]
      },
      {
        "ProgramID": 30374,
        "ProgramName": "Accessia Health: MPS-1 - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type I (MPS I: Hurler / Hurler-Scheie Syndrome)"
        ],
        "Drugs": [
          "Aldurazyme"
        ]
      },
      {
        "ProgramID": 31079,
        "ProgramName": "Accessia Health: MPS-1 - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type I (MPS I: Hurler / Hurler-Scheie Syndrome)"
        ],
        "Drugs": [
          "Aldurazyme"
        ]
      },
      {
        "ProgramID": 30781,
        "ProgramName": "Accessia Health: Multifocal Motor Neuropathy - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Multifocal Motor Neuropathy (MMN)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Flebogamma DIF",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Immune Globulin Intravenous (IGIV)"
        ]
      },
      {
        "ProgramID": 30985,
        "ProgramName": "Accessia Health: Multifocal Motor Neuropathy - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Multifocal Motor Neuropathy (MMN)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Flebogamma DIF",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Immune Globulin Intravenous (IGIV)"
        ]
      },
      {
        "ProgramID": 31082,
        "ProgramName": "Accessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)",
          "Refractory Anemia (RA)"
        ],
        "Drugs": [
          "Gleevec",
          "Revlimid",
          "Vidaza",
          "Zelboraf",
          "Dacogen",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Tibsovo",
          "Reblozyl",
          "Inqovi",
          "Onureg",
          "Lenalidomide",
          "Rytelo"
        ]
      },
      {
        "ProgramID": 31083,
        "ProgramName": "Accessia Health: Myelodysplastic Syndromes - Public Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)",
          "Refractory Anemia (RA)"
        ],
        "Drugs": [
          "Gleevec",
          "Revlimid",
          "Vidaza",
          "Zelboraf",
          "Dacogen",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Tibsovo",
          "Reblozyl",
          "Inqovi",
          "Onureg",
          "Lenalidomide",
          "Rytelo"
        ]
      },
      {
        "ProgramID": 31019,
        "ProgramName": "Accessia Health: Plasminogen Deficiency - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Plasminogen Deficiency Type 1 (Hypoplasminogenemia)"
        ],
        "Drugs": [
          "Ryplazim"
        ]
      },
      {
        "ProgramID": 31020,
        "ProgramName": "Accessia Health: Plasminogen Deficiency - Public Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Plasminogen Deficiency Type 1 (Hypoplasminogenemia)"
        ],
        "Drugs": [
          "Ryplazim"
        ]
      },
      {
        "ProgramID": 30681,
        "ProgramName": "Accessia Health: Pompe Disease - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pompe Disease"
        ],
        "Drugs": [
          "Lumizyme",
          "Miglustat",
          "Nexviazyme",
          "Opfolda & Pombiliti",
          "Opfolda",
          "Pombiliti"
        ]
      },
      {
        "ProgramID": 30375,
        "ProgramName": "Accessia Health: Pompe Disease - Public Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pompe Disease"
        ],
        "Drugs": [
          "Lumizyme",
          "Miglustat",
          "Nexviazyme",
          "Opfolda & Pombiliti",
          "Opfolda",
          "Pombiliti"
        ]
      },
      {
        "ProgramID": 30525,
        "ProgramName": "Accessia Health: Primary Immune Deficiency - Private Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Granulomatous Disease (CGD)",
          "Immunodeficiency",
          "Severe Combined Immunodeficiency Disease (SCID)",
          "Chronic Graft Versus Host Disease (cGVHD)",
          "Oncology - Hemophagocytic Lymphohistiocytosis (HLH)",
          "Acute Graft Versus Host Disease (aGvHD)",
          "Wiskott-Aldrich Syndrome",
          "Hyper-IgM Syndrome",
          "Pediatric Chronic Graft-versus-Host Disease (PcGVHD)",
          "Agranulocytosis",
          "Pediatric Acute Graft-versus-Host Disease (PaGVHD)",
          "Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)",
          "Hypogammaglobulinemia",
          "WHIM Syndrome"
        ],
        "Drugs": [
          "Actimmune",
          "Gammagard Liquid",
          "Gamunex-C",
          "Hizentra",
          "Imbruvica",
          "Jakafi",
          "Orencia",
          "Flebogamma DIF",
          "HyQvia",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Cuvitru",
          "Revcovi",
          "Cutaquig",
          "Rezurock",
          "Asceniv",
          "Xembify",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "Orencia Clickject",
          "Joenja",
          "Alyglo",
          "Xolremdi"
        ]
      },
      {
        "ProgramID": 30839,
        "ProgramName": "Accessia Health: Primary Immune Deficiency - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Granulomatous Disease (CGD)",
          "Immunodeficiency",
          "Severe Combined Immunodeficiency Disease (SCID)",
          "Chronic Graft Versus Host Disease (cGVHD)",
          "Oncology - Hemophagocytic Lymphohistiocytosis (HLH)",
          "Acute Graft Versus Host Disease (aGvHD)",
          "Wiskott-Aldrich Syndrome",
          "Hyper-IgM Syndrome",
          "Pediatric Chronic Graft-versus-Host Disease (PcGVHD)",
          "Agranulocytosis",
          "Pediatric Acute Graft-versus-Host Disease (PaGVHD)",
          "Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)",
          "Hypogammaglobulinemia",
          "WHIM Syndrome"
        ],
        "Drugs": [
          "Actimmune",
          "Gammagard Liquid",
          "Gamunex-C",
          "Hizentra",
          "Imbruvica",
          "Jakafi",
          "Orencia",
          "Flebogamma DIF",
          "HyQvia",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Cuvitru",
          "Revcovi",
          "Cutaquig",
          "Rezurock",
          "Asceniv",
          "Xembify",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "Orencia Clickject",
          "Joenja",
          "Alyglo",
          "Xolremdi"
        ]
      },
      {
        "ProgramID": 30971,
        "ProgramName": "Accessia Health: Pulmonary Fibrosis - Public Insurance: Waitlist",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Idiopathic Pulmonary Fibrosis",
          "Lymphangioleiomyomatosis (LAM)",
          "Systemic Sclerosis",
          "Interstitial Lung Disease (ILD)"
        ],
        "Drugs": [
          "Actemra",
          "Ofev",
          "Esbriet",
          "Pirfenidone",
          "Actemra Actpen"
        ]
      },
      {
        "ProgramID": 31071,
        "ProgramName": "Accessia Health: Thrombotic Thrombocytopenic Purpura - Private Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acquired / Immune-Mediated Thrombotic Thrombocytopenic Purpura (aTTP / iTTP)",
          "Congenital Thrombotic Thrombocytopenic Purpura (cTTP)"
        ],
        "Drugs": [
          "Cablivi",
          "Adzynma"
        ]
      },
      {
        "ProgramID": 31072,
        "ProgramName": "Accessia Health: Thrombotic Thrombocytopenic Purpura - Public Insurance",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acquired / Immune-Mediated Thrombotic Thrombocytopenic Purpura (aTTP / iTTP)",
          "Congenital Thrombotic Thrombocytopenic Purpura (cTTP)"
        ],
        "Drugs": [
          "Cablivi",
          "Adzynma"
        ]
      },
      {
        "ProgramID": 31010,
        "ProgramName": "Assistance Fund: Acid Sphingomyelinase Deficiency (ASMD)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Acid Sphingomyelinase Deficiency (ASMD)"
        ],
        "Drugs": [
          "Xenpozyme"
        ]
      },
      {
        "ProgramID": 30826,
        "ProgramName": "Assistance Fund: Acromegaly: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acromegaly"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Somavert",
          "Signifor LAR",
          "Octreotide Acetate",
          "Sandostatin",
          "Mycapssa"
        ]
      },
      {
        "ProgramID": 31035,
        "ProgramName": "Assistance Fund: Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Hizentra",
          "Flebogamma DIF",
          "HyQvia",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Cuvitru",
          "Cutaquig",
          "Asceniv",
          "Xembify",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "Joenja"
        ]
      },
      {
        "ProgramID": 30753,
        "ProgramName": "Assistance Fund: Acute Myeloid Leukemia: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Acute Myeloid Leukemia (AML)"
        ],
        "Drugs": [
          "Neupogen",
          "Cytarabine",
          "Zarxio",
          "Cyclophosphamide",
          "Mylotarg",
          "Venclexta",
          "Azacitidine",
          "Rydapt",
          "IDHIFA",
          "Vyxeos",
          "Filgrastim",
          "Tibsovo",
          "Nivestym",
          "Daurismo",
          "Xospata",
          "Onureg",
          "Venclexta Starting Pack",
          "Releuko",
          "Rezlidhia",
          "Vanflyta",
          "Nypozi",
          "Revuforj"
        ]
      },
      {
        "ProgramID": 30628,
        "ProgramName": "Assistance Fund: Alpha-1 Antitrypsin Deficiency",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Alpha-1 Antitrypsin Deficiency (Alpha-1)"
        ],
        "Drugs": [
          "Glassia",
          "Prolastin-C",
          "Zemaira",
          "Aralast NP"
        ]
      },
      {
        "ProgramID": 30787,
        "ProgramName": "Assistance Fund: Amyloidosis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Amyloidosis"
        ],
        "Drugs": [
          "Onpattro",
          "Vyndaqel",
          "Vyndamax",
          "Darzalex Faspro",
          "Amvuttra",
          "Wainua",
          "Attruby"
        ]
      },
      {
        "ProgramID": 30850,
        "ProgramName": "Assistance Fund: Amyotrophic Lateral Sclerosis (ALS): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Amyotrophic Lateral Sclerosis (ALS)"
        ],
        "Drugs": [
          "Rilutek",
          "Radicava IV",
          "Tiglutik",
          "Exservan",
          "Relyvrio",
          "Radicava ORS",
          "Qalsody"
        ]
      },
      {
        "ProgramID": 30317,
        "ProgramName": "Assistance Fund: Ankylosing Spondylitis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ankylosing Spondylitis"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Acthar Gel",
          "Humira",
          "Rayos",
          "Remicade",
          "Simponi",
          "Simponi ARIA",
          "Taltz",
          "Inflectra",
          "Renflexis",
          "Cyltezo",
          "Hyrimoz",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Hadlima",
          "Etanercept",
          "Purified Cortrophin Gel",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Simlandi",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30892,
        "ProgramName": "Assistance Fund: Asthma: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Asthma",
          "Severe Asthma",
          "Severe Eosinophilic Asthma"
        ],
        "Drugs": [
          "Rayos",
          "Xolair",
          "Nucala",
          "Cinqair",
          "Dupixent",
          "Fasenra",
          "Tezspire",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Zyflo",
          "Dupixent Pen",
          "Fasenra Pen",
          "Airsupra"
        ]
      },
      {
        "ProgramID": 31060,
        "ProgramName": "Assistance Fund: Atopic Dermatitis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Dermatology - Atopic Dermatitis"
        ],
        "Drugs": [
          "Dupixent",
          "Tacrolimus",
          "Rinvoq",
          "Opzelura",
          "Adbry",
          "Cibinqo",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Dupixent Pen",
          "Purified Cortrophin Gel",
          "Zoryve",
          "Rinvoq LQ",
          "Ebglyss"
        ]
      },
      {
        "ProgramID": 30652,
        "ProgramName": "Assistance Fund: Atypical Hemolytic Uremic Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Atypical Hemolytic Uremic Syndrome (aHUS)"
        ],
        "Drugs": [
          "Soliris",
          "Ultomiris",
          "Bkemv",
          "Epysqli"
        ]
      },
      {
        "ProgramID": 31040,
        "ProgramName": "Assistance Fund: Biliary Tract Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Cholangiocarcinoma (Bile Duct Cancer)",
          "Oncology - Biliary Tract Cancer"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Tafinlar",
          "Imfinzi",
          "Tibsovo",
          "Vitrakvi",
          "Rozlytrek",
          "Jemperli",
          "Pemazyre",
          "Lytgobi",
          "Ziihera"
        ]
      },
      {
        "ProgramID": 30566,
        "ProgramName": "Assistance Fund: Bladder Cancer (Federal Healthcare Program): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Bladder"
        ],
        "Drugs": [
          "Keytruda",
          "Opdivo",
          "Valstar",
          "Tecentriq",
          "Bavencio",
          "Vitrakvi",
          "Balversa",
          "Padcev",
          "Jelmyto",
          "Trodelvy",
          "Adstiladrin",
          "Anktiva"
        ]
      },
      {
        "ProgramID": 30089,
        "ProgramName": "Assistance Fund: Breast Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Perjeta",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Capecitabine",
          "Trexall",
          "Methotrexate",
          "Docetaxel",
          "Tecentriq",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Tepadina",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Phesgo",
          "Margenza",
          "Fulvestrant",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Orserdu",
          "Truqap",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Hercessi",
          "Tepylute",
          "Itovebi"
        ]
      },
      {
        "ProgramID": 30795,
        "ProgramName": "Assistance Fund: Chronic Granulomatous Disease (CGD)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Granulomatous Disease (CGD)"
        ],
        "Drugs": [
          "Actimmune",
          "Tolsura",
          "Posaconazole",
          "Noxafil Tablets"
        ]
      },
      {
        "ProgramID": 30972,
        "ProgramName": "Assistance Fund: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Hizentra",
          "HyQvia",
          "Privigen",
          "Gammaked",
          "Panzyga",
          "Vyvgart Hytrulo"
        ]
      },
      {
        "ProgramID": 30704,
        "ProgramName": "Assistance Fund: Chronic Lymphocytic Leukemia (CLL): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Chronic Lymphocytic Leukemia (CLL)"
        ],
        "Drugs": [
          "Arzerra",
          "Campath",
          "Gazyva",
          "Imbruvica",
          "Rayos",
          "Rituxan",
          "Treanda",
          "Zydelig",
          "Leukeran",
          "Gammagard S/D",
          "Cyclophosphamide",
          "Bendeka",
          "Venclexta",
          "Rituxan Hycela",
          "Calquence",
          "Copiktra",
          "Truxima",
          "Belrapzo",
          "Ruxience",
          "Riabni",
          "Venclexta Starting Pack",
          "Imbruvica & Gazyva",
          "Vivimusta"
        ]
      },
      {
        "ProgramID": 31062,
        "ProgramName": "Assistance Fund: Chronic Obstructive Pulmonary Disease (COPD): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "Drugs": [
          "Rayos",
          "Dupixent",
          "Yupelri",
          "Dupixent Pen",
          "Ohtuvayre"
        ]
      },
      {
        "ProgramID": 30321,
        "ProgramName": "Assistance Fund: Clostridium Difficile Associated Diarrhea",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Clostridium Difficile"
        ],
        "Drugs": [
          "Vancomycin",
          "Vancocin",
          "Zinplava",
          "Dificid",
          "Rebyota",
          "Vowst"
        ]
      },
      {
        "ProgramID": 30894,
        "ProgramName": "Assistance Fund: Cold Agglutinin Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cold Agglutinin Disease (CAD)"
        ],
        "Drugs": [
          "Rayos",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Enjaymo"
        ]
      },
      {
        "ProgramID": 30323,
        "ProgramName": "Assistance Fund: Crohn's Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "IBD - Crohn's Disease",
          "IBD - Pediatric Crohn's Disease"
        ],
        "Drugs": [
          "Cimzia",
          "Entyvio",
          "Humira",
          "Rayos",
          "Remicade",
          "Stelara",
          "Tysabri",
          "Inflectra",
          "Renflexis",
          "Cyltezo",
          "Hyrimoz",
          "Skyrizi",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Humira Pen",
          "Amjevita",
          "Ortikos ER",
          "Hadlima",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Tyruko",
          "Zymfentra",
          "Wezlana",
          "Simlandi",
          "Entyvio Pen",
          "Pyzchiva",
          "Otulfi",
          "Imuldosa",
          "Yesintek",
          "Steqeyma"
        ]
      },
      {
        "ProgramID": 30324,
        "ProgramName": "Assistance Fund: Cystic Fibrosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cystic Fibrosis"
        ],
        "Drugs": [
          "Bethkis",
          "Cayston",
          "Creon",
          "Kalydeco",
          "Pancreaze",
          "Pertzye",
          "Pulmozyme",
          "Tobi Podhaler",
          "Zenpep",
          "Orkambi",
          "Kitabis Pak",
          "Tobramycin Inhalation Solution",
          "Symdeko",
          "Trikafta",
          "Alyftrek"
        ]
      },
      {
        "ProgramID": 30799,
        "ProgramName": "Assistance Fund: Cystinosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Nephropathic Cystinosis"
        ],
        "Drugs": [
          "Procysbi",
          "Cystaran",
          "Cystagon",
          "Cystadrops"
        ]
      },
      {
        "ProgramID": 30502,
        "ProgramName": "Assistance Fund: Duchenne Muscular Dystrophy",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Duchenne Muscular Dystrophy (DMD)"
        ],
        "Drugs": [
          "Reclast",
          "Zoledronic Acid",
          "Exondys 51",
          "Emflaza",
          "Vyondys 53",
          "Viltepso",
          "Amondys 45",
          "Elevidys",
          "Agamree",
          "Duvyzat"
        ]
      },
      {
        "ProgramID": 31044,
        "ProgramName": "Assistance Fund: Epidermolysis Bullosa",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Dermatology - Epidermolysis Bullosa"
        ],
        "Drugs": [
          "Vyjuvek",
          "Filsuvez"
        ]
      },
      {
        "ProgramID": 30688,
        "ProgramName": "Assistance Fund: Epilepsy (Seizures): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Seizures"
        ],
        "Drugs": [
          "Fycompa",
          "Onfi",
          "Sabril",
          "Briviact",
          "Banzel",
          "Vigabatrin",
          "Epidiolex",
          "Vigadrone",
          "Xcopri",
          "Aptiom",
          "Felbatol",
          "Zonisade"
        ]
      },
      {
        "ProgramID": 30706,
        "ProgramName": "Assistance Fund: Fabry Disease: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 30689,
        "ProgramName": "Assistance Fund: Gastric Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Gastric"
        ],
        "Drugs": [
          "Cyramza",
          "Herceptin",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Xeloda",
          "Lonsurf",
          "Fluorouracil",
          "Ogivri",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Enhertu",
          "Tevimbra",
          "Hercessi",
          "Vyloy",
          "Opdivo Qvantig"
        ]
      },
      {
        "ProgramID": 30532,
        "ProgramName": "Assistance Fund: Gaucher Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat"
        ]
      },
      {
        "ProgramID": 30766,
        "ProgramName": "Assistance Fund: Gout",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gout"
        ],
        "Drugs": [
          "Ilaris",
          "Krystexxa",
          "Rayos",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel"
        ]
      },
      {
        "ProgramID": 30454,
        "ProgramName": "Assistance Fund: Head and Neck Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Head and Neck"
        ],
        "Drugs": [
          "Erbitux",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Trexall",
          "Methotrexate",
          "Docetaxel",
          "Bleomycin",
          "Vitrakvi",
          "Opdivo Qvantig"
        ]
      },
      {
        "ProgramID": 31059,
        "ProgramName": "Assistance Fund: Heart Failure: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Congestive Heart Failure",
          "Heart Failure"
        ],
        "Drugs": [
          "Farxiga",
          "Xigduo XR",
          "Jardiance",
          "Inpefa"
        ]
      },
      {
        "ProgramID": 30533,
        "ProgramName": "Assistance Fund: Hemophilia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hemophilia"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Corifact",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Hemgenix",
          "Altuviiio",
          "Roctavian",
          "Beqvez",
          "Hympavzi",
          "Alhemo"
        ]
      },
      {
        "ProgramID": 30171,
        "ProgramName": "Assistance Fund: Hepatitis C: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hepatitis C"
        ],
        "Drugs": [
          "Harvoni",
          "Pegasys",
          "Sovaldi",
          "Ribavirin",
          "Zepatier",
          "Epclusa",
          "Vosevi",
          "Mavyret"
        ]
      },
      {
        "ProgramID": 31013,
        "ProgramName": "Assistance Fund: Hepatocellular Carcinoma (HCC)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Hepatocellular Carcinoma (HCC)"
        ],
        "Drugs": [
          "Avastin",
          "Cyramza",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Stivarga",
          "Yervoy",
          "Cabometyx",
          "Tecentriq",
          "Imfinzi",
          "Sorafenib Tosylate",
          "Opdivo & Yervoy",
          "Keytruda & Lenvima",
          "Imjudo",
          "Imfinzi & Imjudo",
          "Opdivo Qvantig"
        ]
      },
      {
        "ProgramID": 30326,
        "ProgramName": "Assistance Fund: Hereditary Angioedema (HAE)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hereditary Angioedema"
        ],
        "Drugs": [
          "Berinert",
          "Cinryze",
          "Firazyr",
          "Kalbitor",
          "Ruconest",
          "Haegarda",
          "Takhzyro",
          "Icatibant Acetate",
          "Orladeyo",
          "Sajazir"
        ]
      },
      {
        "ProgramID": 30691,
        "ProgramName": "Assistance Fund: Hodgkin Lymphoma: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Hodgkin's Lymphoma"
        ],
        "Drugs": [
          "Adcetris",
          "Keytruda",
          "Opdivo",
          "Leukeran",
          "Vinblastine Sulfate",
          "Matulane",
          "BiCNU",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Gliadel Wafer",
          "Gleostine",
          "Bleomycin",
          "Vincristine Sulfate"
        ]
      },
      {
        "ProgramID": 30728,
        "ProgramName": "Assistance Fund: Hypophosphatasia (HPP)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypophosphatasia (HPP)"
        ],
        "Drugs": [
          "Miacalcin",
          "Strensiq"
        ]
      },
      {
        "ProgramID": 30678,
        "ProgramName": "Assistance Fund: Hypophosphatemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypophosphatemia"
        ],
        "Drugs": [
          "Crysvita"
        ]
      },
      {
        "ProgramID": 31041,
        "ProgramName": "Assistance Fund: Idiopathic Hypersomnia (IH)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Idiopathic Hypersomnia (IH)"
        ],
        "Drugs": [
          "Northera",
          "Xywav",
          "Droxidopa"
        ]
      },
      {
        "ProgramID": 30703,
        "ProgramName": "Assistance Fund: Idiopathic Pulmonary Fibrosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Idiopathic Pulmonary Fibrosis"
        ],
        "Drugs": [
          "Ofev",
          "Rayos",
          "Esbriet"
        ]
      },
      {
        "ProgramID": 31023,
        "ProgramName": "Assistance Fund: Immunoglobulin A Nephropathy (IgAN)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Primary Immunoglobulin A Nephropathy (IgAN)",
          "IgA Nephropathy"
        ],
        "Drugs": [
          "Tarpeyo",
          "Filspari",
          "Fabhalta"
        ]
      },
      {
        "ProgramID": 30417,
        "ProgramName": "Assistance Fund: Infantile Spasms: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Infantile Spasms"
        ],
        "Drugs": [
          "Acthar Gel",
          "Sabril",
          "Vigabatrin",
          "Vigadrone",
          "Vigafyde"
        ]
      },
      {
        "ProgramID": 30440,
        "ProgramName": "Assistance Fund: Iron Deficiency Anemia: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Iron Deficiency Anemia"
        ],
        "Drugs": [
          "Feraheme",
          "Auryxia",
          "Monoferric"
        ]
      },
      {
        "ProgramID": 30329,
        "ProgramName": "Assistance Fund: Juvenile Arthritis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Juvenile Arthritis",
          "Juvenile Idiopathic Arthritis",
          "Juvenile Rheumatoid Arthritis",
          "Polyarticular Juvenile Idiopathic Arthritis (pJIA)",
          "Systemic Juvenile Idiopathic Arthritis (SJIA)"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Trexall",
          "Methotrexate",
          "Cyltezo",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Amjevita",
          "Purified Cortrophin Gel",
          "Tyenne",
          "Acthar Selfject",
          "Actemra",
          "Enbrel",
          "Humira",
          "Ilaris",
          "Orencia",
          "Otrexup",
          "Rasuvo",
          "Hyrimoz",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Actemra Actpen",
          "Hadlima",
          "Etanercept",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Simlandi",
          "Simponi ARIA",
          "Orencia Clickject",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30727,
        "ProgramName": "Assistance Fund: Lambert-Eaton Myasthenic Syndrome (LEMS)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lambert-Eaton Myasthenic Syndrome (LEMS)"
        ],
        "Drugs": [
          "Firdapse"
        ]
      },
      {
        "ProgramID": 30818,
        "ProgramName": "Assistance Fund: Long-Chain Fatty Acid Oxidation Disorders Financial Assistance Program",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Long-Chain Fatty Oxidation Disorders (LC-FAOD)"
        ],
        "Drugs": [
          "Dojolvi"
        ]
      },
      {
        "ProgramID": 30344,
        "ProgramName": "Assistance Fund: Lupus: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Systemic Lupus Erythematosus",
          "Pediatric Systemic Lupus Erythematosus"
        ],
        "Drugs": [
          "Benlysta",
          "Acthar Gel",
          "Rayos",
          "Lupkynis",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Saphnelo",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30730,
        "ProgramName": "Assistance Fund: Lysosomal Acid Lipase Deficiency",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lysosomal Storage Disorders: Lysosomal Acid Lipase Deficiency (LALD)"
        ],
        "Drugs": [
          "Kanuma"
        ]
      },
      {
        "ProgramID": 30332,
        "ProgramName": "Assistance Fund: Melanoma: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Melanoma"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Proleukin",
          "Tafinlar",
          "Yervoy",
          "Zelboraf",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Braftovi",
          "Vitrakvi",
          "Mektovi",
          "Opdivo & Yervoy",
          "Kimmtrak",
          "Braftovi & Mektovi",
          "Opdualag",
          "Amtagvi",
          "Opdivo Qvantig"
        ]
      },
      {
        "ProgramID": 30797,
        "ProgramName": "Assistance Fund: MPS I - Hurler Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type I (MPS I: Hurler / Hurler-Scheie Syndrome)"
        ],
        "Drugs": [
          "Aldurazyme"
        ]
      },
      {
        "ProgramID": 30537,
        "ProgramName": "Assistance Fund: MPS II- Hunter Syndrome: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type II (MPS II: Hunter Syndrome)"
        ],
        "Drugs": [
          "Adcirca",
          "Adempas",
          "Letairis",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tracleer",
          "Tyvaso",
          "Veletri",
          "Ventavis",
          "Elaprase",
          "Flolan",
          "Sildenafil",
          "Uptravi",
          "Epoprostenol Sodium"
        ]
      },
      {
        "ProgramID": 30644,
        "ProgramName": "Assistance Fund: MPS VII - Sly Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type VII (MPS VII: Sly Syndrome)"
        ],
        "Drugs": [
          "Mepsevii"
        ]
      },
      {
        "ProgramID": 30336,
        "ProgramName": "Assistance Fund: Multiple Sclerosis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Multiple Sclerosis (MS)"
        ],
        "Drugs": [
          "Ampyra",
          "Aubagio",
          "Avonex",
          "Betaseron",
          "Copaxone",
          "Gilenya",
          "Acthar Gel",
          "Lemtrada",
          "Plegridy",
          "Rayos",
          "Rebif",
          "Tecfidera",
          "Tysabri",
          "Mitoxantrone",
          "Glatopa",
          "Ocrevus",
          "Avonex Pen",
          "Glatiramer Acetate",
          "Dalfampridine",
          "Mavenclad",
          "Mayzent",
          "Vumerity",
          "Zeposia",
          "Bafiertam",
          "Kesimpta",
          "Dimethyl Fumarate",
          "Ponvory",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel",
          "Tascenso ODT",
          "Dimethyl Fumarate DR",
          "Briumvi",
          "Teriflunomide",
          "Tyruko"
        ]
      },
      {
        "ProgramID": 30641,
        "ProgramName": "Assistance Fund: Myasthenia Gravis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Myasthenia Gravis"
        ],
        "Drugs": [
          "Soliris",
          "Ultomiris",
          "Vyvgart",
          "Mestinon",
          "Vyvgart Hytrulo",
          "Rystiggo",
          "Zilbrysq"
        ]
      },
      {
        "ProgramID": 30418,
        "ProgramName": "Assistance Fund: Myositis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Dermatomyositis",
          "Myositis",
          "Polymyositis"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Octagam",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 31089,
        "ProgramName": "Assistance Fund: Narcolepsy",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Narcolepsy"
        ],
        "Drugs": [
          "Xyrem",
          "Wakix",
          "Xywav",
          "Lumryz"
        ]
      },
      {
        "ProgramID": 30416,
        "ProgramName": "Assistance Fund: Nephrotic Syndrome: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Nephrotic Syndrome"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Cyclophosphamide",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30338,
        "ProgramName": "Assistance Fund: Neuroendocrine Tumors: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Metastatic Carcinoid Tumors",
          "Oncology - Neuroendocrine Tumors",
          "Oncology - Carcinoid Tumors and Associated Symptoms"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Sutent",
          "Octreotide Acetate",
          "Xermelo",
          "Sandostatin",
          "Lutathera",
          "Afinitor"
        ]
      },
      {
        "ProgramID": 31047,
        "ProgramName": "Assistance Fund: Neurofibromatosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Neurofibromatosis"
        ],
        "Drugs": [
          "Forteo",
          "Prolia",
          "Xgeva",
          "Reclast",
          "Zoledronic Acid",
          "Tymlos",
          "Evenity",
          "Koselugo"
        ]
      },
      {
        "ProgramID": 30773,
        "ProgramName": "Assistance Fund: Neuromyelitis Optica Spectrum Disorder (NMOSD)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
        ],
        "Drugs": [
          "Soliris",
          "Ultomiris",
          "Uplizna",
          "Enspryng"
        ]
      },
      {
        "ProgramID": 30824,
        "ProgramName": "Assistance Fund: Neurotrophic Keratitis (NK)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Neurotrophic Keratitis"
        ],
        "Drugs": [
          "Tobramycin",
          "Oxervate",
          "Purified Cortrophin Gel"
        ]
      },
      {
        "ProgramID": 31065,
        "ProgramName": "Assistance Fund: Nonalcoholic Steatohepatitis (NASH)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Steatohepatitis"
        ],
        "Drugs": [
          "Xolair",
          "Gastrocrom",
          "Quzyttir",
          "Rezdiffra"
        ]
      },
      {
        "ProgramID": 30177,
        "ProgramName": "Assistance Fund: Non-Small Cell Lung Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Cyramza",
          "Gilotrif",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Tarceva",
          "Taxotere",
          "Xalkori",
          "Zykadia",
          "Iressa",
          "Photofrin",
          "Docetaxel",
          "Tagrisso",
          "Alecensa",
          "Portrazza",
          "Tecentriq",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Erlotinib Hydrochloride",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Vitrakvi",
          "Zirabev",
          "Rozlytrek",
          "Enhertu",
          "Tabrecta",
          "Retevmo",
          "Opdivo & Yervoy",
          "Gavreto",
          "Rybrevant",
          "Lumakras",
          "Tepmetko",
          "Alymsys",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Krazati",
          "Imfinzi & Imjudo",
          "Augtyro",
          "Avzivi",
          "Lazcluze",
          "Bizengri",
          "Ensacove",
          "Opdivo Qvantig"
        ]
      },
      {
        "ProgramID": 30702,
        "ProgramName": "Assistance Fund: Nontuberculous Mycobacterial (NTM) Lung Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Mycobacterium Avium Complex (MAC)"
        ],
        "Drugs": [
          "Arikayce"
        ]
      },
      {
        "ProgramID": 30893,
        "ProgramName": "Assistance Fund: Ovarian Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Ovarian"
        ],
        "Drugs": [
          "Avastin",
          "Doxil",
          "Lynparza",
          "Paraplatin",
          "Cyclophosphamide",
          "Alkeran",
          "Topotecan",
          "Rubraca",
          "Gemcitabine",
          "Zejula",
          "Mvasi",
          "Melphalan",
          "Tepadina",
          "Thiotepa",
          "Zirabev",
          "Alymsys",
          "Vegzelma",
          "Elahere",
          "Avzivi",
          "Tepylute"
        ]
      },
      {
        "ProgramID": 30957,
        "ProgramName": "Assistance Fund: Pancreatic Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Pancreatic"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Lynparza",
          "Somatuline Depot",
          "Sutent",
          "Tarceva",
          "Xeloda",
          "Mitomycin",
          "Onivyde",
          "Fluorouracil",
          "Mutamycin",
          "Everolimus",
          "Gemcitabine",
          "Erlotinib Hydrochloride",
          "Lutathera",
          "Rozlytrek",
          "Welireg",
          "Lanreotide Acetate",
          "Sunitinib Malate",
          "Bizengri"
        ]
      },
      {
        "ProgramID": 30327,
        "ProgramName": "Assistance Fund: Parkinson's Disease: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Parkinson's Disease"
        ],
        "Drugs": [
          "Apokyn",
          "Northera",
          "Zelapar",
          "Duopa",
          "Nuplazid",
          "Tasmar",
          "Gocovri",
          "Tolcapone",
          "Inbrija",
          "Nourianz",
          "Droxidopa",
          "Apomorphine",
          "Crexont",
          "Vyalev"
        ]
      },
      {
        "ProgramID": 30729,
        "ProgramName": "Assistance Fund: Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
        ],
        "Drugs": [
          "Soliris",
          "Ultomiris",
          "Empaveli",
          "Fabhalta",
          "Voydeya",
          "Bkemv",
          "PiaSky",
          "Epysqli",
          "Soliris & Voydeya",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30796,
        "ProgramName": "Assistance Fund: Pompe Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pompe Disease"
        ],
        "Drugs": [
          "Lumizyme",
          "Nexviazyme",
          "Opfolda & Pombiliti",
          "Opfolda",
          "Pombiliti"
        ]
      },
      {
        "ProgramID": 30803,
        "ProgramName": "Assistance Fund: Porphyria",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acute Porphyria"
        ],
        "Drugs": [
          "Panhematin",
          "Givlaari",
          "Scenesse"
        ]
      },
      {
        "ProgramID": 30451,
        "ProgramName": "Assistance Fund: Primary Biliary Cholangitis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Primary Biliary Cholangitis (PBC)"
        ],
        "Drugs": [
          "Ocaliva",
          "Iqirvo",
          "Livdelzi"
        ]
      },
      {
        "ProgramID": 30835,
        "ProgramName": "Assistance Fund: Primary Hyperoxaluria: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hyperoxaluria"
        ],
        "Drugs": [
          "Oxlumo",
          "Rivfloza"
        ]
      },
      {
        "ProgramID": 30535,
        "ProgramName": "Assistance Fund: Primary Immunodeficiency: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Immunodeficiency",
          "Severe Combined Immunodeficiency Disease (SCID)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Hizentra",
          "Flebogamma DIF",
          "HyQvia",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Cuvitru",
          "Cutaquig",
          "Asceniv",
          "Xembify",
          "Panzyga",
          "Alyglo",
          "Yimmugo"
        ]
      },
      {
        "ProgramID": 30742,
        "ProgramName": "Assistance Fund: Prostate Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Castration-Sensitive Prostate Cancer",
          "Oncology - Non-Metastatic Castration-Resistant Prostate Cancer",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
          "Oncology - Castration-Resistant Prostate Cancer"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Lupron Depot",
          "Lynparza",
          "Nilandron",
          "Provenge",
          "Taxotere",
          "Trelstar",
          "Xofigo",
          "Xtandi",
          "Zoladex",
          "Zytiga",
          "Mitoxantrone",
          "Docetaxel",
          "Rubraca",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Vitrakvi",
          "Abiraterone Acetate",
          "Nubeqa",
          "Orgovyx",
          "Camcevi",
          "Pluvicto",
          "Akeega",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30172,
        "ProgramName": "Assistance Fund: Psoriasis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Dermatology - Psoriasis / Plaque Psoriasis",
          "Dermatology - Pediatric Psoriasis / Plaque Psoriasis"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Gengraf",
          "Humira",
          "Neoral",
          "Otezla",
          "Otrexup",
          "Rasuvo",
          "Remicade",
          "Stelara",
          "Trexall",
          "Enstilar",
          "Taltz",
          "Inflectra",
          "Siliq",
          "Cyclosporine",
          "Renflexis",
          "Tremfya",
          "Cyltezo",
          "Ilumya",
          "Hyrimoz",
          "Skyrizi",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Amjevita",
          "Vtama",
          "Hadlima",
          "Spevigo",
          "Purified Cortrophin Gel",
          "Sotyktu",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Bimzelx",
          "Simlandi",
          "Otulfi",
          "Imuldosa",
          "Yesintek",
          "Selarsdi",
          "Steqeyma"
        ]
      },
      {
        "ProgramID": 30340,
        "ProgramName": "Assistance Fund: Psoriatic Arthritis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Psoriatic Arthritis"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Acthar Gel",
          "Humira",
          "Orencia",
          "Otezla",
          "Rayos",
          "Remicade",
          "Simponi",
          "Simponi ARIA",
          "Stelara",
          "Xeljanz",
          "Taltz",
          "Inflectra",
          "Renflexis",
          "Tremfya",
          "Cyltezo",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Skyrizi",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Amjevita",
          "Hadlima",
          "Purified Cortrophin Gel",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Wezlana",
          "Simlandi",
          "Selarsdi",
          "Pyzchiva",
          "Otulfi",
          "Imuldosa",
          "Yesintek",
          "Steqeyma"
        ]
      },
      {
        "ProgramID": 30660,
        "ProgramName": "Assistance Fund: Pulmonary Hypertension: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pulmonary Arterial Hypertension (PAH)"
        ],
        "Drugs": [
          "Adcirca",
          "Adempas",
          "Letairis",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tracleer",
          "Tyvaso",
          "Veletri",
          "Ventavis",
          "Flolan",
          "Sildenafil",
          "Uptravi",
          "Epoprostenol Sodium",
          "Tadalafil",
          "Ambrisentan",
          "Treprostinil",
          "Bosentan",
          "Treprostinil Diolamine",
          "Tyvaso DPI",
          "Opsynvi",
          "Winrevair"
        ]
      },
      {
        "ProgramID": 30341,
        "ProgramName": "Assistance Fund: Renal Cell Carcinoma (RCC): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Renal Cell Carcinoma (Kidney Cancer) (RCC)"
        ],
        "Drugs": [
          "Afinitor",
          "Avastin",
          "Cometriq",
          "Inlyta",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Proleukin",
          "Sutent",
          "Torisel",
          "Votrient",
          "Yervoy",
          "Cabometyx",
          "Everolimus",
          "Afinitor Disperz",
          "Bavencio",
          "Mvasi",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Opdivo & Yervoy",
          "Opdivo & Cabometyx",
          "Keytruda & Lenvima",
          "Welireg",
          "Fotivda",
          "Alymsys",
          "Vegzelma",
          "Pazopanib",
          "Avzivi",
          "Bevacizumab-bvzr",
          "Opdivo Qvantig"
        ]
      },
      {
        "ProgramID": 31032,
        "ProgramName": "Assistance Fund: Rett Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Rett Syndrome"
        ],
        "Drugs": [
          "Daybue"
        ]
      },
      {
        "ProgramID": 30342,
        "ProgramName": "Assistance Fund: Rheumatoid Arthritis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Juvenile Idiopathic Arthritis",
          "Juvenile Rheumatoid Arthritis",
          "Rheumatoid Arthritis (RA)",
          "Polyarticular Juvenile Idiopathic Arthritis (pJIA)"
        ],
        "Drugs": [
          "Actemra",
          "Enbrel",
          "Acthar Gel",
          "Humira",
          "Orencia",
          "Otrexup",
          "Rasuvo",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Cyltezo",
          "Hyrimoz",
          "Rinvoq",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Actemra Actpen",
          "Hadlima",
          "Etanercept",
          "Purified Cortrophin Gel",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Simlandi",
          "Tyenne",
          "Adalimumab-ryvk",
          "Rinvoq LQ",
          "Xeljanz",
          "Xeljanz XR",
          "Cimzia",
          "Gengraf",
          "Kineret",
          "Neoral",
          "Remicade",
          "Rituxan",
          "Simponi",
          "Simponi ARIA",
          "Inflectra",
          "Cyclosporine",
          "Renflexis",
          "Kevzara",
          "Infliximab",
          "Infliximab-dyyb",
          "Olumiant",
          "Truxima",
          "Avsola",
          "Ruxience",
          "Riabni",
          "Rituximab",
          "Rituximab-pvvr",
          "Infliximab-abda",
          "Orencia Clickject",
          "Infliximab-axxq",
          "Jylamvo",
          "Tofidence",
          "Rituximab-abbs",
          "Rituximab-arrx"
        ]
      },
      {
        "ProgramID": 30419,
        "ProgramName": "Assistance Fund: Sarcoidosis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Sarcoidosis"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30449,
        "ProgramName": "Assistance Fund: Short Bowel Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Short Bowel Syndrome"
        ],
        "Drugs": [
          "Gattex"
        ]
      },
      {
        "ProgramID": 31034,
        "ProgramName": "Assistance Fund: Sickle Cell Disease (SCD): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Sickle Cell Disease (SCD)"
        ],
        "Drugs": [
          "Ferriprox",
          "Adakveo",
          "Endari",
          "Siklos",
          "Deferiprone",
          "Casgevy",
          "Lyfgenia"
        ]
      },
      {
        "ProgramID": 30343,
        "ProgramName": "Assistance Fund: Skin & Skin Structure Infections: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Methicillin-Resistant Staphylococcus Aureus (MRSA)",
          "Skin and Skin Structure Infections"
        ],
        "Drugs": [
          "Zevtera",
          "Dalvance",
          "Teflaro",
          "Deferoxamine Mesylate",
          "Vancomycin",
          "Daptomycin",
          "Orbactiv",
          "Nuzyra",
          "Kimyrsa"
        ]
      },
      {
        "ProgramID": 31038,
        "ProgramName": "Assistance Fund: Small Cell Lung Cancer (SCLC): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Small Cell Lung Cancer (SCLC)"
        ],
        "Drugs": [
          "Afinitor",
          "Hycamtin",
          "Hycamtin Injection",
          "Tecentriq",
          "Everolimus",
          "Topotecan",
          "Etoposide Phosphate",
          "Imfinzi",
          "Zepzelca",
          "Cosela",
          "Imdelltra"
        ]
      },
      {
        "ProgramID": 31054,
        "ProgramName": "Assistance Fund: Systemic Sclerosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Systemic Sclerosis"
        ],
        "Drugs": [
          "Actemra",
          "Ofev"
        ]
      },
      {
        "ProgramID": 30694,
        "ProgramName": "Assistance Fund: Thrombocytopenia: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Immune Thrombocytopenic Purpura (ITP)",
          "Thrombocytopenia",
          "Acquired / Immune-Mediated Thrombotic Thrombocytopenic Purpura (aTTP / iTTP)",
          "Chronic Immune Thrombocytopenia (CITP)",
          "Congenital Thrombotic Thrombocytopenic Purpura (cTTP)"
        ],
        "Drugs": [
          "Gamunex-C",
          "Nplate",
          "Promacta",
          "Flebogamma DIF",
          "Privigen",
          "Octagam",
          "Gammaked",
          "Gammaplex",
          "Rhophylac",
          "Tavalisse",
          "Doptelet",
          "Mulpleta",
          "Cablivi",
          "WinRho SDF",
          "Adzynma"
        ]
      },
      {
        "ProgramID": 30853,
        "ProgramName": "Assistance Fund: Thyroid Cancer: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Thyroid",
          "Oncology - Metastatic Differentiated Thyroid Cancer"
        ],
        "Drugs": [
          "Caprelsa",
          "Cometriq",
          "Lenvima",
          "Mekinist",
          "Nexavar",
          "Tafinlar",
          "Thyrogen",
          "Cabometyx",
          "Vitrakvi",
          "Retevmo",
          "Gavreto",
          "Tafinlar & Mekinist"
        ]
      },
      {
        "ProgramID": 30801,
        "ProgramName": "Assistance Fund: Thyroid Eye Disease (TED)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Thyroid Eye Disease (TED)"
        ],
        "Drugs": [
          "Tepezza",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Teprotumumab-trbw",
          "Miebo"
        ]
      },
      {
        "ProgramID": 30879,
        "ProgramName": "Assistance Fund: Tumor-Induced Osteomalacia (TIO)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Tumor-Induced Osteomalacia (TIO)"
        ],
        "Drugs": [
          "Crysvita"
        ]
      },
      {
        "ProgramID": 30441,
        "ProgramName": "Assistance Fund: Ulcerative Colitis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "IBD - Pediatric Ulcerative Colitis",
          "IBD - Ulcerative Colitis",
          "IBD - Ulcerative Proctitis"
        ],
        "Drugs": [
          "Humira",
          "Rayos",
          "Remicade",
          "Inflectra",
          "Renflexis",
          "Infliximab",
          "Infliximab-dyyb",
          "Avsola",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Infliximab-axxq",
          "Entyvio",
          "Simponi",
          "Stelara",
          "Xeljanz",
          "Dipentum",
          "Rowasa",
          "SF Rowasa",
          "Tremfya",
          "Cyltezo",
          "Hyrimoz",
          "Rinvoq",
          "Zeposia",
          "Hulio",
          "Abrilada",
          "Amjevita",
          "Hadlima",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-aacf",
          "Velsipity",
          "Zymfentra",
          "Omvoh",
          "Wezlana",
          "Simlandi",
          "Entyvio Pen",
          "Rinvoq LQ",
          "Pyzchiva",
          "Otulfi",
          "Imuldosa",
          "Yesintek",
          "Steqeyma"
        ]
      },
      {
        "ProgramID": 30798,
        "ProgramName": "Assistance Fund: Urea Cycle Disorders (UCD)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)",
          "Hyperammonemia"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva",
          "Pheburane"
        ]
      },
      {
        "ProgramID": 30420,
        "ProgramName": "Assistance Fund: Uveitis: Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Uveitis"
        ],
        "Drugs": [
          "Acthar Gel",
          "Humira",
          "Rayos",
          "Triesence",
          "Tobramycin",
          "Cyltezo",
          "Yutiq",
          "Hyrimoz",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Amjevita",
          "Hadlima",
          "Purified Cortrophin Gel",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Simlandi"
        ]
      },
      {
        "ProgramID": 31026,
        "ProgramName": "Baby Quest",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Reproductive Health - Infertility"
        ],
        "Drugs": [
          "Cetrotide",
          "Endometrin",
          "Follistim AQ Cartridge",
          "Gonal-f Multi-Dose",
          "Gonal-f RFF",
          "Gonal-f RFF Redi-ject",
          "Menopur",
          "Novarel",
          "Ovidrel",
          "Crinone",
          "Ganirelix Acetate",
          "Fyremadel",
          "Pregnyl",
          "Cetrorelix Acetate"
        ]
      },
      {
        "ProgramID": 30588,
        "ProgramName": "CancerCare: Acute Lymphoblastic Leukemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Acute Lymphoblastic Leukemia (ALL)"
        ],
        "Drugs": [
          "Arranon",
          "Blincyto",
          "Bosulif",
          "Gleevec",
          "Iclusig",
          "Rituxan",
          "Sprycel",
          "Tasigna",
          "Velcade",
          "Cytarabine",
          "Purixan",
          "Mitoxantrone",
          "Trexall",
          "Methotrexate",
          "Dacogen",
          "Cyclophosphamide",
          "Darzalex",
          "Vincasar PFS",
          "Oncaspar",
          "Venclexta",
          "Clolar",
          "Vincristine Sulfate",
          "Imatinib",
          "Besponsa",
          "Kymriah",
          "Fludarabine Phosphate",
          "Truxima",
          "Asparlas",
          "Tabloid",
          "Darzalex Faspro",
          "Ruxience",
          "Riabni",
          "Rylaze",
          "Tecartus",
          "Rituximab",
          "Aucatzyl"
        ]
      },
      {
        "ProgramID": 30573,
        "ProgramName": "CancerCare: Acute Myeloid Leukemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Acute Myeloid Leukemia (AML)"
        ],
        "Drugs": [
          "Nexavar",
          "Vidaza",
          "Venclexta",
          "Decitabine",
          "Clolar",
          "Rydapt",
          "IDHIFA",
          "Fludarabine Phosphate",
          "Tibsovo",
          "Daurismo",
          "Xospata",
          "Onureg",
          "Rezlidhia",
          "Vanflyta"
        ]
      },
      {
        "ProgramID": 30580,
        "ProgramName": "CancerCare: Bladder Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bladder"
        ],
        "Drugs": [
          "Ellence",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Xeloda",
          "Mitomycin",
          "Paraplatin",
          "Capecitabine",
          "Trexall",
          "Methotrexate",
          "Valstar",
          "Fluorouracil",
          "Docetaxel",
          "Tecentriq",
          "Bavencio",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Balversa",
          "Padcev",
          "Jelmyto",
          "Trodelvy",
          "Paclitaxel Protein-Bound",
          "Adstiladrin"
        ]
      },
      {
        "ProgramID": 30961,
        "ProgramName": "CancerCare: Bone Metastases",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bone"
        ],
        "Drugs": [
          "Xgeva",
          "Xofigo",
          "Zometa",
          "Methotrexate",
          "Zoledronic Acid",
          "Miacalcin",
          "Dactinomycin",
          "Herceptin Hylecta",
          "Immune Globulin Intravenous (IGIV)",
          "Levoleucovorin",
          "Trastuzumab & Hyaluronidase-oysk"
        ]
      },
      {
        "ProgramID": 30618,
        "ProgramName": "CancerCare: Breast Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Cyramza",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Perjeta",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Paraplatin",
          "Capecitabine",
          "Methotrexate",
          "Fluorouracil",
          "Docetaxel",
          "Cyclophosphamide",
          "Leuprolide Acetate",
          "Everolimus",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Rozlytrek",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Retevmo",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Fulvestrant",
          "Paclitaxel Protein-Bound",
          "Orserdu",
          "Truqap",
          "Trastuzumab-pkrb",
          "Docivyx",
          "Itovebi"
        ]
      },
      {
        "ProgramID": 30582,
        "ProgramName": "CancerCare: Cancer Related Pain Management",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Supportive"
        ],
        "Drugs": [
          "Sprix",
          "Azacitidine"
        ]
      },
      {
        "ProgramID": 30583,
        "ProgramName": "CancerCare: Cervical Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Cervical",
          "Oncology - Metastatic Cervical Cancer"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Camptosar",
          "Hycamtin Injection",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Mitomycin",
          "Paraplatin",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Tecentriq",
          "Topotecan",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Imfinzi",
          "Mvasi",
          "Vitrakvi",
          "Zirabev",
          "Rozlytrek",
          "Retevmo",
          "Tivdak",
          "Alymsys",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Avzivi"
        ]
      },
      {
        "ProgramID": 30963,
        "ProgramName": "CancerCare: Chemotherapy Induced Neutropenia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neutropenia"
        ],
        "Drugs": [
          "Neulasta",
          "Neupogen",
          "Vidaza",
          "Granix",
          "Zarxio",
          "Leukine",
          "Mozobil",
          "Filgrastim",
          "Fulphila",
          "Nivestym",
          "Udenyca",
          "Ziextenzo",
          "Nyvepria",
          "Neulasta Onpro",
          "Posaconazole",
          "Pegfilgrastim-bmez",
          "Releuko"
        ]
      },
      {
        "ProgramID": 30962,
        "ProgramName": "CancerCare: Cholangiocarcinoma (Bile Duct Cancer)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Cholangiocarcinoma (Bile Duct Cancer)"
        ],
        "Drugs": [
          "Abraxane",
          "Camptosar",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Opdivo",
          "Perjeta",
          "Stivarga",
          "Tafinlar",
          "Xeloda",
          "Yervoy",
          "Capecitabine",
          "Fluorouracil",
          "Irinotecan",
          "Gemcitabine",
          "Imfinzi",
          "Tibsovo",
          "Vitrakvi",
          "Kanjinti",
          "Rozlytrek",
          "Enhertu",
          "Retevmo",
          "Pemazyre",
          "Paclitaxel Protein-Bound",
          "Lytgobi",
          "Krazati"
        ]
      },
      {
        "ProgramID": 30624,
        "ProgramName": "CancerCare: Chronic Lymphocytic Leukemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Lymphocytic Leukemia (CLL)"
        ],
        "Drugs": [
          "Campath",
          "Gazyva",
          "Imbruvica",
          "Keytruda",
          "Opdivo",
          "Revlimid",
          "Rituxan",
          "Treanda",
          "Zydelig",
          "Leukeran",
          "Nipent",
          "Cyclophosphamide",
          "Bendeka",
          "Venclexta",
          "Bendamustine",
          "Vincristine Sulfate",
          "Etoposide Phosphate",
          "Calquence",
          "Fludarabine Phosphate",
          "Copiktra",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Rituximab",
          "Breyanzi",
          "Lenalidomide",
          "Vivimusta",
          "Jaypirca"
        ]
      },
      {
        "ProgramID": 30723,
        "ProgramName": "CancerCare: Chronic Myeloid Leukemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Myeloid Leukemia (CML)"
        ],
        "Drugs": [
          "Bosulif",
          "Gleevec",
          "Iclusig",
          "Sprycel",
          "Tasigna",
          "Imatinib",
          "Scemblix"
        ]
      },
      {
        "ProgramID": 31077,
        "ProgramName": "CancerCare: Esophageal Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Esophageal Cancer"
        ],
        "Drugs": [
          "Herceptin",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Xeloda",
          "Yervoy",
          "Capecitabine",
          "Photofrin",
          "Cyclophosphamide",
          "Ogivri",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Enhertu",
          "Retevmo",
          "Opdivo & Yervoy",
          "Jemperli",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Augtyro",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Tevimbra"
        ]
      },
      {
        "ProgramID": 30488,
        "ProgramName": "CancerCare: Gastric Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Gastric"
        ],
        "Drugs": [
          "Camptosar",
          "Cyramza",
          "Herceptin",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Taxotere",
          "Xeloda",
          "Paraplatin",
          "Lonsurf",
          "Capecitabine",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Ogivri",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Rozlytrek",
          "Enhertu",
          "Retevmo",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Vyloy"
        ]
      },
      {
        "ProgramID": 30964,
        "ProgramName": "CancerCare: Gastrointestinal Stromal Tumor (GIST)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Gastrointestinal Stromal Tumor (GIST)"
        ],
        "Drugs": [
          "Gleevec",
          "Stivarga",
          "Sutent",
          "Imatinib",
          "Ayvakit",
          "Qinlock",
          "Immune Globulin Intravenous (IGIV)",
          "Sunitinib Malate"
        ]
      },
      {
        "ProgramID": 30489,
        "ProgramName": "CancerCare: Glioblastoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Glioblastoma"
        ],
        "Drugs": [
          "Avastin",
          "Stivarga",
          "Temodar",
          "Matulane",
          "BiCNU",
          "Gliadel Wafer",
          "Gleostine",
          "Temozolomide",
          "Etoposide Phosphate",
          "Mvasi",
          "Bevacizumab",
          "Zirabev"
        ]
      },
      {
        "ProgramID": 30506,
        "ProgramName": "CancerCare: Head and Neck Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Head and Neck"
        ],
        "Drugs": [
          "Erbitux",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Methotrexate",
          "Docetaxel",
          "Ethyol"
        ]
      },
      {
        "ProgramID": 30695,
        "ProgramName": "CancerCare: Hepatocellular Carcinoma (HCC)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Hepatocellular Carcinoma (HCC)"
        ],
        "Drugs": [
          "Avastin",
          "Cometriq",
          "Cyramza",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Stivarga",
          "Yervoy",
          "Cabometyx",
          "Tecentriq",
          "Imfinzi",
          "Mvasi",
          "Sorafenib Tosylate",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Rozlytrek",
          "Retevmo",
          "Alymsys",
          "Vegzelma",
          "Imjudo"
        ]
      },
      {
        "ProgramID": 30855,
        "ProgramName": "CancerCare: Malignant Mesothelioma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Mesothelioma"
        ],
        "Drugs": [
          "Alimta",
          "Avastin",
          "Keytruda",
          "Yervoy",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Pemetrexed",
          "Pemfexy",
          "Bevacizumab",
          "Opdivo & Yervoy"
        ]
      },
      {
        "ProgramID": 30497,
        "ProgramName": "CancerCare: Melanoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Melanoma"
        ],
        "Drugs": [
          "Abraxane",
          "Gleevec",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Opdivo",
          "Proleukin",
          "Sprycel",
          "Tafinlar",
          "Tasigna",
          "Xalkori",
          "Yervoy",
          "Zelboraf",
          "Paraplatin",
          "Alkeran",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Imatinib",
          "Temozolomide",
          "Braftovi",
          "Vitrakvi",
          "Mektovi",
          "Rozlytrek",
          "Qinlock",
          "Kimmtrak",
          "Opdualag",
          "Paclitaxel Protein-Bound",
          "Amtagvi"
        ]
      },
      {
        "ProgramID": 30569,
        "ProgramName": "CancerCare: Merkel Cell Carcinoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Merkel Cell Carcinoma (MCC)"
        ],
        "Drugs": [
          "Ellence",
          "Hycamtin",
          "Hycamtin Injection",
          "Keytruda",
          "Opdivo",
          "Yervoy",
          "Cyclophosphamide",
          "Vincristine Sulfate",
          "Bavencio",
          "Etoposide Phosphate",
          "Opdivo & Yervoy",
          "Zynyz"
        ]
      },
      {
        "ProgramID": 30494,
        "ProgramName": "CancerCare: Metastatic Breast Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Avastin",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Perjeta",
          "Taxotere",
          "Tykerb",
          "Votrient",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Paraplatin",
          "Capecitabine",
          "Methotrexate",
          "Docetaxel",
          "Cyclophosphamide",
          "Leuprolide Acetate",
          "Everolimus",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Zirabev",
          "Rozlytrek",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Retevmo",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Fulvestrant",
          "Paclitaxel Protein-Bound",
          "Orserdu",
          "Truqap",
          "Hercessi",
          "Docivyx",
          "Itovebi",
          "Eribulin Mesylate"
        ]
      },
      {
        "ProgramID": 30505,
        "ProgramName": "CancerCare: Metastatic Colorectal Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Colon",
          "Oncology - Metastatic Colorectal Cancer (mCRC)"
        ],
        "Drugs": [
          "Avastin",
          "Camptosar",
          "Erbitux",
          "Herceptin",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Perjeta",
          "Stivarga",
          "Tafinlar",
          "Tykerb",
          "Vectibix",
          "Xeloda",
          "Yervoy",
          "Zaltrap",
          "Lonsurf",
          "Capecitabine",
          "Fluorouracil",
          "Floxuridine",
          "Irinotecan",
          "Mvasi",
          "Ogivri",
          "Braftovi",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Mektovi",
          "Kanjinti",
          "Zirabev",
          "Rozlytrek",
          "Tukysa",
          "Lapatinib Ditosylate",
          "Braftovi & Mektovi",
          "Alymsys",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Krazati",
          "Fruzaqla",
          "Avzivi",
          "Enhertu",
          "Opdivo & Yervoy"
        ]
      },
      {
        "ProgramID": 30389,
        "ProgramName": "CancerCare: Metastatic Differentiated Thyroid Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Metastatic Differentiated Thyroid Cancer"
        ],
        "Drugs": [
          "Afinitor",
          "Caprelsa",
          "Cometriq",
          "Inlyta",
          "Lenvima",
          "Nexavar",
          "Sutent",
          "Tafinlar",
          "Votrient",
          "Zelboraf",
          "Vitrakvi",
          "Rozlytrek"
        ]
      },
      {
        "ProgramID": 30740,
        "ProgramName": "CancerCare: Metastatic Pheochromocytoma and Paraganglioma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Pheochromocytoma or Paraganglioma"
        ],
        "Drugs": [
          "Temodar",
          "Cyclophosphamide",
          "Temozolomide",
          "Lutathera",
          "Demser",
          "Immune Globulin Intravenous (IGIV)"
        ]
      },
      {
        "ProgramID": 30724,
        "ProgramName": "CancerCare: Metastatic Prostate Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lynparza",
          "Nilandron",
          "Provenge",
          "Taxotere",
          "Trelstar",
          "Xtandi",
          "Zoladex",
          "Zytiga",
          "Paraplatin",
          "Docetaxel",
          "Leuprolide Acetate",
          "Rubraca",
          "Etoposide Phosphate",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Abiraterone Acetate",
          "Nubeqa",
          "Orgovyx",
          "Camcevi",
          "Akeega"
        ]
      },
      {
        "ProgramID": 30741,
        "ProgramName": "CancerCare: Metastatic Skin Cancer - Non Melanoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Basal Cell Carcinoma (BCC)",
          "Oncology - Cutaneous Squamous Cell Carcinoma (CSCC)"
        ],
        "Drugs": [
          "Carac",
          "Erivedge",
          "Fluorouracil",
          "Odomzo",
          "Libtayo"
        ]
      },
      {
        "ProgramID": 30492,
        "ProgramName": "CancerCare: Multiple Myeloma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma"
        ],
        "Drugs": [
          "Kyprolis",
          "Pomalyst",
          "Revlimid",
          "Thalomid",
          "Treanda",
          "Velcade",
          "Cyclophosphamide",
          "Darzalex",
          "Ninlaro",
          "Empliciti",
          "Bendeka",
          "Venclexta",
          "Belrapzo",
          "Xpovio",
          "Sarclisa",
          "Blenrep",
          "Bortezomib",
          "Lenalidomide",
          "Talvey",
          "Elrexfio"
        ]
      },
      {
        "ProgramID": 31076,
        "ProgramName": "CancerCare: Myelodysplastic Syndromes",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)"
        ],
        "Drugs": [
          "Gleevec",
          "Jakafi",
          "Neupogen",
          "Rayos",
          "Revlimid",
          "Vidaza",
          "Zarxio",
          "Dacogen",
          "Leukine",
          "Deferasirox",
          "Cyclophosphamide",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Vyxeos",
          "Fulphila",
          "Tibsovo",
          "Udenyca",
          "Reblozyl",
          "Inqovi",
          "Levoleucovorin",
          "Pemazyre",
          "Lenalidomide",
          "Udenyca Autoinjector",
          "Udenyca Onbody",
          "Rytelo",
          "Nypozi"
        ]
      },
      {
        "ProgramID": 30501,
        "ProgramName": "CancerCare: Myeloproliferative Neoplasms",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Myeloproliferative Neoplasms",
          "Oncology - Myelodysplastic Syndromes (MDS)",
          "Oncology - Myelofibrosis",
          "Polycythemia Vera",
          "Thrombocythemia"
        ],
        "Drugs": [
          "Jakafi",
          "Pegasys",
          "Revlimid",
          "Thalomid",
          "Vidaza",
          "Dacogen",
          "Decitabine",
          "Azacitidine",
          "Inrebic",
          "Onureg",
          "Besremi",
          "Pemazyre",
          "Siklos",
          "Lenalidomide",
          "Vonjo",
          "Ojjaara"
        ]
      },
      {
        "ProgramID": 30696,
        "ProgramName": "CancerCare: Non-Hodgkin Lymphoma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Mantle Cell Lymphoma (MCL)",
          "Oncology - Non-Hodgkin’s Lymphoma",
          "Oncology - Small Lymphocytic Lymphoma (SLL)",
          "Oncology - Waldenstrom’s Macroglobulinemia",
          "Oncology - T-Cell Lymphoma",
          "Oncology - Mycosis Fungoides",
          "Oncology - B-Cell Lymphoma",
          "Oncology - Follicular Lymphoma",
          "Oncology - Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
          "Oncology - Extranodal NK/T-Cell Lymphoma",
          "Oncology - Diffuse Large B-cell  Lymphoma (DLBCL)"
        ],
        "Drugs": [
          "Arzerra",
          "Gazyva",
          "Imbruvica",
          "Revlimid",
          "Rituxan",
          "Targretin",
          "Treanda",
          "Velcade",
          "Leukeran",
          "Mitoxantrone",
          "Nipent",
          "Cyclophosphamide",
          "Bendeka",
          "Venclexta",
          "Bendamustine",
          "Etoposide Phosphate",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Bexarotene",
          "Tecartus",
          "Rituximab",
          "Bortezomib",
          "Breyanzi",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Jaypirca",
          "Adcetris",
          "Afinitor",
          "Beleodaq",
          "Campath",
          "Ellence",
          "Folotyn",
          "Keytruda",
          "Kyprolis",
          "Pomalyst",
          "Temodar",
          "Xalkori",
          "Zevalin",
          "Zydelig",
          "Actimmune",
          "Istodax",
          "Matulane",
          "Zolinza",
          "Vincristine Sulfate",
          "Temozolomide",
          "Kymriah",
          "Yescarta",
          "Poteligeo",
          "Copiktra",
          "Polivy",
          "Xpovio",
          "Monjuvi",
          "Tazverik",
          "Riabni",
          "Lunsumio",
          "Imbruvica & Gazyva"
        ]
      },
      {
        "ProgramID": 30493,
        "ProgramName": "CancerCare: Non-Small Cell Lung Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Cyramza",
          "Erbitux",
          "Gilotrif",
          "Kadcyla",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Tarceva",
          "Taxotere",
          "Xalkori",
          "Yervoy",
          "Zelboraf",
          "Zykadia",
          "Iressa",
          "Paraplatin",
          "Docetaxel",
          "Tagrisso",
          "Alecensa",
          "Cabometyx",
          "Tecentriq",
          "Gemcitabine",
          "Temozolomide",
          "Etoposide Phosphate",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Pemfexy",
          "Braftovi",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Vitrakvi",
          "Mektovi",
          "Zirabev",
          "Rozlytrek",
          "Enhertu",
          "Tabrecta",
          "Retevmo",
          "Opdivo & Yervoy",
          "Gavreto",
          "Rybrevant",
          "Lumakras",
          "Braftovi & Mektovi",
          "Tepmetko",
          "Alymsys",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Imjudo",
          "Krazati",
          "Imfinzi & Imjudo",
          "Gefitinib",
          "Augtyro",
          "Avzivi",
          "Lazcluze",
          "Lazcluze & Rybrevant",
          "Bizengri"
        ]
      },
      {
        "ProgramID": 30508,
        "ProgramName": "CancerCare: Ovarian Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Ovarian"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Arimidex",
          "Avastin",
          "Camptosar",
          "Faslodex",
          "Femara",
          "Hycamtin Injection",
          "Ixempra",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Nexavar",
          "Tafinlar",
          "Taxotere",
          "Votrient",
          "Xeloda",
          "Paraplatin",
          "Capecitabine",
          "Docetaxel",
          "Cyclophosphamide",
          "Alkeran",
          "Topotecan",
          "Rubraca",
          "Gemcitabine",
          "Zejula",
          "Etoposide Phosphate",
          "Mvasi",
          "Pemetrexed",
          "Sorafenib Tosylate",
          "Melphalan",
          "Vitrakvi",
          "Zirabev",
          "Rozlytrek",
          "Retevmo",
          "Alymsys",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Elahere",
          "Pazopanib",
          "Avzivi"
        ]
      },
      {
        "ProgramID": 30490,
        "ProgramName": "CancerCare: Pancreatic Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Pancreatic"
        ],
        "Drugs": [
          "Abraxane",
          "Camptosar",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Tafinlar",
          "Tarceva",
          "Xeloda",
          "Yervoy",
          "Capecitabine",
          "Onivyde",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Rubraca",
          "Gemcitabine",
          "Erlotinib Hydrochloride",
          "Vitrakvi",
          "Rozlytrek",
          "Retevmo",
          "Paclitaxel Protein-Bound",
          "Krazati"
        ]
      },
      {
        "ProgramID": 30965,
        "ProgramName": "CancerCare: Pancreatic Neuroendocrine Tumor (PNET)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Neuroendocrine Tumors of Pancreatic Origin (PNET)"
        ],
        "Drugs": [
          "Afinitor",
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Sutent",
          "Temodar",
          "Xeloda",
          "Zortress",
          "Capecitabine",
          "Afinitor Disperz",
          "Octreotide Acetate",
          "Temozolomide",
          "Sandostatin",
          "Lutathera",
          "Rozlytrek",
          "Welireg",
          "Sunitinib Malate"
        ]
      },
      {
        "ProgramID": 30507,
        "ProgramName": "CancerCare: Prostate Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Nilandron",
          "Provenge",
          "Taxotere",
          "Trelstar",
          "Xtandi",
          "Zoladex",
          "Zytiga",
          "Docetaxel",
          "Leuprolide Acetate",
          "Rubraca",
          "Etoposide Phosphate",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Abiraterone Acetate",
          "Nubeqa",
          "Orgovyx",
          "Akeega"
        ]
      },
      {
        "ProgramID": 30491,
        "ProgramName": "CancerCare: Renal Cell Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Renal Cell Carcinoma (Kidney Cancer) (RCC)"
        ],
        "Drugs": [
          "Afinitor",
          "Avastin",
          "Inlyta",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Sutent",
          "Tarceva",
          "Torisel",
          "Votrient",
          "Yervoy",
          "Cabometyx",
          "Everolimus",
          "Bavencio",
          "Gemcitabine",
          "Mvasi",
          "Sorafenib Tosylate",
          "Erlotinib Hydrochloride",
          "Zirabev",
          "Welireg",
          "Fotivda",
          "Alymsys",
          "Sunitinib Malate",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Pazopanib",
          "Avzivi"
        ]
      },
      {
        "ProgramID": 30769,
        "ProgramName": "CancerCare: Small Cell Lung Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Small Cell Lung Cancer (SCLC)"
        ],
        "Drugs": [
          "Camptosar",
          "Hycamtin",
          "Hycamtin Injection",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Temodar",
          "Treanda",
          "Paraplatin",
          "Docetaxel",
          "Irinotecan",
          "Cyclophosphamide",
          "Bendeka",
          "Tecentriq",
          "Vincristine Sulfate",
          "Topotecan",
          "Gemcitabine",
          "Temozolomide",
          "Etoposide Phosphate",
          "Imfinzi",
          "Zepzelca",
          "Paclitaxel Protein-Bound",
          "Imdelltra"
        ]
      },
      {
        "ProgramID": 30509,
        "ProgramName": "CancerCare: Soft Tissue Sarcoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Soft Tissue Sarcoma (STS)"
        ],
        "Drugs": [
          "Votrient"
        ]
      },
      {
        "ProgramID": 30856,
        "ProgramName": "CancerCare: Uterine/Endometrial Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Uterine/Endometrial Cancer"
        ],
        "Drugs": [
          "Afinitor",
          "Arimidex",
          "Avastin",
          "Doxil",
          "Femara",
          "Keytruda",
          "Lenvima",
          "Lupron Depot",
          "Taxotere",
          "Torisel",
          "Zoladex",
          "Letrozole",
          "Docetaxel",
          "Leuprolide Acetate",
          "Afinitor Disperz",
          "Herzuma",
          "Jemperli",
          "Keytruda & Lenvima",
          "Immune Globulin Intravenous (IGIV)",
          "Trastuzumab"
        ]
      },
      {
        "ProgramID": 30404,
        "ProgramName": "Good Days: Anaplastic Large Cell Lymphoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Anaplastic Large Cell Lymphoma (ALCL)"
        ],
        "Drugs": [
          "Adcetris",
          "Rayos",
          "Purixan",
          "Trexall",
          "Methotrexate",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Vincristine Sulfate"
        ]
      },
      {
        "ProgramID": 30218,
        "ProgramName": "Good Days: Chronic Granulomatous Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Granulomatous Disease (CGD)"
        ],
        "Drugs": [
          "Actimmune",
          "Tolsura",
          "Posaconazole",
          "Noxafil Tablets"
        ]
      },
      {
        "ProgramID": 30219,
        "ProgramName": "Good Days: Chronic Iron Overload",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Iron Overload"
        ],
        "Drugs": [
          "Exjade",
          "Jadenu",
          "Ferriprox",
          "Deferasirox",
          "Deferoxamine Mesylate",
          "Desferal"
        ]
      },
      {
        "ProgramID": 30816,
        "ProgramName": "Good Days: Chronic Myeloid Leukemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Myeloid Leukemia (CML)"
        ],
        "Drugs": [
          "Gleevec",
          "Iclusig",
          "Sprycel",
          "Tasigna",
          "Cyclophosphamide",
          "Imatinib"
        ]
      },
      {
        "ProgramID": 30774,
        "ProgramName": "Good Days: Chronic Noninfectious Uveitis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Uveitis"
        ],
        "Drugs": [
          "Humira",
          "Ozurdex",
          "Rayos",
          "Triesence",
          "Retisert",
          "Cyltezo",
          "Yutiq",
          "Hyrimoz",
          "Hulio",
          "Abrilada",
          "Amjevita",
          "Xipere",
          "Hadlima",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Simlandi"
        ]
      },
      {
        "ProgramID": 31061,
        "ProgramName": "Good Days: Cytomegalovirus Retinitis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Cytomegalovirus Retinitis"
        ],
        "Drugs": [
          "Valcyte"
        ]
      },
      {
        "ProgramID": 30402,
        "ProgramName": "Good Days: Hepatitis C",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hepatitis C"
        ],
        "Drugs": [
          "Harvoni",
          "Pegasys",
          "Sovaldi",
          "Ribavirin",
          "Zepatier",
          "Epclusa",
          "Peginterferon Alfa-2A",
          "Vosevi",
          "Mavyret",
          "Peginterferon Alfa-2B"
        ]
      },
      {
        "ProgramID": 30705,
        "ProgramName": "Good Days: HIV, AIDS Treatment & Prevention",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "HIV Infection",
          "HIV/AIDS - Supportive",
          "HIV-1 Integrase Strand Transfer Inhibitor (INSTI)",
          "HIV-1 Pre-Exposure Prophylaxis (PrEP)"
        ],
        "Drugs": [
          "Atripla",
          "Complera",
          "Edurant",
          "Emtriva",
          "Epivir",
          "Evotaz",
          "Fuzeon",
          "Intelence",
          "Isentress",
          "Kaletra",
          "Norvir",
          "Prezcobix",
          "Prezista",
          "Retrovir",
          "Reyataz",
          "Selzentry",
          "Stribild",
          "Tivicay",
          "Triumeq",
          "Truvada",
          "Tybost",
          "Viracept",
          "Viread",
          "Ziagen",
          "Aptivus",
          "Lamivudine & Zidovudine",
          "Didanosine",
          "Lamivudine",
          "Nevirapine",
          "Nevirapine ER",
          "Stavudine",
          "Zidovudine",
          "Genvoya",
          "Odefsey",
          "Descovy",
          "Juluca",
          "Biktarvy",
          "Trogarzo",
          "Symtuza",
          "Pifeltro",
          "Delstrigo",
          "Cimduo",
          "Symfi Lo",
          "Dovato",
          "Tenofovir Disoproxil",
          "Tivicay PD",
          "Rukobia",
          "Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Efavirenz & Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Cabenuva",
          "Apretude",
          "Symfi",
          "Triumeq PD",
          "Lopinavir & Ritonavir",
          "Maraviroc",
          "Efavirenz & Lamivudine & Tenofovir Disoproxil Fumarate",
          "Efavirenz",
          "Fosamprenavir Calcium",
          "Isentress HD",
          "Abacavir",
          "Ritonavir",
          "Abacavir & Lamivudine",
          "Abacavir & Lamivudine & Zidovudine",
          "Darunavir"
        ]
      },
      {
        "ProgramID": 30225,
        "ProgramName": "Good Days: Hodgkin's Lymphoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Hodgkin's Lymphoma"
        ],
        "Drugs": [
          "Adcetris",
          "Doxil",
          "Keytruda",
          "Opdivo",
          "Rayos",
          "Valchlor",
          "Leukeran",
          "Vinblastine Sulfate",
          "Matulane",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Gleostine",
          "Vincristine Sulfate"
        ]
      },
      {
        "ProgramID": 30226,
        "ProgramName": "Good Days: Liver Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Liver",
          "Oncology - Hepatocellular Carcinoma (HCC)"
        ],
        "Drugs": [
          "Avastin",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Stivarga",
          "Yervoy",
          "Mitomycin",
          "Cabometyx",
          "Tecentriq",
          "Mvasi",
          "Sorafenib Tosylate",
          "Vitrakvi",
          "Zirabev",
          "Keytruda & Lenvima",
          "Alymsys",
          "Vegzelma",
          "Tecentriq & Avastin"
        ]
      },
      {
        "ProgramID": 30227,
        "ProgramName": "Good Days: Macular Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Diabetic Macular Edema",
          "Ophthalmic - Diabetic Retinopathy",
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD",
          "Ophthalmic - Macular Edema Following Retinal Vein Occlusion",
          "Ophthalmic - Vitreomacular Adhesion",
          "Ophthalmic - Macular Edema",
          "Ophthalmic - Myopic Choroidal Neovascularization"
        ],
        "Drugs": [
          "Lucentis",
          "Ozurdex",
          "Iluvien",
          "Visudyne",
          "Eylea",
          "Beovu",
          "Byooviz",
          "Susvimo",
          "Vabysmo",
          "Xipere",
          "Cimerli",
          "Eylea HD",
          "Pavblu",
          "Syfovre",
          "Izervay"
        ]
      },
      {
        "ProgramID": 30228,
        "ProgramName": "Good Days: Medullary Thyroid Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Thyroid"
        ],
        "Drugs": [
          "Caprelsa",
          "Cometriq",
          "Keytruda",
          "Vitrakvi"
        ]
      },
      {
        "ProgramID": 30148,
        "ProgramName": "Good Days: Metastatic Breast Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Doxil",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Perjeta",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Letrozole",
          "Capecitabine",
          "Docetaxel",
          "Everolimus",
          "Kisqali",
          "Gemcitabine",
          "Verzenio",
          "Ogivri",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Herceptin Hylecta",
          "Lapatinib Ditosylate",
          "Fulvestrant",
          "Paclitaxel Protein-Bound",
          "Orserdu",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30153,
        "ProgramName": "Good Days: Metastatic Castrate Resistant Prostate Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
        ],
        "Drugs": [
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Provenge",
          "Taxotere",
          "Xofigo",
          "Xtandi",
          "Zytiga",
          "Docetaxel",
          "Yonsa",
          "Vitrakvi",
          "Abiraterone Acetate",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30229,
        "ProgramName": "Good Days: Metastatic Colorectal Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Metastatic Colorectal Cancer (mCRC)"
        ],
        "Drugs": [
          "Avastin",
          "Camptosar",
          "Cyramza",
          "Erbitux",
          "Keytruda",
          "Opdivo",
          "Stivarga",
          "Vectibix",
          "Xeloda",
          "Yervoy",
          "Zaltrap",
          "Lonsurf",
          "Capecitabine",
          "Fluorouracil",
          "Irinotecan",
          "Mvasi",
          "Zirabev",
          "Alymsys",
          "Vegzelma",
          "Fruzaqla",
          "Opdivo & Yervoy"
        ]
      },
      {
        "ProgramID": 30230,
        "ProgramName": "Good Days: Metastatic Melanoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Melanoma"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Proleukin",
          "Tafinlar",
          "Yervoy",
          "Zelboraf",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Braftovi",
          "Vitrakvi",
          "Mektovi",
          "Braftovi & Mektovi",
          "Opdualag",
          "Tafinlar & Mekinist"
        ]
      },
      {
        "ProgramID": 30231,
        "ProgramName": "Good Days: Multiple Myeloma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma"
        ],
        "Drugs": [
          "Doxil",
          "Kyprolis",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Thalomid",
          "Velcade",
          "Cyclophosphamide",
          "Darzalex",
          "Ninlaro",
          "Empliciti",
          "Evomela",
          "Xpovio",
          "Bortezomib",
          "Kimmtrak",
          "Lenalidomide",
          "Talvey",
          "Elrexfio",
          "Kyprolis & Darzalex"
        ]
      },
      {
        "ProgramID": 30232,
        "ProgramName": "Good Days: Multiple Sclerosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Multiple Sclerosis (MS)"
        ],
        "Drugs": [
          "Ampyra",
          "Aubagio",
          "Avonex",
          "Betaseron",
          "Copaxone",
          "Gilenya",
          "Lemtrada",
          "Plegridy",
          "Rebif",
          "Tecfidera",
          "Tysabri",
          "Glatopa",
          "Ocrevus",
          "Avonex Pen",
          "Glatiramer Acetate",
          "Rebif Rebidose",
          "Dalfampridine",
          "Mayzent",
          "Vumerity",
          "Dimethyl Fumarate",
          "Fingolimod",
          "Dimethyl Fumarate DR",
          "Teriflunomide"
        ]
      },
      {
        "ProgramID": 30233,
        "ProgramName": "Good Days: Myelodysplastic Syndrome (MDS)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)"
        ],
        "Drugs": [
          "Gleevec",
          "Revlimid",
          "Vidaza",
          "Dacogen",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Onureg",
          "Lenalidomide"
        ]
      },
      {
        "ProgramID": 30235,
        "ProgramName": "Good Days: Nephropathic Cystinosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Nephropathic Cystinosis"
        ],
        "Drugs": [
          "Procysbi",
          "Cystaran",
          "Cystagon",
          "Cystadrops"
        ]
      },
      {
        "ProgramID": 31053,
        "ProgramName": "Good Days: Neuromyelitis Optica Spectrum Disorder",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
        ],
        "Drugs": [
          "Soliris",
          "Uplizna",
          "Enspryng"
        ]
      },
      {
        "ProgramID": 30151,
        "ProgramName": "Good Days: Non-Small Cell Lung Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Cyramza",
          "Gilotrif",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Tarceva",
          "Taxotere",
          "Xalkori",
          "Zykadia",
          "Iressa",
          "Trexall",
          "Methotrexate",
          "Docetaxel",
          "Tagrisso",
          "Alecensa",
          "Portrazza",
          "Tecentriq",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Pemfexy",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Mektovi",
          "Zirabev",
          "Rozlytrek",
          "Tabrecta",
          "Retevmo",
          "Gavreto",
          "Rybrevant",
          "Lumakras",
          "Tepmetko",
          "Alymsys",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Krazati",
          "Gefitinib",
          "Augtyro",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30236,
        "ProgramName": "Good Days: Pancreatic Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Pancreatic"
        ],
        "Drugs": [
          "Abraxane",
          "Keytruda",
          "Lynparza",
          "Tarceva",
          "Mitomycin",
          "Onivyde",
          "Fluorouracil",
          "Gemcitabine",
          "Erlotinib Hydrochloride",
          "Vitrakvi",
          "Paclitaxel Protein-Bound"
        ]
      },
      {
        "ProgramID": 30238,
        "ProgramName": "Good Days: Pulmonary Arterial Hypertension",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pulmonary Arterial Hypertension (PAH)"
        ],
        "Drugs": [
          "Adcirca",
          "Adempas",
          "Letairis",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tracleer",
          "Tyvaso",
          "Veletri",
          "Ventavis",
          "Flolan",
          "Sildenafil",
          "Uptravi",
          "Epoprostenol Sodium",
          "Tadalafil",
          "Ambrisentan",
          "Treprostinil",
          "Bosentan",
          "Tadliq",
          "Liqrev",
          "Opsynvi",
          "Winrevair"
        ]
      },
      {
        "ProgramID": 30409,
        "ProgramName": "Good Days: Retinal Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Diabetic Retinopathy",
          "Ophthalmic - Macular Edema Following Retinal Vein Occlusion",
          "Ophthalmic - Retinal Vein Occlusion",
          "Ophthalmic - Macular Edema",
          "Ophthalmic - Inherited Retinal Disease"
        ],
        "Drugs": [
          "Lucentis",
          "Eylea",
          "Cimerli",
          "Eylea HD",
          "Pavblu",
          "Ozurdex",
          "Byooviz",
          "Vabysmo"
        ]
      },
      {
        "ProgramID": 30763,
        "ProgramName": "Good Days: Spinal Muscular Atrophy",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Spinal Muscular Atrophy (SMA)"
        ],
        "Drugs": [
          "Spinraza",
          "Zolgensma",
          "Evrysdi"
        ]
      },
      {
        "ProgramID": 30243,
        "ProgramName": "Good Days: Urea Cycle Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)",
          "Hyperammonemia"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva"
        ]
      },
      {
        "ProgramID": 30645,
        "ProgramName": "HealthWell: Acromegaly",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acromegaly"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Somavert",
          "Signifor LAR",
          "Octreotide Acetate",
          "Sandostatin",
          "Mycapssa",
          "Lanreotide Acetate"
        ]
      },
      {
        "ProgramID": 30620,
        "ProgramName": "HealthWell: Acute Myeloid Leukemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Acute Myeloid Leukemia (AML)"
        ],
        "Drugs": [
          "Jakafi",
          "Nexavar",
          "Otrexup",
          "Ozurdex",
          "Rasuvo",
          "Vidaza",
          "Cytarabine",
          "Mitoxantrone",
          "Trexall",
          "Methotrexate",
          "Zarxio",
          "Dacogen",
          "Cyclophosphamide",
          "Mylotarg",
          "Venclexta",
          "Decitabine",
          "Cladribine",
          "Azacitidine",
          "Clofarabine",
          "Clolar",
          "Etoposide Phosphate",
          "Rydapt",
          "IDHIFA",
          "Vyxeos",
          "Fludarabine Phosphate",
          "Tibsovo",
          "Nivestym",
          "Daurismo",
          "Xospata",
          "Ayvakit",
          "Tabloid",
          "Onureg",
          "Rezlidhia",
          "Vanflyta"
        ]
      },
      {
        "ProgramID": 30838,
        "ProgramName": "HealthWell: Adrenal Insufficiency",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Adrenal Insufficiency"
        ],
        "Drugs": [
          "Rayos",
          "Triesence",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate"
        ]
      },
      {
        "ProgramID": 30749,
        "ProgramName": "HealthWell: Amyloidosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Amyloidosis"
        ],
        "Drugs": [
          "Ozurdex",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Velcade",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Evomela",
          "Melphalan",
          "Onpattro",
          "Vyndaqel",
          "Vyndamax",
          "Darzalex Faspro",
          "Bortezomib",
          "Lenalidomide",
          "Amvuttra",
          "Wainua"
        ]
      },
      {
        "ProgramID": 30576,
        "ProgramName": "HealthWell: Amyotrophic Lateral Sclerosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Amyotrophic Lateral Sclerosis (ALS)"
        ],
        "Drugs": [
          "Botox",
          "Recombinate",
          "Increlex",
          "Rilutek",
          "Radicava IV",
          "Tiglutik",
          "Exservan",
          "Radicava ORS",
          "Qalsody"
        ]
      },
      {
        "ProgramID": 30178,
        "ProgramName": "HealthWell: ANCA-Associated Vasculitis and Granulomatosis with Polyangiitis (formerly Wegeners)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Granulomatosis with Polyangiitis (GPA)"
        ],
        "Drugs": [
          "Gengraf",
          "Rituxan",
          "Leukeran",
          "Cyclophosphamide",
          "Nucala",
          "Cyclosporine",
          "Etoposide Phosphate",
          "Rituxan Hycela",
          "Infliximab",
          "Truxima",
          "Ruxience",
          "Riabni",
          "Rituximab",
          "Tavneos",
          "Rituximab-pvvr"
        ]
      },
      {
        "ProgramID": 30194,
        "ProgramName": "HealthWell: Asthma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Asthma",
          "Severe Asthma",
          "Severe Eosinophilic Asthma"
        ],
        "Drugs": [
          "Rayos",
          "Xolair",
          "Methotrexate",
          "Nucala",
          "Cinqair",
          "Dupixent",
          "Fasenra",
          "Tezspire",
          "Zyflo",
          "Immune Globulin Intravenous (IGIV)",
          "Ketamine Hydrochloride",
          "Dupixent Pen",
          "Fasenra Pen",
          "Airsupra"
        ]
      },
      {
        "ProgramID": 30653,
        "ProgramName": "HealthWell: AutoImmune - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ankylosing Spondylitis",
          "Dermatology - Psoriasis / Plaque Psoriasis",
          "Psoriatic Arthritis",
          "Rheumatoid Arthritis (RA)"
        ],
        "Drugs": [
          "Actemra",
          "Astagraf XL",
          "CellCept",
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Gengraf",
          "Humira",
          "Kineret",
          "Myfortic",
          "Neoral",
          "Ofev",
          "Orencia",
          "Otezla",
          "Otrexup",
          "Ozurdex",
          "Prograf",
          "Rasuvo",
          "Rayos",
          "Remicade",
          "Rituxan",
          "Sandimmune",
          "Simponi",
          "Simponi ARIA",
          "Stelara",
          "Targretin",
          "Xeljanz",
          "Leukeran",
          "Trexall",
          "Methotrexate",
          "Arestin",
          "Enstilar",
          "Adalimumab-afzb",
          "Cyclophosphamide",
          "Cuprimine",
          "Depen",
          "Envarsus XR",
          "Taltz",
          "Inflectra",
          "Mycophenolate Mofetil",
          "Siliq",
          "Cyclosporine",
          "Renflexis",
          "Kevzara",
          "Rituxan Hycela",
          "Tremfya",
          "Olumiant",
          "Skyrizi",
          "Tacrolimus",
          "Rinvoq",
          "Avsola",
          "Tabloid",
          "Ruxience",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Infliximab-qbtx",
          "Orencia Clickject",
          "Idacio",
          "Yuflyma",
          "Rinvoq LQ",
          "Vtama",
          "Spevigo",
          "Zoryve",
          "Wezlana",
          "Ebglyss",
          "Truxima",
          "Rituximab",
          "Zyflo",
          "Penicillamine",
          "Rituximab-pvvr",
          "Actemra Actpen",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30820,
        "ProgramName": "HealthWell: B-Cell Lymphoma - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - B-Cell Lymphoma",
          "Oncology - Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
          "Oncology - Diffuse Large B-cell  Lymphoma (DLBCL)"
        ],
        "Drugs": [
          "Actemra",
          "Adcetris",
          "Arzerra",
          "Doxil",
          "Gazyva",
          "Imbruvica",
          "Keytruda",
          "Kineret",
          "Opdivo",
          "Otrexup",
          "Ozurdex",
          "Rasuvo",
          "Rayos",
          "Retrovir",
          "Revlimid",
          "Rituxan",
          "Sylvant",
          "Thalomid",
          "Treanda",
          "Valcyte",
          "Velcade",
          "Zevalin",
          "Zydelig",
          "Paraplatin",
          "Leukeran",
          "Cytarabine",
          "Mitoxantrone",
          "Vinblastine Sulfate",
          "Matulane",
          "Cyclophosphamide",
          "Bendeka",
          "Venclexta",
          "Bendamustine",
          "Vincristine Sulfate",
          "Rituxan Hycela",
          "Kymriah",
          "Yescarta",
          "Calquence",
          "Copiktra",
          "Khapzory",
          "Truxima",
          "Polivy",
          "Belrapzo",
          "Xpovio",
          "Brukinsa",
          "Ruxience",
          "Monjuvi",
          "Tazverik",
          "Riabni",
          "Zynlonta",
          "Rituximab",
          "Breyanzi",
          "Levoleucovorin",
          "Venclexta Starting Pack",
          "Actemra Actpen",
          "Epkinly",
          "Columvi",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30611,
        "ProgramName": "HealthWell: Bladder and Urothelial Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bladder"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Carac",
          "Ellence",
          "Keytruda",
          "Opdivo",
          "Otrexup",
          "Rasuvo",
          "Taxotere",
          "Xeloda",
          "Mitomycin",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Trexall",
          "Methotrexate",
          "Valstar",
          "Fluorouracil",
          "Photofrin",
          "Docetaxel",
          "Tecentriq",
          "Bavencio",
          "Gemcitabine",
          "Imfinzi",
          "Tepadina",
          "Thiotepa",
          "Balversa",
          "Padcev",
          "Jelmyto",
          "Paclitaxel Protein-Bound"
        ]
      },
      {
        "ProgramID": 31045,
        "ProgramName": "HealthWell: Blepharitis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Blepharitis"
        ],
        "Drugs": [
          "Xdemvy"
        ]
      },
      {
        "ProgramID": 30195,
        "ProgramName": "HealthWell: Bone Metastases - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bone"
        ],
        "Drugs": [
          "Prolia",
          "Xgeva",
          "Xofigo",
          "Zometa",
          "Reclast",
          "Zoledronic Acid",
          "Miacalcin"
        ]
      },
      {
        "ProgramID": 30168,
        "ProgramName": "HealthWell: Breast Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Alimta",
          "Arimidex",
          "Avastin",
          "Doxil",
          "Eligard",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Otrexup",
          "Perjeta",
          "Prolia",
          "Taxotere",
          "Trelstar",
          "Tykerb",
          "Xeloda",
          "Xgeva",
          "Zoladex",
          "Zometa",
          "Zortress",
          "Letrozole",
          "Paraplatin",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Trexall",
          "Methotrexate",
          "Docetaxel",
          "Cyclophosphamide",
          "Alkeran",
          "Leuprolide Acetate",
          "Tecentriq",
          "Everolimus",
          "Vinorelbine Tartrate",
          "Kisqali",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Mvasi",
          "Verzenio",
          "Ogivri",
          "Bevacizumab",
          "Talzenna",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Zirabev",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Phesgo",
          "Margenza",
          "Fulvestrant",
          "Vijoice",
          "Bevacizumab-awwb",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Orserdu",
          "Truqap",
          "Itovebi"
        ]
      },
      {
        "ProgramID": 30888,
        "ProgramName": "HealthWell: Cancer-Related Behavioral Health",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Behavioral Health - Anxiety Disorders",
          "Behavioral Health - Bipolar Disorder",
          "Behavioral Health - Depression",
          "Behavioral Health - Schizophrenia",
          "Behavioral Health - Major Depressive Disorder (MDD)",
          "Neurocognitive Disease with Psychosis"
        ],
        "Drugs": [
          "Rexulti",
          "Aristada",
          "Abilify Maintena",
          "Spravato",
          "Zyprexa Relprevv",
          "Invega Sustenna",
          "Invega Trinza",
          "Aplenzin",
          "Zyprexa Zydis",
          "Invega Hafyera",
          "Letrozole"
        ]
      },
      {
        "ProgramID": 30313,
        "ProgramName": "HealthWell: Carcinoid Tumors and Associated Symptoms - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Carcinoid Tumors and Associated Symptoms"
        ],
        "Drugs": [
          "Afinitor",
          "Carac",
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Sutent",
          "Temodar",
          "Torisel",
          "Xeloda",
          "Zortress",
          "Paraplatin",
          "Everolimus",
          "Afinitor Disperz",
          "Xermelo",
          "Sandostatin",
          "Lutathera",
          "VP-16"
        ]
      },
      {
        "ProgramID": 30889,
        "ProgramName": "HealthWell: Cardiomyopathy - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cardiomyopathy",
          "Obstructive Hypertrophic Cardiomyopathy (HCM)"
        ],
        "Drugs": [
          "Farxiga",
          "Onpattro",
          "Vyndaqel",
          "Vyndamax",
          "Camzyos",
          "Amvuttra",
          "Jardiance",
          "Wainua",
          "Attruby"
        ]
      },
      {
        "ProgramID": 30615,
        "ProgramName": "HealthWell: Chemotherapy Induced Nausea or Vomiting - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Nausea & Vomiting Associated with Chemotherapy & Radiation"
        ],
        "Drugs": [
          "Emend Capsules",
          "Emend for Injection",
          "Syndros",
          "Sustol",
          "Emend for Oral Suspension",
          "Cinvanti",
          "Nivestym",
          "Zyprexa Relprevv",
          "Zyprexa Zydis",
          "Akynzeo (Injection)"
        ]
      },
      {
        "ProgramID": 30196,
        "ProgramName": "HealthWell: Chemotherapy Induced Neutropenia - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neutropenia"
        ],
        "Drugs": [
          "Neulasta",
          "Neupogen",
          "Vidaza",
          "Granix",
          "Zarxio",
          "Leukine",
          "Mozobil",
          "Filgrastim",
          "Fulphila",
          "Nivestym",
          "Udenyca",
          "Ziextenzo",
          "Nyvepria",
          "Neulasta Onpro",
          "Pegfilgrastim-bmez",
          "Filgrastim-sndz",
          "Noxafil Oral Suspension",
          "Noxafil Tablets",
          "Udenyca Autoinjector",
          "Udenyca Onbody"
        ]
      },
      {
        "ProgramID": 30792,
        "ProgramName": "HealthWell: Chronic Heart Failure - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Heart Failure"
        ],
        "Drugs": [
          "Farxiga",
          "Jardiance"
        ]
      },
      {
        "ProgramID": 30726,
        "ProgramName": "HealthWell: Chronic Lymphocytic Leukemia - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Lymphocytic Leukemia (CLL)"
        ],
        "Drugs": [
          "Arranon",
          "Arzerra",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gazyva",
          "Hizentra",
          "Imbruvica",
          "Keytruda",
          "Lemtrada",
          "Opdivo",
          "Otrexup",
          "Rasuvo",
          "Revlimid",
          "Rituxan",
          "Treanda",
          "Valchlor",
          "Zydelig",
          "Leukeran",
          "Cytarabine",
          "HyQvia",
          "Privigen",
          "Mitoxantrone",
          "Nipent",
          "Octagam",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Bendeka",
          "Elitek",
          "Venclexta",
          "Cladribine",
          "Bendamustine",
          "Etoposide Phosphate",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Copiktra",
          "Truxima",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "Immune Globulin Intravenous (IGIV)",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Imbruvica & Gazyva",
          "Rituximab-pvvr",
          "Jaypirca"
        ]
      },
      {
        "ProgramID": 30197,
        "ProgramName": "HealthWell: Chronic Myeloid Leukemia - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Myeloid Leukemia (CML)"
        ],
        "Drugs": [
          "Bosulif",
          "Gleevec",
          "Iclusig",
          "Pegasys",
          "Sprycel",
          "Tasigna",
          "Vidaza",
          "Cytarabine",
          "Mitoxantrone",
          "Methotrexate",
          "Dacogen",
          "Cyclophosphamide",
          "Busulfex",
          "Decitabine",
          "Cladribine",
          "Azacitidine",
          "Myleran",
          "Vincristine Sulfate",
          "Imatinib",
          "Melphalan",
          "Scemblix",
          "Peginterferon Alfa-2B"
        ]
      },
      {
        "ProgramID": 31063,
        "ProgramName": "HealthWell: Chronic Obstructive Pulmonary Disease - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "Drugs": [
          "Ozurdex",
          "Prolastin-C",
          "Rayos",
          "Zemaira",
          "Dupixent",
          "Yupelri",
          "Aralast NP",
          "Dupixent Pen",
          "Zoryve"
        ]
      },
      {
        "ProgramID": 30198,
        "ProgramName": "HealthWell: Colorectal Carcinoma - Medicare Access: RE-ENROLLMENT ONLY",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Mismatch Repair-Deficient Colorectal Cancer (CRC)",
          "Oncology - Metastatic Colorectal Cancer (mCRC)"
        ],
        "Drugs": [
          "Alimta",
          "Avastin",
          "Camptosar",
          "Cyramza",
          "Erbitux",
          "Keytruda",
          "Opdivo",
          "Stivarga",
          "Sutent",
          "Vectibix",
          "Xeloda",
          "Zaltrap",
          "Mitomycin",
          "Paraplatin",
          "Lonsurf",
          "Capecitabine",
          "Fluorouracil",
          "Floxuridine",
          "Irinotecan",
          "BiCNU",
          "Cyclophosphamide",
          "Mutamycin",
          "Vincasar PFS",
          "Ethyol",
          "Mvasi",
          "Bevacizumab",
          "Braftovi",
          "Khapzory",
          "Zirabev",
          "Levoleucovorin",
          "Alymsys",
          "Bevacizumab-awwb",
          "Vegzelma",
          "Krazati",
          "Fruzaqla"
        ]
      },
      {
        "ProgramID": 30710,
        "ProgramName": "HealthWell: Congenital Sucrase-Isomaltase Deficiency",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Congenital Sucrase Isomaltase Deficiency (CSID)"
        ],
        "Drugs": [
          "Sucraid"
        ]
      },
      {
        "ProgramID": 30804,
        "ProgramName": "HealthWell: Cushing's Disease or Cushing's Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cushing’s Disease"
        ],
        "Drugs": [
          "Signifor",
          "Korlym",
          "Lysodren",
          "Metopirone",
          "Signifor LAR",
          "Isturisa",
          "Recorlev"
        ]
      },
      {
        "ProgramID": 30353,
        "ProgramName": "HealthWell: Cystic Fibrosis Treatments",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cystic Fibrosis"
        ],
        "Drugs": [
          "Bethkis",
          "Cayston",
          "Creon",
          "Kalydeco",
          "Pancreaze",
          "Pertzye",
          "Pulmozyme",
          "Tobi Podhaler",
          "Zenpep",
          "Orkambi",
          "Avycaz",
          "Kitabis Pak",
          "Vancomycin",
          "Vancocin",
          "Tobramycin",
          "Tobramycin Inhalation Solution",
          "Symdeko",
          "Arikayce",
          "Trikafta",
          "Bronchitol"
        ]
      },
      {
        "ProgramID": 30182,
        "ProgramName": "HealthWell: Cytomegalovirus Disease - Prevention and Treatment",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Cytomegalovirus (CMV) Disease"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Valcyte",
          "Gammagard S/D",
          "Bivigam",
          "CytoGam",
          "Prevymis",
          "Livtencity",
          "Immune Globulin Intravenous (IGIV)"
        ]
      },
      {
        "ProgramID": 30621,
        "ProgramName": "HealthWell: Diabetic Foot Ulcers",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Diabetic Foot Ulcers"
        ],
        "Drugs": [
          "Cayston",
          "Monovisc",
          "Orthovisc",
          "Regranex",
          "Vancomycin",
          "Vancocin",
          "Hymovis",
          "Epifix"
        ]
      },
      {
        "ProgramID": 30183,
        "ProgramName": "HealthWell: Dupuytren's Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Dupuytren’s Contracture"
        ],
        "Drugs": [
          "Xiaflex",
          "Fluorouracil"
        ]
      },
      {
        "ProgramID": 30840,
        "ProgramName": "HealthWell: Emergency/Medical Workers Behavioral Health Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Behavioral Health - Anxiety Disorders",
          "Behavioral Health - Depression",
          "Behavioral Health - Major Depressive Disorder (MDD)"
        ],
        "Drugs": [
          "Rexulti",
          "Aristada",
          "Abilify Maintena",
          "Spravato",
          "Zyprexa Relprevv",
          "Aplenzin",
          "Zyprexa Zydis"
        ]
      },
      {
        "ProgramID": 30503,
        "ProgramName": "HealthWell: Fungal Infections-Aspergillosis and Candidiasis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Fungal Infections",
          "Oropharyngeal Candidiasis",
          "Invasive Aspergillosis",
          "Candidemia"
        ],
        "Drugs": [
          "Cresemba",
          "Tolsura",
          "Noxafil Oral Suspension",
          "Noxafil Tablets"
        ]
      },
      {
        "ProgramID": 30687,
        "ProgramName": "HealthWell: Gastric Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Gastric"
        ],
        "Drugs": [
          "Alimta",
          "Camptosar",
          "Carac",
          "Cyramza",
          "Ellence",
          "Herceptin",
          "Keytruda",
          "Opdivo",
          "Taxotere",
          "Xeloda",
          "Mitomycin",
          "Lonsurf",
          "Capecitabine",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Mutamycin",
          "Pemetrexed",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Enhertu",
          "Levoleucovorin",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Paclitaxel Protein-Bound"
        ]
      },
      {
        "ProgramID": 30612,
        "ProgramName": "HealthWell: Giant Cell Arteritis or Temporal Arteritis - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Giant Cell Arteritis (Temporal Arteritis)"
        ],
        "Drugs": [
          "Actemra",
          "Arzerra",
          "Ozurdex",
          "Rayos",
          "Triesence",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Actemra Actpen",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30200,
        "ProgramName": "HealthWell: Glioblastoma Multiforme/Anaplastic Astrocytoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Astrocytoma",
          "Oncology - Glioblastoma",
          "Oncology - Tuberous Sclerosis-Related Subependymal Giant Cell Astrocytoma (SEGA)"
        ],
        "Drugs": [
          "Avastin",
          "Temodar",
          "BiCNU",
          "Cyclophosphamide",
          "Gliadel Wafer",
          "Gleostine",
          "Bevacizumab",
          "Zirabev",
          "Bevacizumab-awwb",
          "Voranigo",
          "Camptosar",
          "Torisel",
          "Paraplatin",
          "Matulane",
          "Irinotecan",
          "Vincasar PFS",
          "Etoposide Phosphate"
        ]
      },
      {
        "ProgramID": 30184,
        "ProgramName": "HealthWell: Gout - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Gout"
        ],
        "Drugs": [
          "Krystexxa",
          "Purified Cortrophin Gel"
        ]
      },
      {
        "ProgramID": 30452,
        "ProgramName": "HealthWell: Gout Travel Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gout"
        ],
        "Drugs": [
          "Krystexxa"
        ]
      },
      {
        "ProgramID": 30201,
        "ProgramName": "HealthWell: Growth Hormone Deficiency",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Growth Hormone Deficiency",
          "Pediatric Growth Hormone Deficiency"
        ],
        "Drugs": [
          "Eligard",
          "Genotropin",
          "Humatrope",
          "Lupron Depot",
          "Omnitrope",
          "Serostim",
          "Zomacton",
          "Genotropin Miniquick",
          "Nutropin AQ Nuspin",
          "Norditropin Flexpro",
          "Sogroya",
          "Skytrofa"
        ]
      },
      {
        "ProgramID": 30202,
        "ProgramName": "HealthWell: Head and Neck Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Head and Neck"
        ],
        "Drugs": [
          "Abraxane",
          "Erbitux",
          "Gleevec",
          "Keytruda",
          "Opdivo",
          "Tarceva",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Mitomycin",
          "Capecitabine",
          "Mitoxantrone",
          "Trexall",
          "Methotrexate",
          "Fluorouracil",
          "Docetaxel",
          "Ethyol",
          "Decitabine",
          "Bleomycin",
          "Vincristine Sulfate",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Paclitaxel Protein-Bound"
        ]
      },
      {
        "ProgramID": 30127,
        "ProgramName": "HealthWell: Hepatitis C",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hepatitis C"
        ],
        "Drugs": [
          "Avonex",
          "Epogen",
          "Harvoni",
          "Pegasys",
          "Procrit",
          "Promacta",
          "Rebif",
          "Sovaldi",
          "Ribavirin",
          "Zepatier",
          "Epclusa",
          "Alferon N",
          "Avonex Pen",
          "Vosevi",
          "Mavyret",
          "Virazole",
          "Retacrit",
          "Sofosbuvir & Velpatasvir",
          "Ledipasvir & Sofosbuvir"
        ]
      },
      {
        "ProgramID": 30736,
        "ProgramName": "HealthWell: Hepatocellular Carcinoma - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Hepatocellular Carcinoma (HCC)"
        ],
        "Drugs": [
          "Avastin",
          "Carac",
          "Cometriq",
          "Cyramza",
          "Ellence",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Stivarga",
          "Mitoxantrone",
          "Fluorouracil",
          "Floxuridine",
          "Cabometyx",
          "Imfinzi",
          "Khapzory",
          "Keytruda & Lenvima",
          "Imjudo",
          "Imfinzi & Imjudo",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30578,
        "ProgramName": "HealthWell: Homocystinuria and Organic Acidemias",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Homocystinuria"
        ],
        "Drugs": [
          "Xifaxan",
          "Carbaglu",
          "Cystadane",
          "Buphenyl",
          "Ammonul"
        ]
      },
      {
        "ProgramID": 30614,
        "ProgramName": "HealthWell: Huntington's Disease - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Huntington's Disease"
        ],
        "Drugs": [
          "Xenazine",
          "Rilutek",
          "Austedo",
          "Tetrabenazine"
        ]
      },
      {
        "ProgramID": 30793,
        "ProgramName": "HealthWell: Hypercholesterolemia - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypercholesterolemia",
          "Homozygous Familial Hypercholesterolemia (HoFH)",
          "Heterozygous Familial Hypercholesterolemia (HeFH)"
        ],
        "Drugs": [
          "Juxtapid",
          "Repatha",
          "Praluent",
          "Evkeeza",
          "Leqvio",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30830,
        "ProgramName": "HealthWell: Hyperoxaluria",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hyperoxaluria"
        ],
        "Drugs": [
          "Oxlumo",
          "Rivfloza"
        ]
      },
      {
        "ProgramID": 30203,
        "ProgramName": "HealthWell: Idiopathic Thrombocytopenic Purpura",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Immune Thrombocytopenic Purpura (ITP)"
        ],
        "Drugs": [
          "CellCept",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gengraf",
          "Neoral",
          "Nplate",
          "Promacta",
          "Rituxan",
          "Sandimmune",
          "Leukeran",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Gammaked",
          "Cyclophosphamide",
          "Vincasar PFS",
          "RhoGAM Ultra-Filtered PLUS",
          "Vincristine Sulfate",
          "Cyclosporine",
          "Rituxan Hycela",
          "Rhophylac",
          "Tavalisse",
          "Doptelet",
          "Truxima",
          "Ruxience",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "HyperRHO S/D",
          "Panzyga",
          "WinRho SDF"
        ]
      },
      {
        "ProgramID": 31009,
        "ProgramName": "HealthWell: IgA Nephropathy",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Primary Immunoglobulin A Nephropathy (IgAN)",
          "IgA Nephropathy"
        ],
        "Drugs": [
          "Rayos",
          "Tarpeyo",
          "Fabhalta"
        ]
      },
      {
        "ProgramID": 30204,
        "ProgramName": "HealthWell: Immunosuppressive Treatment for Solid Organ Transplant Recipients - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Transplant Rejection",
          "Organ Transplantation",
          "Kidney Transplant"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Gengraf",
          "Myfortic",
          "Neoral",
          "Nulojix",
          "Prograf",
          "Rayos",
          "Sandimmune",
          "Zortress",
          "Thymoglobulin",
          "Simulect",
          "Atgam",
          "Envarsus XR",
          "Mycophenolate Mofetil",
          "Everolimus",
          "Cyclosporine",
          "Tacrolimus"
        ]
      },
      {
        "ProgramID": 30205,
        "ProgramName": "HealthWell: Inflammatory Bowel Disease - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "IBD - Crohn's Disease",
          "Inflammatory Bowel Disease (IBD)",
          "IBD - Ulcerative Colitis"
        ],
        "Drugs": [
          "Cimzia",
          "Enbrel",
          "Entyvio",
          "Gengraf",
          "Humira",
          "Neoral",
          "Remicade",
          "Sandimmune",
          "Simponi",
          "Stelara",
          "Thalomid",
          "Tysabri",
          "Xeljanz",
          "Xifaxan",
          "Purixan",
          "Trexall",
          "Leukine",
          "Adalimumab-afzb",
          "Viberzi",
          "Dipentum",
          "Gastrocrom",
          "Rowasa",
          "Inflectra",
          "Leuprolide Acetate",
          "Cyclosporine",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Etanercept",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Yuflyma",
          "Tyruko",
          "Wezlana",
          "Entyvio Pen",
          "Rinvoq LQ",
          "Tremfya"
        ]
      },
      {
        "ProgramID": 30794,
        "ProgramName": "HealthWell: Lambert-Eaton Myasthenic Syndrome",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Lambert-Eaton Myasthenic Syndrome (LEMS)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Rayos",
          "Flebogamma DIF",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaplex",
          "Firdapse",
          "Asceniv",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga"
        ]
      },
      {
        "ProgramID": 30207,
        "ProgramName": "HealthWell: Macular Degeneration (Wet and Dry)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD"
        ],
        "Drugs": [
          "Avastin",
          "Lucentis",
          "Ozurdex",
          "Visudyne",
          "Eylea",
          "Mvasi",
          "Bevacizumab",
          "Zirabev",
          "Beovu",
          "Byooviz",
          "Susvimo",
          "Vabysmo",
          "Bevacizumab-awwb",
          "Cimerli",
          "Izervay"
        ]
      },
      {
        "ProgramID": 30777,
        "ProgramName": "HealthWell: Mantle Cell Lymphoma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Mantle Cell Lymphoma (MCL)"
        ],
        "Drugs": [
          "Arzerra",
          "Gazyva",
          "Imbruvica",
          "Otrexup",
          "Ozurdex",
          "Rasuvo",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Torisel",
          "Treanda",
          "Velcade",
          "Cytarabine",
          "Mitoxantrone",
          "Trexall",
          "Matulane",
          "Cyclophosphamide",
          "Bendeka",
          "Venclexta",
          "Bendamustine",
          "Vincristine Sulfate",
          "Rituxan Hycela",
          "Calquence",
          "Khapzory",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Tecartus",
          "Rituximab",
          "Bortezomib",
          "Lenalidomide",
          "Rituximab-pvvr",
          "Jaypirca",
          "Boruzu"
        ]
      },
      {
        "ProgramID": 30392,
        "ProgramName": "HealthWell: Melanoma - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Melanoma"
        ],
        "Drugs": [
          "Avastin",
          "Doxil",
          "Keytruda",
          "Mekinist",
          "Nexavar",
          "Opdivo",
          "Proleukin",
          "Tafinlar",
          "Taxotere",
          "Torisel",
          "Yervoy",
          "Zelboraf",
          "Vinblastine Sulfate",
          "Leukine",
          "Imlygic",
          "Cotellic",
          "Decitabine",
          "Dactinomycin",
          "Bleomycin",
          "Vincristine Sulfate",
          "Imatinib",
          "Temozolomide",
          "Mvasi",
          "Sorafenib Tosylate",
          "Temsirolimus",
          "Vemurafenib",
          "Bevacizumab",
          "Melphalan",
          "Braftovi",
          "Mektovi",
          "Zirabev",
          "Kimmtrak",
          "Braftovi & Mektovi",
          "Opdualag",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Peginterferon Alfa-2B",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 31064,
        "ProgramName": "HealthWell: Metabolic Dysfunction-Associated Steatohepatitis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Steatohepatitis"
        ],
        "Drugs": [
          "Wegovy",
          "Rezdiffra"
        ]
      },
      {
        "ProgramID": 30734,
        "ProgramName": "HealthWell: Migraine",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Migraine Headaches"
        ],
        "Drugs": [
          "Botox",
          "Aimovig",
          "Ajovy",
          "Emgality",
          "Ubrelvy",
          "Vyepti",
          "Nurtec ODT",
          "Qulipta"
        ]
      },
      {
        "ProgramID": 30585,
        "ProgramName": "HealthWell: Movement Disorders - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Huntington's Disease",
          "Neurology - Parkinson's Disease",
          "Neurology - Tourette's Syndrome",
          "Neurology - Tardive Dyskinesia",
          "Neurology - Dyskinesia (related to Parkinson's)",
          "Neurology - Chorea"
        ],
        "Drugs": [
          "Apokyn",
          "Botox",
          "Xenazine",
          "Dysport",
          "Duopa",
          "Aristada",
          "Rilutek",
          "Abilify Maintena",
          "Tasmar",
          "Austedo",
          "Ingrezza",
          "Tetrabenazine",
          "Gocovri",
          "Tiglutik",
          "Nourianz",
          "Exservan",
          "Aristada Initio",
          "Zyprexa Zydis",
          "Valbenazine Tosylate",
          "Rykindo",
          "Austedo XR",
          "Abilify Asimtufii",
          "Ingrezza Sprinkle",
          "Zelapar",
          "Tolcapone",
          "Inbrija",
          "Zyprexa Relprevv",
          "Fleqsuvy",
          "Gimoti",
          "Ozobax DS",
          "Zonisade",
          "Apomorphine",
          "Uzedy",
          "Risperidone ER Injectable Suspension",
          "Crexont",
          "Risperdal Consta",
          "Perseris"
        ]
      },
      {
        "ProgramID": 30366,
        "ProgramName": "HealthWell: Multiple Myeloma - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma"
        ],
        "Drugs": [
          "Doxil",
          "Ellence",
          "Gammagard Liquid",
          "Gamunex-C",
          "Kyprolis",
          "Neupogen",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Thalomid",
          "Treanda",
          "Velcade",
          "Xgeva",
          "Zometa",
          "Granix",
          "Privigen",
          "Reclast",
          "Zarxio",
          "Octagam",
          "Mozobil",
          "Zoledronic Acid",
          "Zolinza",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Gammaplex",
          "Vincasar PFS",
          "Empliciti",
          "Venclexta",
          "Melphalan",
          "Filgrastim",
          "Nivestym",
          "Xpovio",
          "Sarclisa",
          "Darzalex Faspro",
          "Blenrep",
          "Kyprolis & Darzalex",
          "Bortezomib",
          "Immune Globulin Intravenous (IGIV)",
          "Abecma",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Filgrastim-sndz",
          "Tecvayli",
          "Talvey",
          "Elrexfio",
          "Boruzu"
        ]
      },
      {
        "ProgramID": 30210,
        "ProgramName": "HealthWell: Multiple Sclerosis - Medicare Access: Re-enrollment Only",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Multiple Sclerosis (MS)"
        ],
        "Drugs": [
          "Ampyra",
          "Aubagio",
          "Avonex",
          "Betaseron",
          "Botox",
          "Copaxone",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gilenya",
          "Acthar Gel",
          "Lemtrada",
          "Plegridy",
          "Rebif",
          "Rituxan",
          "Tecfidera",
          "Tysabri",
          "Mitoxantrone",
          "Methotrexate",
          "Gammagard S/D",
          "Glatopa",
          "Cyclophosphamide",
          "Gammaplex",
          "Cladribine",
          "Ocrevus",
          "Avonex Pen",
          "Rituxan Hycela",
          "Pirfenidone",
          "Glatiramer Acetate",
          "Rebif Rebidose",
          "Truxima",
          "Mavenclad",
          "Mayzent",
          "Vumerity",
          "Zeposia",
          "Bafiertam",
          "Ruxience",
          "Kesimpta",
          "Ponvory",
          "Rituximab",
          "Fleqsuvy",
          "Penicillamine",
          "Rituximab-pvvr",
          "Tascenso ODT",
          "Briumvi",
          "Tyruko",
          "Acthar Selfject",
          "Ocrevus Zunovo"
        ]
      },
      {
        "ProgramID": 30211,
        "ProgramName": "HealthWell: Myelodysplastic Syndromes - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)"
        ],
        "Drugs": [
          "Aranesp",
          "Epogen",
          "Gleevec",
          "Hycamtin",
          "Hycamtin Injection",
          "Jakafi",
          "Neoral",
          "Neupogen",
          "Nplate",
          "Procrit",
          "Promacta",
          "Revlimid",
          "Sandimmune",
          "Thalomid",
          "Trisenox",
          "Vidaza",
          "Granix",
          "Zarxio",
          "Dacogen",
          "Leukine",
          "Thymoglobulin",
          "Atgam",
          "Ethyol",
          "Venclexta",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Topotecan",
          "Retacrit",
          "Tibsovo",
          "Nivestym",
          "Reblozyl",
          "Inqovi",
          "Onureg",
          "Rytelo"
        ]
      },
      {
        "ProgramID": 30851,
        "ProgramName": "HealthWell: Neurocognitive Disease with Psychosis - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurocognitive Disease with Psychosis"
        ],
        "Drugs": [
          "Invega Sustenna",
          "Risperdal Consta",
          "Rexulti",
          "Aristada",
          "Vraylar",
          "Nuplazid",
          "Abilify Maintena",
          "Invega Trinza",
          "Perseris",
          "Secuado",
          "Aristada Initio",
          "Zyprexa Relprevv",
          "Zyprexa Zydis",
          "Invega Hafyera"
        ]
      },
      {
        "ProgramID": 30393,
        "ProgramName": "HealthWell: Non-Small Cell Lung Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Camptosar",
          "Cometriq",
          "Cyramza",
          "Ellence",
          "Erbitux",
          "Gilotrif",
          "Herceptin",
          "Hycamtin",
          "Hycamtin Injection",
          "Keytruda",
          "Mekinist",
          "Nexavar",
          "Opdivo",
          "Sutent",
          "Tafinlar",
          "Tarceva",
          "Taxotere",
          "Thalomid",
          "Xalkori",
          "Xgeva",
          "Yervoy",
          "Zelboraf",
          "Zometa",
          "Zykadia",
          "Iressa",
          "Paraplatin",
          "Vinblastine Sulfate",
          "Methotrexate",
          "Photofrin",
          "Zoledronic Acid",
          "Docetaxel",
          "Irinotecan",
          "Tagrisso",
          "Gleostine",
          "Alecensa",
          "Portrazza",
          "Cabometyx",
          "Tecentriq",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Bevacizumab",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Zirabev",
          "Rozlytrek",
          "Enhertu",
          "Tabrecta",
          "Retevmo",
          "Gavreto",
          "Rybrevant",
          "Lumakras",
          "Tepmetko",
          "Bevacizumab-awwb",
          "Trastuzumab-qyyp",
          "Krazati",
          "Augtyro",
          "Pemrydi RTU",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30735,
        "ProgramName": "HealthWell: Nontuberculous Mycobacterium - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Mycobacterium Avium Complex (MAC)"
        ],
        "Drugs": [
          "Amikacin Sulfate",
          "Arikayce",
          "Nuzyra",
          "Sirturo"
        ]
      },
      {
        "ProgramID": 31074,
        "ProgramName": "HealthWell: Oncology Caregiver Behavioral Health",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Behavioral Health - Anxiety Disorders",
          "Behavioral Health - Bipolar Disorder",
          "Behavioral Health - Depression",
          "Behavioral Health - Schizophrenia",
          "Behavioral Health - Major Depressive Disorder (MDD)",
          "Neurocognitive Disease with Psychosis"
        ],
        "Drugs": [
          "Rexulti",
          "Aristada",
          "Abilify Maintena",
          "Spravato",
          "Zyprexa Relprevv",
          "Invega Sustenna",
          "Invega Trinza",
          "Aplenzin",
          "Zyprexa Zydis",
          "Invega Hafyera",
          "Letrozole"
        ]
      },
      {
        "ProgramID": 30619,
        "ProgramName": "HealthWell: Ovarian Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Ovarian"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Arimidex",
          "Avastin",
          "Camptosar",
          "Carac",
          "Doxil",
          "Eligard",
          "Femara",
          "Hycamtin Injection",
          "Lupron Depot",
          "Lynparza",
          "Taxotere",
          "Votrient",
          "Xeloda",
          "Letrozole",
          "Paraplatin",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Cyclophosphamide",
          "Alkeran",
          "Vincasar PFS",
          "Ethyol",
          "Evomela",
          "Leuprolide Acetate",
          "Bleomycin",
          "Vincristine Sulfate",
          "Vinorelbine Tartrate",
          "Topotecan",
          "Rubraca",
          "Gemcitabine",
          "Zejula",
          "Etoposide Phosphate",
          "Mvasi",
          "Bevacizumab",
          "Melphalan",
          "Tepadina",
          "Thiotepa",
          "Zirabev",
          "Levoleucovorin",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Elahere"
        ]
      },
      {
        "ProgramID": 30841,
        "ProgramName": "HealthWell: Pancreatic Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Pancreatic"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Camptosar",
          "Carac",
          "Creon",
          "Keytruda",
          "Lynparza",
          "Tarceva",
          "Taxotere",
          "Xeloda",
          "Zenpep",
          "Mitomycin",
          "Capecitabine",
          "Onivyde",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Mutamycin",
          "Gemcitabine",
          "Erlotinib Hydrochloride",
          "Khapzory",
          "Vitrakvi",
          "Rozlytrek",
          "Jelmyto",
          "Levoleucovorin"
        ]
      },
      {
        "ProgramID": 31088,
        "ProgramName": "HealthWell: Pediatric Assistance Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Behavioral Health - ADHD / ADD / Autism Spectrum Disorder",
          "Oncology - Acute Lymphoblastic Leukemia (ALL)",
          "Ophthalmic",
          "Pediatric Congenital Heart Disease"
        ],
        "Drugs": [
          "Invega Sustenna",
          "Risperdal Consta",
          "Aristada",
          "Abilify Maintena",
          "Invega Trinza",
          "Gocovri",
          "Perseris",
          "Aristada Initio",
          "Zyprexa Relprevv",
          "Zyprexa Zydis",
          "Invega Hafyera",
          "Rykindo",
          "Uzedy",
          "Abilify Asimtufii",
          "Risperidone ER Injectable Suspension",
          "Arranon",
          "Blincyto",
          "Gleevec",
          "Iclusig",
          "Jakafi",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Rituxan",
          "Sprycel",
          "Tasigna",
          "Velcade",
          "Cytarabine",
          "Purixan",
          "Mitoxantrone",
          "Trexall",
          "Methotrexate",
          "Cyclophosphamide",
          "Darzalex",
          "Oncaspar",
          "Venclexta",
          "Clolar",
          "Vincristine Sulfate",
          "Imatinib",
          "Etoposide Phosphate",
          "Besponsa",
          "Kymriah",
          "Khapzory",
          "Truxima",
          "Asparlas",
          "Tabloid",
          "Darzalex Faspro",
          "Ruxience",
          "Riabni",
          "Rylaze",
          "Bortezomib",
          "Venclexta Starting Pack",
          "Jylamvo",
          "Triesence",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Adempas",
          "Farxiga",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tyvaso",
          "Xarelto",
          "Sildenafil",
          "Uptravi",
          "Treprostinil",
          "Treprostinil Diolamine",
          "Tyvaso DPI",
          "Jardiance"
        ]
      },
      {
        "ProgramID": 30186,
        "ProgramName": "HealthWell: Peyronie's Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Peyronie's Disease"
        ],
        "Drugs": [
          "Xiaflex",
          "Sildenafil"
        ]
      },
      {
        "ProgramID": 30314,
        "ProgramName": "HealthWell: Porphyrias",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acute Porphyria"
        ],
        "Drugs": [
          "Deferoxamine Mesylate",
          "Panhematin",
          "Givlaari",
          "Scenesse"
        ]
      },
      {
        "ProgramID": 30213,
        "ProgramName": "HealthWell: Post Menopausal Osteoporosis - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Osteoporosis"
        ],
        "Drugs": [
          "Forteo",
          "Prolia",
          "Xgeva",
          "Zometa",
          "Reclast",
          "Zoledronic Acid",
          "Miacalcin",
          "Tymlos",
          "Evenity",
          "Teriparatide",
          "Romosozumab-aqqg"
        ]
      },
      {
        "ProgramID": 30821,
        "ProgramName": "HealthWell: Prostate Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Castration-Sensitive Prostate Cancer",
          "Oncology - Non-Metastatic Castration-Resistant Prostate Cancer",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
          "Oncology - Castration-Resistant Prostate Cancer"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Nilandron",
          "Prolia",
          "Provenge",
          "Rayos",
          "Supprelin LA",
          "Taxotere",
          "Trelstar",
          "Xgeva",
          "Xofigo",
          "Xtandi",
          "Zoladex",
          "Zometa",
          "Zytiga",
          "Paraplatin",
          "Mitoxantrone",
          "Zoledronic Acid",
          "Docetaxel",
          "Leuprolide Acetate",
          "Tecentriq",
          "Rubraca",
          "Erleada",
          "Yonsa",
          "Talzenna",
          "Abiraterone Acetate",
          "Nubeqa",
          "Fensolvi",
          "Orgovyx",
          "Camcevi",
          "Pluvicto",
          "Akeega"
        ]
      },
      {
        "ProgramID": 30188,
        "ProgramName": "HealthWell: Pulmonary Fibrosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Idiopathic Pulmonary Fibrosis"
        ],
        "Drugs": [
          "CellCept",
          "Myfortic",
          "Ofev",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Revatio",
          "Trexall",
          "Methotrexate",
          "Cyclophosphamide",
          "Sildenafil",
          "Esbriet",
          "Mycophenolate Mofetil",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30834,
        "ProgramName": "HealthWell: Pulmonary Hypertension - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pulmonary Arterial Hypertension (PAH)"
        ],
        "Drugs": [
          "Adcirca",
          "Adempas",
          "Letairis",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tracleer",
          "Tyvaso",
          "Veletri",
          "Ventavis",
          "Flolan",
          "Sildenafil",
          "Uptravi",
          "Epoprostenol Sodium",
          "Tadalafil",
          "Ambrisentan",
          "Treprostinil",
          "Bosentan",
          "Treprostinil Diolamine",
          "Tyvaso DPI",
          "Opsynvi",
          "Winrevair"
        ]
      },
      {
        "ProgramID": 30410,
        "ProgramName": "HealthWell: Renal Cell Carcinoma - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Renal Cell Carcinoma (Kidney Cancer) (RCC)"
        ],
        "Drugs": [
          "Afinitor",
          "Avastin",
          "Cometriq",
          "Doxil",
          "Inlyta",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Proleukin",
          "Sutent",
          "Tarceva",
          "Torisel",
          "Votrient",
          "Xgeva",
          "Cabometyx",
          "Everolimus",
          "Bavencio",
          "Mvasi",
          "Bevacizumab",
          "Zirabev",
          "Opdivo & Yervoy",
          "Welireg",
          "Fotivda",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound"
        ]
      },
      {
        "ProgramID": 31085,
        "ProgramName": "HealthWell: Schizophrenia - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Behavioral Health - Schizophrenia"
        ],
        "Drugs": [
          "Invega Sustenna",
          "Risperdal Consta",
          "Rexulti",
          "Aristada",
          "Vraylar",
          "Abilify Maintena",
          "Invega Trinza",
          "Perseris",
          "Secuado",
          "Aristada Initio",
          "Zyprexa Relprevv",
          "Zyprexa Zydis",
          "Caplyta",
          "Lybalvi",
          "Invega Hafyera",
          "Rykindo",
          "Uzedy",
          "Abilify Asimtufii",
          "Risperidone ER Injectable Suspension",
          "Risvan",
          "Erzofri",
          "Cobenfy"
        ]
      },
      {
        "ProgramID": 30214,
        "ProgramName": "HealthWell: Secondary Hyperparathyroidism",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hyperparathyroidism"
        ],
        "Drugs": [
          "Sensipar",
          "Rayaldee",
          "Parsabiv",
          "Cinacalcet"
        ]
      },
      {
        "ProgramID": 30808,
        "ProgramName": "HealthWell: Sickle Cell Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Sickle Cell Disease (SCD)"
        ],
        "Drugs": [
          "Exjade",
          "Jadenu",
          "Ferriprox",
          "Deferasirox",
          "Desferal",
          "Adakveo",
          "Endari",
          "Siklos",
          "Casgevy",
          "Lyfgenia"
        ]
      },
      {
        "ProgramID": 30800,
        "ProgramName": "HealthWell: Small Cell Lung Cancer - Medicare Access",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Small Cell Lung Cancer (SCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Camptosar",
          "Hycamtin",
          "Hycamtin Injection",
          "Keytruda",
          "Opdivo",
          "Otrexup",
          "Rasuvo",
          "Taxotere",
          "Temodar",
          "Treanda",
          "Yervoy",
          "Trexall",
          "Methotrexate",
          "Docetaxel",
          "Irinotecan",
          "Cyclophosphamide",
          "Bendeka",
          "Tecentriq",
          "Vincristine Sulfate",
          "Vinorelbine Tartrate",
          "Topotecan",
          "Gemcitabine",
          "Temozolomide",
          "Etoposide Phosphate",
          "Imfinzi",
          "Belrapzo",
          "Zepzelca",
          "Paclitaxel Protein-Bound",
          "Cosela",
          "Imdelltra",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30189,
        "ProgramName": "HealthWell: Systemic Lupus Erythematosus",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Systemic Lupus Erythematosus"
        ],
        "Drugs": [
          "Benlysta",
          "CellCept",
          "Gammagard Liquid",
          "Gamunex-C",
          "Acthar Gel",
          "Myfortic",
          "Orencia",
          "Rasuvo",
          "Rituxan",
          "Thalomid",
          "Leukeran",
          "Privigen",
          "Methotrexate",
          "Gammagard S/D",
          "Octagam",
          "Gammaked",
          "Cyclophosphamide",
          "Gammaplex",
          "Mycophenolate Mofetil",
          "Cyclosporine",
          "Rituxan Hycela",
          "Fludarabine Phosphate",
          "Truxima",
          "Ruxience",
          "Lupkynis",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Saphnelo",
          "Rituximab",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "Rituximab-pvvr"
        ]
      },
      {
        "ProgramID": 31014,
        "ProgramName": "HealthWell: Systemic Sclerosis with Interstitial Lung Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Systemic Sclerosis"
        ],
        "Drugs": [
          "Actemra",
          "CellCept",
          "Ofev",
          "Rituxan",
          "Cyclophosphamide",
          "Actemra Actpen",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30663,
        "ProgramName": "HealthWell: Tardive Dyskinesia - Medicare Access",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Tardive Dyskinesia"
        ],
        "Drugs": [
          "Botox",
          "Xenazine",
          "Austedo",
          "Ingrezza",
          "Tetrabenazine"
        ]
      },
      {
        "ProgramID": 30190,
        "ProgramName": "HealthWell: Urea Cycle Disorders: RE-ENROLLMENT ONLY",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva"
        ]
      },
      {
        "ProgramID": 30191,
        "ProgramName": "HealthWell: Urticaria: RE-ENROLLMENT ONLY",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Urticaria"
        ],
        "Drugs": [
          "Ilaris",
          "Xolair",
          "Cyclosporine"
        ]
      },
      {
        "ProgramID": 30995,
        "ProgramName": "HealthWell: Waldenstrom Macroglobulinemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Waldenstrom’s Macroglobulinemia"
        ],
        "Drugs": [
          "Afinitor",
          "Arzerra",
          "Imbruvica",
          "Kyprolis",
          "Otrexup",
          "Ozurdex",
          "Rasuvo",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Thalomid",
          "Treanda",
          "Velcade",
          "Zortress",
          "Leukeran",
          "Cytarabine",
          "Methotrexate",
          "Cyclophosphamide",
          "Alkeran",
          "Ninlaro",
          "Bendeka",
          "Venclexta",
          "Cladribine",
          "Everolimus",
          "Vincristine Sulfate",
          "Afinitor Disperz",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Melphalan",
          "Truxima",
          "Mavenclad",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Kesimpta",
          "Riabni",
          "Venclexta Starting Pack"
        ]
      },
      {
        "ProgramID": 30192,
        "ProgramName": "HealthWell: Wilms' Tumor",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Wilm's Tumor"
        ],
        "Drugs": [
          "Cyclophosphamide",
          "Vincasar PFS",
          "Dactinomycin",
          "Topotecan",
          "Etoposide Phosphate"
        ]
      },
      {
        "ProgramID": 30354,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Acute Lymphoblastic Leukemia (ALL)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Acute Lymphoblastic Leukemia (ALL)",
          "Oncology - Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL)"
        ],
        "Drugs": [
          "Arranon",
          "Blincyto",
          "Gleevec",
          "Iclusig",
          "Rayos",
          "Sprycel",
          "Cytarabine",
          "Purixan",
          "Trexall",
          "Methotrexate",
          "Cyclophosphamide",
          "Mutamycin",
          "Vincasar PFS",
          "Elitek",
          "Oncaspar",
          "Clofarabine",
          "Clolar",
          "Vincristine Sulfate",
          "Besponsa",
          "Kymriah",
          "Asparlas",
          "Tabloid",
          "Bexarotene",
          "Rylaze",
          "Tecartus",
          "Jylamvo",
          "Phyrago",
          "Aucatzyl"
        ]
      },
      {
        "ProgramID": 30589,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Acute Myeloid Leukemia (AML)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Aggressive Systemic Mastocytosis (ASM)",
          "Oncology - Acute Myeloid Leukemia (AML)",
          "Oncology - Acute Promyelocytic Leukemia (APL)",
          "Oncology - Erdheim Chester Disease",
          "Oncology - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",
          "Oncology - Indolent Systemic Mastocytosis (ISM)"
        ],
        "Drugs": [
          "Gleevec",
          "Cyclophosphamide",
          "Gastrocrom",
          "Imatinib",
          "Rydapt",
          "Ayvakit",
          "Neupogen",
          "Rayos",
          "Trisenox",
          "Cytarabine",
          "Leukine",
          "Mutamycin",
          "Mylotarg",
          "Elitek",
          "Venclexta",
          "Vincristine Sulfate",
          "IDHIFA",
          "Vyxeos",
          "Filgrastim",
          "Tibsovo",
          "Nivestym",
          "Daurismo",
          "Xospata",
          "Tabloid",
          "Onureg",
          "Venclexta Starting Pack",
          "Filgrastim-sndz",
          "Releuko",
          "Rezlidhia",
          "Vanflyta",
          "Nypozi",
          "Arsenic Trioxide",
          "Zelboraf",
          "Cotellic",
          "Cladribine",
          "Vemurafenib",
          "Elzonris"
        ]
      },
      {
        "ProgramID": 30356,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Chronic Lymphocytic Leukemia (CLL/SLL)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Chronic Lymphocytic Leukemia (CLL)",
          "Oncology - Small Lymphocytic Lymphoma (SLL)",
          "Oncology - Hairy Cell Leukemia",
          "Oncology - B-Cell Prolymphocytic Leukemia (B-PLL)",
          "Oncology - Large Granular Lymphocyte Leukemia (LGLL)"
        ],
        "Drugs": [
          "Arzerra",
          "Campath",
          "Gazyva",
          "Imbruvica",
          "Mekinist",
          "Rayos",
          "Rituxan",
          "Treanda",
          "Zydelig",
          "Leukeran",
          "Methotrexate",
          "Gammagard S/D",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Bendeka",
          "Elitek",
          "Venclexta",
          "Cladribine",
          "Bendamustine",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Copiktra",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "Breyanzi",
          "Immune Globulin Intravenous (IGIV)",
          "Venclexta Starting Pack",
          "Imbruvica & Gazyva",
          "Rituximab-pvvr",
          "Vivimusta",
          "Jaypirca",
          "Rituximab-abbs",
          "Rituximab-arrx",
          "Trexall",
          "BiCNU",
          "Retevmo",
          "Cytarabine",
          "Nipent",
          "Enhertu",
          "Tabloid",
          "Vincristine Sulfate"
        ]
      },
      {
        "ProgramID": 30355,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Chronic Myeloid Leukemia (CML)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Chronic Myeloid Leukemia (CML)"
        ],
        "Drugs": [
          "Bosulif",
          "Gleevec",
          "Iclusig",
          "Mekinist",
          "Sprycel",
          "Tasigna",
          "Cytarabine",
          "Cyclophosphamide",
          "Alkeran",
          "Busulfex",
          "Elitek",
          "Azacitidine",
          "Myleran",
          "Tabloid",
          "Scemblix",
          "Phyrago"
        ]
      },
      {
        "ProgramID": 30357,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Lymphoma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Kaposi Sarcoma",
          "Oncology - Hodgkin's Lymphoma",
          "Oncology - Lymphomas",
          "Oncology - Non-Hodgkin’s Lymphoma",
          "Oncology - Anaplastic Large Cell Lymphoma (ALCL)",
          "Oncology - T-Cell Lymphoma",
          "Oncology - Mycosis Fungoides",
          "Oncology - B-Cell Lymphoma",
          "Oncology - Marginal Zone Lymphoma",
          "Oncology - Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
          "Oncology - Lymphomatoid Papulosis (LyP)",
          "Oncology - Follicular Lymphoma",
          "Post-Transplant Lymphoproliferative Disease (PTLD)",
          "Oncology - Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
          "Oncology - Extranodal NK/T-Cell Lymphoma",
          "Oncology - Diffuse Large B-cell  Lymphoma (DLBCL)"
        ],
        "Drugs": [
          "Doxil",
          "Pomalyst",
          "Vinblastine Sulfate",
          "Methotrexate",
          "Cyclophosphamide",
          "Elitek",
          "Paclitaxel Protein-Bound",
          "Adcetris",
          "Keytruda",
          "Opdivo",
          "Rayos",
          "Leukeran",
          "Matulane",
          "BiCNU",
          "Alkeran",
          "Vincasar PFS",
          "Gleostine",
          "Bleomycin",
          "Vincristine Sulfate",
          "Retevmo",
          "Jemperli",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Arranon",
          "Beleodaq",
          "Gazyva",
          "Revlimid",
          "Valchlor",
          "Trexall",
          "Zolinza",
          "Bendamustine",
          "Rituxan Hycela",
          "Thiotepa",
          "Belrapzo",
          "Ruxience",
          "Bexarotene",
          "Tazverik",
          "Rituximab-abbs",
          "Rituxan",
          "Treanda",
          "Zevalin",
          "Mozobil",
          "Bendeka",
          "Truxima",
          "Monjuvi",
          "Riabni",
          "Rituximab",
          "Breyanzi",
          "Rituximab-pvvr",
          "Jylamvo",
          "Vivimusta",
          "Lunsumio",
          "Epkinly",
          "Rituximab-arrx",
          "Xalkori",
          "Alecensa",
          "Folotyn",
          "Targretin",
          "Istodax",
          "Poteligeo",
          "Lymphir",
          "Calquence",
          "Brukinsa",
          "Imbruvica & Gazyva",
          "Columvi",
          "Kymriah",
          "Yescarta",
          "Polivy",
          "Xpovio",
          "Zynlonta",
          "Immune Globulin Intravenous (IGIV)",
          "Imbruvica",
          "Lenalidomide",
          "Copiktra",
          "Enhertu",
          "Gengraf",
          "Sandimmune",
          "Thymoglobulin",
          "Tacrolimus",
          "Romidepsin",
          "Augtyro"
        ]
      },
      {
        "ProgramID": 30358,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Mantle Cell Lymphoma (MCL)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Mantle Cell Lymphoma (MCL)"
        ],
        "Drugs": [
          "Imbruvica",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Velcade",
          "Trexall",
          "Methotrexate",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Elitek",
          "Vincristine Sulfate",
          "Calquence",
          "Brukinsa",
          "Retevmo",
          "Ruxience",
          "Riabni",
          "Tecartus",
          "Rituximab",
          "Bortezomib",
          "Breyanzi",
          "Lenalidomide",
          "Rituximab-pvvr",
          "Jaypirca",
          "Rituximab-abbs",
          "Rituximab-arrx",
          "Boruzu"
        ]
      },
      {
        "ProgramID": 30359,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Myelodysplastic Syndromes (MDS)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)",
          "Oncology - Juvenile Myelomonocytic Leukemia (JMML)",
          "Oncology - Chronic Myelomonocytic Leukemia (CMMoL)"
        ],
        "Drugs": [
          "Gleevec",
          "Jakafi",
          "Neupogen",
          "Rayos",
          "Revlimid",
          "Vidaza",
          "Zarxio",
          "Dacogen",
          "Leukine",
          "Deferasirox",
          "Cyclophosphamide",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Vyxeos",
          "Fulphila",
          "Tibsovo",
          "Udenyca",
          "Reblozyl",
          "Inqovi",
          "Levoleucovorin",
          "Pemazyre",
          "Lenalidomide",
          "Udenyca Autoinjector",
          "Udenyca Onbody",
          "Rytelo",
          "Nypozi",
          "Cytarabine",
          "Elitek",
          "Tabloid"
        ]
      },
      {
        "ProgramID": 30360,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Myeloma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma",
          "POEMS Syndrome"
        ],
        "Drugs": [
          "Doxil",
          "Kyprolis",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Thalomid",
          "Velcade",
          "Xgeva",
          "Zometa",
          "Cytarabine",
          "Mozobil",
          "Zoledronic Acid",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Mutamycin",
          "Empliciti",
          "Evomela",
          "Vincristine Sulfate",
          "Melphalan",
          "Xpovio",
          "Sarclisa",
          "Darzalex Faspro",
          "Blenrep",
          "Kyprolis & Darzalex",
          "Bortezomib",
          "Abecma",
          "Lenalidomide",
          "Carvykti",
          "Tecvayli",
          "Talvey",
          "Elrexfio",
          "Aphexda",
          "Wyost",
          "Boruzu"
        ]
      },
      {
        "ProgramID": 30788,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Myeloproliferative Neoplasms (MPN)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myeloproliferative Neoplasms",
          "Oncology - Myelofibrosis",
          "Oncology - Chronic Eosinophilic Leukemia (CEL)",
          "Polycythemia Vera",
          "Thrombocythemia",
          "Oncology - Chronic Neutrophilic Leukemia (CNL)"
        ],
        "Drugs": [
          "Gleevec",
          "Jakafi",
          "Rayos",
          "Vidaza",
          "Dacogen",
          "Cyclophosphamide",
          "Alkeran",
          "Cotellic",
          "Azacitidine",
          "Inrebic",
          "Reblozyl",
          "Inqovi",
          "Levoleucovorin",
          "Pemazyre",
          "Vonjo",
          "Cytarabine",
          "Ojjaara",
          "Elitek",
          "Imatinib",
          "Tabloid",
          "Besremi",
          "Releuko"
        ]
      },
      {
        "ProgramID": 30361,
        "ProgramName": "Leukemia & Lymphoma Society (LLS): Waldenstrom Macroglobulinemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Waldenstrom’s Macroglobulinemia"
        ],
        "Drugs": [
          "Imbruvica",
          "Rayos",
          "Methotrexate",
          "Cyclophosphamide",
          "Alkeran",
          "Vincasar PFS",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Imbruvica & Gazyva"
        ]
      },
      {
        "ProgramID": 30516,
        "ProgramName": "Melvin Weinstein Parkinson's Foundation (MWPF)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Parkinson's Disease",
          "Neurology - Dyskinesia (related to Parkinson's)"
        ],
        "Drugs": [
          "Apokyn",
          "Xeomin",
          "Zelapar",
          "Duopa",
          "Nuplazid",
          "Tasmar",
          "Gocovri",
          "Tolcapone",
          "Inbrija",
          "Nourianz",
          "Apomorphine",
          "Crexont",
          "Vyalev",
          "Austedo XR"
        ]
      },
      {
        "ProgramID": 30444,
        "ProgramName": "Musella Foundation For Brain Tumor Research & Information",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Primary Malignant Brain Tumors (Grade 3 or 4)"
        ],
        "Drugs": [
          "Avastin",
          "Temodar"
        ]
      },
      {
        "ProgramID": 30547,
        "ProgramName": "NORD: Alpha-1 Antitrypsin Deficiency (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Alpha-1 Antitrypsin Deficiency (Alpha-1)"
        ],
        "Drugs": [
          "Glassia",
          "Prolastin-C",
          "Zemaira",
          "Aralast NP"
        ]
      },
      {
        "ProgramID": 31066,
        "ProgramName": "NORD: Amyloidosis (Medical Assistance): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Amyloidosis"
        ],
        "Drugs": [
          "Rayos",
          "Cyclophosphamide",
          "Alkeran",
          "Onpattro",
          "Vyndaqel",
          "Vyndamax",
          "Amvuttra",
          "Wainua",
          "Attruby"
        ]
      },
      {
        "ProgramID": 31067,
        "ProgramName": "NORD: Amyloidosis (Premium & Copay): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Amyloidosis"
        ],
        "Drugs": [
          "Rayos",
          "Cyclophosphamide",
          "Alkeran",
          "Onpattro",
          "Vyndaqel",
          "Vyndamax",
          "Amvuttra",
          "Wainua",
          "Attruby"
        ]
      },
      {
        "ProgramID": 30752,
        "ProgramName": "NORD: Atypical Hemolytic Uremic Syndrome (aHUS) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Atypical Hemolytic Uremic Syndrome (aHUS)"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Cyclophosphamide",
          "Ultomiris",
          "Bkemv",
          "Epysqli",
          "Soliris & Voydeya",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30751,
        "ProgramName": "NORD: Atypical Hemolytic Uremic Syndrome (aHUS) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Atypical Hemolytic Uremic Syndrome (aHUS)"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Cyclophosphamide",
          "Ultomiris",
          "Bkemv",
          "Epysqli",
          "Soliris & Voydeya",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 31024,
        "ProgramName": "NORD: Bardet-Biedl Syndrome (BBS) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Bardet-Biedl Syndrome"
        ],
        "Drugs": [
          "Imcivree"
        ]
      },
      {
        "ProgramID": 31008,
        "ProgramName": "NORD: Batten Disease (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Batten Disease",
          "Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)"
        ],
        "Drugs": [
          "Brineura"
        ]
      },
      {
        "ProgramID": 30666,
        "ProgramName": "NORD: Bile Acid Synthesis and Zellweger Spectrum Disorders (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Bile Acid Synthesis Disorders / Bile Acid Deficiency",
          "Zellweger Spectrum Disorders"
        ],
        "Drugs": [
          "Cholbam"
        ]
      },
      {
        "ProgramID": 30665,
        "ProgramName": "NORD: Bile Acid Synthesis and Zellweger Spectrum Disorders (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Bile Acid Synthesis Disorders / Bile Acid Deficiency",
          "Zellweger Spectrum Disorders"
        ],
        "Drugs": [
          "Cholbam"
        ]
      },
      {
        "ProgramID": 30748,
        "ProgramName": "NORD: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"
        ],
        "Drugs": [
          "Cyclophosphamide",
          "Cotellic",
          "Elzonris"
        ]
      },
      {
        "ProgramID": 30643,
        "ProgramName": "NORD: Cerebrotendinous Xanthomatosus (CTX) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cerebrotendinous Xanthomatosus (CTX)"
        ],
        "Drugs": [
          "Chenodal"
        ]
      },
      {
        "ProgramID": 31005,
        "ProgramName": "NORD: Chronic Granulomatous Disease (CGD) (Co-Pay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Granulomatous Disease (CGD)"
        ],
        "Drugs": [
          "Rayos",
          "Actimmune",
          "Cyclophosphamide",
          "Posaconazole"
        ]
      },
      {
        "ProgramID": 30746,
        "ProgramName": "NORD: Chronic Granulomatous Disease (CGD) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Granulomatous Disease (CGD)"
        ],
        "Drugs": [
          "Rayos",
          "Actimmune",
          "Cyclophosphamide",
          "Posaconazole"
        ]
      },
      {
        "ProgramID": 30598,
        "ProgramName": "NORD: Cushings Syndrome (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cushing’s Disease"
        ],
        "Drugs": [
          "Signifor",
          "Korlym",
          "Metopirone",
          "Signifor LAR",
          "Isturisa",
          "Recorlev",
          "Mifepristone"
        ]
      },
      {
        "ProgramID": 30551,
        "ProgramName": "NORD: Cushings Syndrome (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cushing’s Disease"
        ],
        "Drugs": [
          "Signifor",
          "Korlym",
          "Metopirone",
          "Signifor LAR",
          "Isturisa",
          "Recorlev",
          "Mifepristone"
        ]
      },
      {
        "ProgramID": 30784,
        "ProgramName": "NORD: Cystinosis (Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Nephropathic Cystinosis"
        ],
        "Drugs": [
          "Procysbi",
          "Cystaran",
          "Cystagon",
          "Cyclophosphamide",
          "Cystadrops"
        ]
      },
      {
        "ProgramID": 30785,
        "ProgramName": "NORD: Cystinosis (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Nephropathic Cystinosis"
        ],
        "Drugs": [
          "Procysbi",
          "Cystaran",
          "Cystagon",
          "Cyclophosphamide",
          "Cystadrops"
        ]
      },
      {
        "ProgramID": 30719,
        "ProgramName": "NORD: Cystinuria (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cystinuria"
        ],
        "Drugs": [
          "Cuprimine",
          "Depen",
          "Thiola EC",
          "Penicillamine",
          "Thiola",
          "Tiopronin"
        ]
      },
      {
        "ProgramID": 30720,
        "ProgramName": "NORD: Cystinuria (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cystinuria"
        ],
        "Drugs": [
          "Cuprimine",
          "Depen",
          "Thiola EC",
          "Penicillamine",
          "Thiola",
          "Tiopronin"
        ]
      },
      {
        "ProgramID": 31006,
        "ProgramName": "NORD: Duchenne Muscular Dystrophy (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Duchenne Muscular Dystrophy (DMD)"
        ],
        "Drugs": [
          "Rayos",
          "Exondys 51",
          "Emflaza",
          "Vyondys 53",
          "Viltepso",
          "Amondys 45",
          "Elevidys",
          "Agamree",
          "Duvyzat"
        ]
      },
      {
        "ProgramID": 30590,
        "ProgramName": "NORD: Duchenne Muscular Dystrophy (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Duchenne Muscular Dystrophy (DMD)"
        ],
        "Drugs": [
          "Rayos",
          "Exondys 51",
          "Emflaza",
          "Vyondys 53",
          "Viltepso",
          "Amondys 45",
          "Elevidys",
          "Agamree",
          "Duvyzat"
        ]
      },
      {
        "ProgramID": 31042,
        "ProgramName": "NORD: Fabry Disease (Medical Assistance): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 31043,
        "ProgramName": "NORD: Fabry Disease (Premium & Copay): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 30976,
        "ProgramName": "NORD: Floxuridine Medication Assistance Program",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Gastric",
          "Oncology - Liver",
          "Oncology - Hepatocellular Carcinoma (HCC)",
          "Oncology - Cholangiocarcinoma (Bile Duct Cancer)"
        ],
        "Drugs": [
          "Floxuridine"
        ]
      },
      {
        "ProgramID": 30553,
        "ProgramName": "NORD: Gaucher Disease (Premium & Copay)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat",
          "Yargesa"
        ]
      },
      {
        "ProgramID": 30601,
        "ProgramName": "NORD: Hunter Syndrome (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type II (MPS II: Hunter Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Tyvaso",
          "Elaprase",
          "Tyvaso DPI"
        ]
      },
      {
        "ProgramID": 30596,
        "ProgramName": "NORD: Hunter Syndrome (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type II (MPS II: Hunter Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Tyvaso",
          "Elaprase",
          "Tyvaso DPI"
        ]
      },
      {
        "ProgramID": 30602,
        "ProgramName": "NORD: Hypophosphatasia (HPP) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypophosphatasia (HPP)"
        ],
        "Drugs": [
          "Strensiq",
          "Xphozah"
        ]
      },
      {
        "ProgramID": 30554,
        "ProgramName": "NORD: Hypophosphatasia (HPP) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypophosphatasia (HPP)"
        ],
        "Drugs": [
          "Strensiq",
          "Xphozah"
        ]
      },
      {
        "ProgramID": 31021,
        "ProgramName": "NORD: IgA Nephropathy (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "IgA Nephropathy"
        ],
        "Drugs": [
          "Rayos",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Jardiance",
          "Tarpeyo",
          "Filspari",
          "Fabhalta"
        ]
      },
      {
        "ProgramID": 31022,
        "ProgramName": "NORD: IgA Nephropathy (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "IgA Nephropathy"
        ],
        "Drugs": [
          "Rayos",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Jardiance",
          "Tarpeyo",
          "Filspari",
          "Fabhalta"
        ]
      },
      {
        "ProgramID": 31095,
        "ProgramName": "NORD: Lambert Eaton Myasthenic Syndrome (LEMS) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lambert-Eaton Myasthenic Syndrome (LEMS)"
        ],
        "Drugs": [
          "Rayos",
          "Firdapse"
        ]
      },
      {
        "ProgramID": 30743,
        "ProgramName": "NORD: Lambert Eaton Myasthenic Syndrome (LEMS) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lambert-Eaton Myasthenic Syndrome (LEMS)"
        ],
        "Drugs": [
          "Rayos",
          "Firdapse"
        ]
      },
      {
        "ProgramID": 30791,
        "ProgramName": "NORD: Lennox-Gastaut Syndrome (LGS) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lennox Gastaut Syndrome (LGS)"
        ],
        "Drugs": [
          "Onfi",
          "Banzel",
          "Epidiolex",
          "Fintepla",
          "Felbatol"
        ]
      },
      {
        "ProgramID": 30603,
        "ProgramName": "NORD: Morquio A Syndrome (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type IV (MPS IV: Morquio Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Vimizim"
        ]
      },
      {
        "ProgramID": 30561,
        "ProgramName": "NORD: Morquio A Syndrome (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type IV (MPS IV: Morquio Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Vimizim"
        ]
      },
      {
        "ProgramID": 30604,
        "ProgramName": "NORD: Mucopolysaccharidosis Type VI (MPS VI) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type VI (MPS VI: Maroteaux-Lamy Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Naglazyme"
        ]
      },
      {
        "ProgramID": 30572,
        "ProgramName": "NORD: Mucopolysaccharidosis Type VI (MPS VI) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type VI (MPS VI: Maroteaux-Lamy Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Naglazyme"
        ]
      },
      {
        "ProgramID": 31068,
        "ProgramName": "NORD: Multifocal Motor Neuropathy (MMN) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Multifocal Motor Neuropathy (MMN)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Cyclophosphamide",
          "Immune Globulin Intravenous (IGIV)"
        ]
      },
      {
        "ProgramID": 31069,
        "ProgramName": "NORD: Multifocal Motor Neuropathy (MMN) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Multifocal Motor Neuropathy (MMN)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Cyclophosphamide",
          "Immune Globulin Intravenous (IGIV)"
        ]
      },
      {
        "ProgramID": 30837,
        "ProgramName": "NORD: Myasthenia Gravis (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Myasthenia Gravis"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Methotrexate",
          "Cyclophosphamide",
          "Ultomiris",
          "Vyvgart",
          "Mestinon",
          "Vyvgart Hytrulo",
          "Rystiggo",
          "Zilbrysq",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30836,
        "ProgramName": "NORD: Myasthenia Gravis (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Myasthenia Gravis"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Methotrexate",
          "Cyclophosphamide",
          "Ultomiris",
          "Vyvgart",
          "Mestinon",
          "Vyvgart Hytrulo",
          "Rystiggo",
          "Zilbrysq",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30563,
        "ProgramName": "NORD: Narcolepsy (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Narcolepsy"
        ],
        "Drugs": [
          "Xyrem",
          "Wakix",
          "Xywav",
          "Lumryz"
        ]
      },
      {
        "ProgramID": 31002,
        "ProgramName": "NORD: Neurofibromatosis Type 1 (NF1) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Neurofibromatosis"
        ],
        "Drugs": [
          "Mekinist",
          "Somavert",
          "Reclast",
          "BiCNU",
          "Cyclophosphamide",
          "Miacalcin",
          "Gleostine",
          "Banzel",
          "Xcopri",
          "Retevmo",
          "Jemperli",
          "Skytrofa",
          "Romidepsin",
          "Alymsys",
          "Koselugo",
          "Motpoly XR",
          "Coxanto"
        ]
      },
      {
        "ProgramID": 30999,
        "ProgramName": "NORD: Neuromyelitis Optica Spectrum Disorder (NMOSD) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Soliris",
          "Cyclophosphamide",
          "Ultomiris",
          "Uplizna",
          "Enspryng",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30817,
        "ProgramName": "NORD: Neuromyelitis Optica Spectrum Disorder (NMOSD) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Soliris",
          "Cyclophosphamide",
          "Ultomiris",
          "Uplizna",
          "Enspryng",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30725,
        "ProgramName": "NORD: Neurotrophic Keratitis (Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Keratitis",
          "Ophthalmic - Neurotrophic Keratitis"
        ],
        "Drugs": [
          "Acthar Gel",
          "Acthar Selfject",
          "Oxervate",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel"
        ]
      },
      {
        "ProgramID": 31086,
        "ProgramName": "NORD: Organic Acidemia (Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)",
          "Homocystinuria",
          "Hyperammonemia",
          "Pyruvate Kinase (PK) Deficiency"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva",
          "Pheburane",
          "Cystadane",
          "Thiola EC",
          "Thiola",
          "Tiopronin",
          "Pyrukynd"
        ]
      },
      {
        "ProgramID": 31087,
        "ProgramName": "NORD: Organic Acidemia (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)",
          "Homocystinuria",
          "Hyperammonemia",
          "Pyruvate Kinase (PK) Deficiency"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva",
          "Pheburane",
          "Cystadane",
          "Thiola EC",
          "Thiola",
          "Tiopronin",
          "Pyrukynd"
        ]
      },
      {
        "ProgramID": 30605,
        "ProgramName": "NORD: Paroxysmal Nocturnal Hemoglobinuria (PNH) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
        ],
        "Drugs": [
          "Xarelto",
          "Soliris",
          "Arixtra",
          "Ultomiris",
          "Empaveli",
          "Fabhalta",
          "Voydeya",
          "Bkemv",
          "PiaSky",
          "Epysqli",
          "Soliris & Voydeya",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30595,
        "ProgramName": "NORD: Paroxysmal Nocturnal Hemoglobinuria (PNH) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
        ],
        "Drugs": [
          "Xarelto",
          "Soliris",
          "Arixtra",
          "Ultomiris",
          "Empaveli",
          "Fabhalta",
          "Voydeya",
          "Bkemv",
          "PiaSky",
          "Epysqli",
          "Soliris & Voydeya",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30606,
        "ProgramName": "NORD: Periodic Paralysis (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Primary Hyperkalemic Periodic Paralysis",
          "Primary Hypokalemic Periodic Paralysis"
        ],
        "Drugs": [
          "Keveyis",
          "Ormalvi"
        ]
      },
      {
        "ProgramID": 30592,
        "ProgramName": "NORD: Periodic Paralysis (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Primary Hyperkalemic Periodic Paralysis",
          "Primary Hypokalemic Periodic Paralysis"
        ],
        "Drugs": [
          "Keveyis",
          "Ormalvi"
        ]
      },
      {
        "ProgramID": 30607,
        "ProgramName": "NORD: Phenylketonuria (PKU) (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Phenylketonuria (PKU)"
        ],
        "Drugs": [
          "Aldurazyme",
          "Kuvan",
          "Cholbam",
          "Elaprase",
          "Orfadin",
          "Palynziq",
          "Javygtor"
        ]
      },
      {
        "ProgramID": 30557,
        "ProgramName": "NORD: Phenylketonuria (PKU) (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Phenylketonuria (PKU)"
        ],
        "Drugs": [
          "Aldurazyme",
          "Kuvan",
          "Cholbam",
          "Elaprase",
          "Orfadin",
          "Palynziq",
          "Javygtor"
        ]
      },
      {
        "ProgramID": 30845,
        "ProgramName": "NORD: Progeria & Progeroid Laminopathies (Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Progeria and Progeroid Laminopathies"
        ],
        "Drugs": [
          "Zokinvy"
        ]
      },
      {
        "ProgramID": 31007,
        "ProgramName": "NORD: Progeria & Progeroid Laminopathies (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Progeria and Progeroid Laminopathies"
        ],
        "Drugs": [
          "Zokinvy"
        ]
      },
      {
        "ProgramID": 31046,
        "ProgramName": "NORD: Rare Pediatric GI (Medical Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "IBD - Pediatric Crohn's Disease",
          "IBD - Pediatric Ulcerative Colitis"
        ],
        "Drugs": [
          "Humira",
          "Rayos",
          "Remicade",
          "Adalimumab-afzb",
          "Inflectra",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Humira Pen",
          "Amjevita",
          "Ortikos ER",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Simlandi",
          "Adalimumab-ryvk",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate"
        ]
      },
      {
        "ProgramID": 30560,
        "ProgramName": "NORD: Short Bowel Syndrome (Premium & Copay)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Short Bowel Syndrome"
        ],
        "Drugs": [
          "Gattex",
          "Mycapssa"
        ]
      },
      {
        "ProgramID": 30567,
        "ProgramName": "NORD: Urea Cycle Disorder (Copay): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva",
          "Pheburane"
        ]
      },
      {
        "ProgramID": 30609,
        "ProgramName": "NORD: Urea Cycle Disorder (Medical Assistance): Waitlist",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Urea Cycle Disorders (UCD)"
        ],
        "Drugs": [
          "Ravicti",
          "Carbaglu",
          "Buphenyl",
          "Ammonul",
          "Olpruva",
          "Pheburane"
        ]
      },
      {
        "ProgramID": 30829,
        "ProgramName": "PAF Co-Pay Relief: Acromegaly",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acromegaly"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Somavert",
          "Signifor LAR",
          "Octreotide Acetate",
          "Sandostatin",
          "Mycapssa",
          "Lanreotide Acetate"
        ]
      },
      {
        "ProgramID": 30896,
        "ProgramName": "PAF Co-Pay Relief: Acute Myeloid Leukemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Acute Myeloid Leukemia (AML)"
        ],
        "Drugs": [
          "Neupogen",
          "Rayos",
          "Trisenox",
          "Cytarabine",
          "Leukine",
          "Cyclophosphamide",
          "Mutamycin",
          "Mylotarg",
          "Elitek",
          "Venclexta",
          "Vincristine Sulfate",
          "Rydapt",
          "IDHIFA",
          "Vyxeos",
          "Filgrastim",
          "Tibsovo",
          "Nivestym",
          "Daurismo",
          "Xospata",
          "Tabloid",
          "Onureg",
          "Venclexta Starting Pack",
          "Filgrastim-sndz",
          "Releuko",
          "Rezlidhia",
          "Vanflyta",
          "Nypozi",
          "Revuforj"
        ]
      },
      {
        "ProgramID": 30897,
        "ProgramName": "PAF Co-Pay Relief: Alpha-1 Antitrypsin Deficiency",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Alpha-1 Antitrypsin Deficiency (Alpha-1)"
        ],
        "Drugs": [
          "Glassia",
          "Prolastin-C",
          "Zemaira",
          "Aralast NP"
        ]
      },
      {
        "ProgramID": 30898,
        "ProgramName": "PAF Co-Pay Relief: Alzheimer’s Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Alzheimer’s Disease"
        ],
        "Drugs": [
          "Rexulti",
          "Aduhelm",
          "Leqembi",
          "Kisunla",
          "Zunveyl"
        ]
      },
      {
        "ProgramID": 30864,
        "ProgramName": "PAF Co-Pay Relief: Alzheimer’s Disease Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Alzheimer’s Disease"
        ],
        "Drugs": [
          "Rexulti",
          "Aduhelm",
          "Leqembi",
          "Kisunla",
          "Zunveyl"
        ]
      },
      {
        "ProgramID": 30899,
        "ProgramName": "PAF Co-Pay Relief: Amyloidosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Amyloidosis"
        ],
        "Drugs": [
          "Rayos",
          "Cyclophosphamide",
          "Alkeran",
          "Onpattro",
          "Vyndaqel",
          "Vyndamax",
          "Amvuttra",
          "Wainua"
        ]
      },
      {
        "ProgramID": 30900,
        "ProgramName": "PAF Co-Pay Relief: Amyotrophic Lateral Sclerosis (ALS)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Amyotrophic Lateral Sclerosis (ALS)"
        ],
        "Drugs": [
          "Rilutek",
          "Radicava IV",
          "Edaravone",
          "Tiglutik",
          "Exservan",
          "Relyvrio",
          "Radicava ORS",
          "Qalsody"
        ]
      },
      {
        "ProgramID": 30901,
        "ProgramName": "PAF Co-Pay Relief: Ankylosing Spondylitis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ankylosing Spondylitis"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Acthar Gel",
          "Humira",
          "Rayos",
          "Remicade",
          "Simponi",
          "Simponi ARIA",
          "Xeljanz",
          "Adalimumab-afzb",
          "Taltz",
          "Inflectra",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Etanercept",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Purified Cortrophin Gel",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Bimzelx",
          "Simlandi",
          "Adalimumab-ryvk",
          "Rinvoq LQ",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30902,
        "ProgramName": "PAF Co-Pay Relief: Aplastic Anemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Aplastic Anemia"
        ],
        "Drugs": [
          "Promacta",
          "Rayos",
          "Ferriprox",
          "Cyclophosphamide",
          "Atgam",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Lenalidomide",
          "Alvaiz"
        ]
      },
      {
        "ProgramID": 30697,
        "ProgramName": "PAF Co-Pay Relief: Asthma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Asthma",
          "Severe Asthma",
          "Severe Eosinophilic Asthma"
        ],
        "Drugs": [
          "Rayos",
          "Xolair",
          "Cinqair",
          "Dupixent",
          "Fasenra",
          "Tezspire",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Zyflo",
          "Dupixent Pen",
          "Fasenra Pen",
          "Airsupra",
          "Nucala"
        ]
      },
      {
        "ProgramID": 30903,
        "ProgramName": "PAF Co-Pay Relief: Batten Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Batten Disease"
        ],
        "Drugs": [
          "Brineura"
        ]
      },
      {
        "ProgramID": 30904,
        "ProgramName": "PAF Co-Pay Relief: Bile Duct Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Cholangiocarcinoma (Bile Duct Cancer)",
          "Oncology - Biliary Tract Cancer"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Tafinlar",
          "Xeloda",
          "Yervoy",
          "Cyclophosphamide",
          "Elitek",
          "Imfinzi",
          "Tibsovo",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Pemazyre",
          "Tafinlar & Mekinist",
          "Lytgobi",
          "Augtyro"
        ]
      },
      {
        "ProgramID": 30309,
        "ProgramName": "PAF Co-Pay Relief: Bladder Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bladder"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Vinblastine Sulfate",
          "Valstar",
          "Yondelis",
          "Cyclophosphamide",
          "Mutamycin",
          "Tecentriq",
          "Bavencio",
          "Tepadina",
          "Thiotepa",
          "Vitrakvi",
          "Balversa",
          "Padcev",
          "Enhertu",
          "Jelmyto",
          "Trodelvy",
          "Retevmo",
          "Jemperli",
          "Pemazyre",
          "Valrubicin",
          "Tafinlar & Mekinist",
          "Adstiladrin",
          "Kemoplat",
          "Augtyro",
          "Anktiva",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30905,
        "ProgramName": "PAF Co-Pay Relief: Brain Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Astrocytoma",
          "Oncology - Glioblastoma",
          "Oncology - Tuberous Sclerosis-Related Subependymal Giant Cell Astrocytoma (SEGA)",
          "Oncology - Neuroblastoma",
          "Oncology - Primary Malignant Brain Tumors (Grade 3 or 4)",
          "Oncology - Central Nervous System (CNS) Hemangioblastomas",
          "Oncology - Brain Tumors",
          "Oncology - Glioma"
        ],
        "Drugs": [
          "Afinitor",
          "Mekinist",
          "Tafinlar",
          "Temodar",
          "BiCNU",
          "Cyclophosphamide",
          "Gleostine",
          "Everolimus",
          "Afinitor Disperz",
          "Temozolomide",
          "Mvasi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Alymsys",
          "Tafinlar & Mekinist",
          "Augtyro",
          "Voranigo",
          "Avastin",
          "Mutamycin",
          "Gliadel Wafer",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Bevacizumab-awwb",
          "Vegzelma",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Torpenz",
          "Vincasar PFS",
          "Vincristine Sulfate",
          "Danyelza",
          "Unituxin",
          "Iwilfin",
          "Rayos",
          "Welireg",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Ojemda"
        ]
      },
      {
        "ProgramID": 30154,
        "ProgramName": "PAF Co-Pay Relief: Breast Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Perjeta",
          "Prolia",
          "Tafinlar",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Trexall",
          "Methotrexate",
          "Yondelis",
          "Fluorouracil",
          "Docetaxel",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Everolimus",
          "Afinitor Disperz",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Tepadina",
          "Thiotepa",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Retevmo",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Jemperli",
          "Fulvestrant",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Trastuzumab & Hyaluronidase-oysk",
          "Orserdu",
          "Augtyro",
          "Truqap",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Jubbonti",
          "Hercessi",
          "Docivyx",
          "Tepylute",
          "Torpenz",
          "Itovebi",
          "Eribulin Mesylate",
          "Palbociclib"
        ]
      },
      {
        "ProgramID": 30865,
        "ProgramName": "PAF Co-Pay Relief: Breast Cancer Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Perjeta",
          "Prolia",
          "Tafinlar",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Trexall",
          "Methotrexate",
          "Yondelis",
          "Fluorouracil",
          "Docetaxel",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Everolimus",
          "Afinitor Disperz",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Tepadina",
          "Thiotepa",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Retevmo",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Jemperli",
          "Fulvestrant",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Trastuzumab & Hyaluronidase-oysk",
          "Orserdu",
          "Augtyro",
          "Truqap",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Jubbonti",
          "Hercessi",
          "Docivyx",
          "Tepylute",
          "Torpenz",
          "Itovebi",
          "Eribulin Mesylate",
          "Palbociclib"
        ]
      },
      {
        "ProgramID": 30906,
        "ProgramName": "PAF Co-Pay Relief: Cardiac Arrhythmias",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Antiarrhythmics / Atrial Fib"
        ],
        "Drugs": [
          "Xarelto",
          "Tikosyn",
          "Dofetilide",
          "Sotylize"
        ]
      },
      {
        "ProgramID": 30858,
        "ProgramName": "PAF Co-Pay Relief: Cardiac Arrhythmias Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Antiarrhythmics / Atrial Fib"
        ],
        "Drugs": [
          "Xarelto",
          "Tikosyn",
          "Dofetilide",
          "Sotylize"
        ]
      },
      {
        "ProgramID": 30986,
        "ProgramName": "PAF Co-Pay Relief: Cardiomyopathy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Cardiomyopathy",
          "Obstructive Hypertrophic Cardiomyopathy (HCM)"
        ],
        "Drugs": [
          "Vyndaqel",
          "Vyndamax",
          "Camzyos",
          "Jardiance"
        ]
      },
      {
        "ProgramID": 30294,
        "ProgramName": "PAF Co-Pay Relief: Cervical Cancer",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Cervical",
          "Oncology - Metastatic Cervical Cancer"
        ],
        "Drugs": [
          "Avastin",
          "Hycamtin Injection",
          "Keytruda",
          "Mekinist",
          "Tafinlar",
          "Paraplatin",
          "Cyclophosphamide",
          "Topotecan",
          "Mvasi",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Tivdak",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr"
        ]
      },
      {
        "ProgramID": 30866,
        "ProgramName": "PAF Co-Pay Relief: Cervical Cancer Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Cervical",
          "Oncology - Metastatic Cervical Cancer"
        ],
        "Drugs": [
          "Avastin",
          "Hycamtin Injection",
          "Keytruda",
          "Mekinist",
          "Tafinlar",
          "Paraplatin",
          "Cyclophosphamide",
          "Topotecan",
          "Mvasi",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Tivdak",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr"
        ]
      },
      {
        "ProgramID": 30958,
        "ProgramName": "PAF Co-Pay Relief: Chronic Obstructive Pulmonary Disease (COPD)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "Drugs": [
          "Prolastin-C",
          "Rayos",
          "Zemaira",
          "Dupixent",
          "Yupelri",
          "Aralast NP",
          "Dupixent Pen",
          "Ohtuvayre"
        ]
      },
      {
        "ProgramID": 30863,
        "ProgramName": "PAF Co-Pay Relief: Chronic Obstructive Pulmonary Disease Health Equity Fund (COPD)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "Drugs": [
          "Prolastin-C",
          "Rayos",
          "Zemaira",
          "Dupixent",
          "Yupelri",
          "Aralast NP",
          "Dupixent Pen",
          "Ohtuvayre"
        ]
      },
      {
        "ProgramID": 30907,
        "ProgramName": "PAF Co-Pay Relief: Coronary Artery Disease (CAD)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Coronary Artery Disease (CAD)"
        ],
        "Drugs": [
          "Repatha",
          "Fragmin",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30867,
        "ProgramName": "PAF Co-Pay Relief: Coronary Artery Disease (CAD) Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Coronary Artery Disease (CAD)"
        ],
        "Drugs": [
          "Repatha",
          "Fragmin",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30811,
        "ProgramName": "PAF Co-Pay Relief: COVID-19 & Post COVID Conditions",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "COVID-19"
        ],
        "Drugs": [
          "Actemra",
          "Olumiant",
          "Veklury",
          "Tofidence",
          "Paxlovid"
        ]
      },
      {
        "ProgramID": 30908,
        "ProgramName": "PAF Co-Pay Relief: Crohn’s Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "IBD - Crohn's Disease",
          "IBD - Pediatric Crohn's Disease"
        ],
        "Drugs": [
          "Cimzia",
          "Entyvio",
          "Humira",
          "Rayos",
          "Remicade",
          "Stelara",
          "Tysabri",
          "Adalimumab-afzb",
          "Inflectra",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Skyrizi",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Amjevita",
          "Ortikos ER",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Tyruko",
          "Zymfentra",
          "Wezlana",
          "Simlandi",
          "Adalimumab-ryvk",
          "Entyvio Pen",
          "Rinvoq LQ",
          "Pyzchiva",
          "Otulfi",
          "Imuldosa"
        ]
      },
      {
        "ProgramID": 30909,
        "ProgramName": "PAF Co-Pay Relief: Cushing’s Syndrome",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Cushing’s Disease"
        ],
        "Drugs": [
          "Signifor",
          "Korlym",
          "Metopirone",
          "Signifor LAR",
          "Isturisa",
          "Recorlev",
          "Mifepristone"
        ]
      },
      {
        "ProgramID": 30790,
        "ProgramName": "PAF Co-Pay Relief: Cystic Fibrosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Cystic Fibrosis"
        ],
        "Drugs": [
          "Bethkis",
          "Cayston",
          "Creon",
          "Kalydeco",
          "Pancreaze",
          "Pertzye",
          "Pulmozyme",
          "Tobi Podhaler",
          "Zenpep",
          "Orkambi",
          "Kitabis Pak",
          "Tobramycin",
          "Tobramycin Inhalation Solution",
          "Symdeko",
          "Trikafta",
          "Bronchitol"
        ]
      },
      {
        "ProgramID": 30868,
        "ProgramName": "PAF Co-Pay Relief: Cystic Fibrosis Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Cystic Fibrosis"
        ],
        "Drugs": [
          "Bethkis",
          "Cayston",
          "Creon",
          "Kalydeco",
          "Pancreaze",
          "Pertzye",
          "Pulmozyme",
          "Tobi Podhaler",
          "Zenpep",
          "Orkambi",
          "Kitabis Pak",
          "Tobramycin",
          "Tobramycin Inhalation Solution",
          "Symdeko",
          "Trikafta",
          "Bronchitol"
        ]
      },
      {
        "ProgramID": 30910,
        "ProgramName": "PAF Co-Pay Relief: Cystinosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Nephropathic Cystinosis"
        ],
        "Drugs": [
          "Procysbi",
          "Cystaran",
          "Cystagon",
          "Cyclophosphamide",
          "Cystadrops"
        ]
      },
      {
        "ProgramID": 30914,
        "ProgramName": "PAF Co-Pay Relief: Epilepsy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Infantile Spasms",
          "Seizures"
        ],
        "Drugs": [
          "Botox",
          "Acthar Gel",
          "Sabril",
          "Briviact",
          "Vigabatrin",
          "Vigadrone",
          "Vigpoder",
          "Vigafyde",
          "Acthar Selfject",
          "Afinitor",
          "Fycompa",
          "Onfi",
          "Afinitor Disperz",
          "Epidiolex",
          "Xcopri",
          "Fintepla",
          "Ztalmy",
          "Aptiom",
          "Felbatol",
          "Diacomit",
          "Zonisade",
          "Motpoly XR"
        ]
      },
      {
        "ProgramID": 30915,
        "ProgramName": "PAF Co-Pay Relief: Esophageal Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Esophageal Cancer",
          "Oncology - Gastroesophageal Junction Cancer"
        ],
        "Drugs": [
          "Herceptin",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Xeloda",
          "Yervoy",
          "Capecitabine",
          "Photofrin",
          "Cyclophosphamide",
          "Ogivri",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Enhertu",
          "Retevmo",
          "Opdivo & Yervoy",
          "Jemperli",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Augtyro",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Tevimbra",
          "Cyramza",
          "Taxotere",
          "Lonsurf",
          "Docetaxel",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Hercessi",
          "Docivyx",
          "Vyloy"
        ]
      },
      {
        "ProgramID": 30916,
        "ProgramName": "PAF Co-Pay Relief: Fabry Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 30827,
        "ProgramName": "PAF Co-Pay Relief: Gaucher Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat",
          "Yargesa"
        ]
      },
      {
        "ProgramID": 31049,
        "ProgramName": "PAF Co-Pay Relief: Gaucher Disease Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat",
          "Yargesa"
        ]
      },
      {
        "ProgramID": 31078,
        "ProgramName": "PAF Co-Pay Relief: Gout",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Gout"
        ],
        "Drugs": [
          "Acthar Gel",
          "Ilaris",
          "Krystexxa",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30917,
        "ProgramName": "PAF Co-Pay Relief: Graft vs Host Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Graft Versus Host Disease (cGVHD)",
          "Steroid-Refractory Acute Graft Versus Host Disease",
          "Acute Graft Versus Host Disease (aGvHD)",
          "Pediatric Chronic Graft-versus-Host Disease (PcGVHD)",
          "Pediatric Acute Graft-versus-Host Disease (PaGVHD)"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Imbruvica",
          "Jakafi",
          "Neoral",
          "Prograf",
          "Rayos",
          "Sandimmune",
          "Envarsus XR",
          "Sirolimus",
          "Tacrolimus",
          "Rezurock",
          "Posaconazole",
          "Imbruvica & Gazyva",
          "Noxafil Oral Suspension",
          "Noxafil Tablets",
          "Niktimvo",
          "Thymoglobulin",
          "Orencia",
          "Orencia Clickject"
        ]
      },
      {
        "ProgramID": 30918,
        "ProgramName": "PAF Co-Pay Relief: Growth Hormone Deficiency",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Growth Hormone Deficiency",
          "Pediatric Growth Hormone Deficiency"
        ],
        "Drugs": [
          "Genotropin",
          "Humatrope",
          "Omnitrope",
          "Increlex",
          "Zomacton",
          "Genotropin Miniquick",
          "Nutropin AQ Nuspin",
          "Norditropin Flexpro",
          "Sogroya",
          "Skytrofa",
          "Ngenla"
        ]
      },
      {
        "ProgramID": 30919,
        "ProgramName": "PAF Co-Pay Relief: Head & Neck Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Head and Neck",
          "Oncology - Nasopharyngeal Carcinoma (NPC)"
        ],
        "Drugs": [
          "Erbitux",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Taxotere",
          "Temodar",
          "Docetaxel",
          "Cyclophosphamide",
          "Mutamycin",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Tafinlar & Mekinist",
          "Augtyro",
          "Docivyx",
          "Elitek",
          "Loqtorzi"
        ]
      },
      {
        "ProgramID": 30920,
        "ProgramName": "PAF Co-Pay Relief: Heart Failure",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Congestive Heart Failure",
          "Heart Failure"
        ],
        "Drugs": [
          "Farxiga",
          "Rayos",
          "Xigduo XR",
          "Jardiance",
          "Samsca",
          "Inpefa"
        ]
      },
      {
        "ProgramID": 30854,
        "ProgramName": "PAF Co-Pay Relief: Heart Failure Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Congestive Heart Failure",
          "Heart Failure"
        ],
        "Drugs": [
          "Farxiga",
          "Rayos",
          "Xigduo XR",
          "Jardiance",
          "Samsca",
          "Inpefa"
        ]
      },
      {
        "ProgramID": 30831,
        "ProgramName": "PAF Co-Pay Relief: Hemophilia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hemophilia"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Corifact",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Tretten",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Coagadex",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Andexxa",
          "Hemgenix",
          "Altuviiio",
          "Roctavian",
          "Beqvez",
          "Hympavzi",
          "Alhemo"
        ]
      },
      {
        "ProgramID": 31096,
        "ProgramName": "PAF Co-Pay Relief: Hemophilia Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hemophilia"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Corifact",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Tretten",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Coagadex",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Andexxa",
          "Hemgenix",
          "Altuviiio",
          "Roctavian",
          "Beqvez",
          "Hympavzi",
          "Alhemo"
        ]
      },
      {
        "ProgramID": 30300,
        "ProgramName": "PAF Co-Pay Relief: Hepatitis B",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hepatitis B"
        ],
        "Drugs": [
          "Baraclude",
          "Pegasys",
          "Viread",
          "Hepsera",
          "Nabi-HB",
          "HepaGam B",
          "Vemlidy",
          "Peginterferon Alfa-2A",
          "Tenofovir Disoproxil",
          "Entecavir",
          "Immune Globulin Intravenous (IGIV)",
          "HyperHEP B",
          "Adefovir Dipivoxil",
          "Tenofovir Alafenamide"
        ]
      },
      {
        "ProgramID": 30872,
        "ProgramName": "PAF Co-Pay Relief: Hepatitis B Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hepatitis B"
        ],
        "Drugs": [
          "Baraclude",
          "Pegasys",
          "Viread",
          "Hepsera",
          "Nabi-HB",
          "HepaGam B",
          "Vemlidy",
          "Peginterferon Alfa-2A",
          "Tenofovir Disoproxil",
          "Entecavir",
          "Immune Globulin Intravenous (IGIV)",
          "HyperHEP B",
          "Adefovir Dipivoxil",
          "Tenofovir Alafenamide"
        ]
      },
      {
        "ProgramID": 30068,
        "ProgramName": "PAF Co-Pay Relief: Hepatitis C",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hepatitis C"
        ],
        "Drugs": [
          "Harvoni",
          "Pegasys",
          "Promacta",
          "Sovaldi",
          "Ribavirin",
          "Zepatier",
          "Epclusa",
          "Peginterferon Alfa-2A",
          "Vosevi",
          "Mavyret",
          "Sofosbuvir & Velpatasvir",
          "Ledipasvir & Sofosbuvir",
          "Alvaiz",
          "Peginterferon Alfa-2B"
        ]
      },
      {
        "ProgramID": 30859,
        "ProgramName": "PAF Co-Pay Relief: Hepatitis C Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hepatitis C"
        ],
        "Drugs": [
          "Harvoni",
          "Pegasys",
          "Promacta",
          "Sovaldi",
          "Ribavirin",
          "Zepatier",
          "Epclusa",
          "Peginterferon Alfa-2A",
          "Vosevi",
          "Mavyret",
          "Sofosbuvir & Velpatasvir",
          "Ledipasvir & Sofosbuvir",
          "Alvaiz",
          "Peginterferon Alfa-2B"
        ]
      },
      {
        "ProgramID": 30842,
        "ProgramName": "PAF Co-Pay Relief: Hepatocellular Carcinoma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Liver",
          "Oncology - Hepatocellular Carcinoma (HCC)"
        ],
        "Drugs": [
          "Avastin",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Opdivo",
          "Stivarga",
          "Tafinlar",
          "Yervoy",
          "Floxuridine",
          "Cyclophosphamide",
          "Cabometyx",
          "Tecentriq",
          "Imfinzi",
          "Bevacizumab",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Keytruda & Lenvima",
          "Tafinlar & Mekinist",
          "Imjudo",
          "Imfinzi & Imjudo",
          "Augtyro",
          "Tecentriq Hybreza",
          "Cyramza",
          "Nexavar",
          "Elitek",
          "Sorafenib Tosylate",
          "Opdivo & Yervoy",
          "Tecentriq & Avastin"
        ]
      },
      {
        "ProgramID": 30921,
        "ProgramName": "PAF Co-Pay Relief: Hereditary Angioedema",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hereditary Angioedema"
        ],
        "Drugs": [
          "Berinert",
          "Cinryze",
          "Firazyr",
          "Kalbitor",
          "Ruconest",
          "Haegarda",
          "Takhzyro",
          "Icatibant Acetate",
          "Orladeyo",
          "Sajazir"
        ]
      },
      {
        "ProgramID": 30301,
        "ProgramName": "PAF Co-Pay Relief: HIV, AIDS and Prevention",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "HIV Infection",
          "HIV/AIDS - Supportive",
          "HIV-1 Integrase Strand Transfer Inhibitor (INSTI)",
          "HIV-1 Pre-Exposure Prophylaxis (PrEP)"
        ],
        "Drugs": [
          "Atripla",
          "Complera",
          "Edurant",
          "Egrifta SV",
          "Emtriva",
          "Epivir",
          "Evotaz",
          "Fuzeon",
          "Intelence",
          "Isentress",
          "Kaletra",
          "Norvir",
          "Prezcobix",
          "Prezista",
          "Retrovir",
          "Reyataz",
          "Selzentry",
          "Serostim",
          "Stribild",
          "Tivicay",
          "Triumeq",
          "Truvada",
          "Tybost",
          "Viracept",
          "Viread",
          "Ziagen",
          "Aptivus",
          "Lamivudine & Zidovudine",
          "Didanosine",
          "Lamivudine",
          "Nevirapine",
          "Nevirapine ER",
          "Stavudine",
          "Zidovudine",
          "Genvoya",
          "Odefsey",
          "Descovy",
          "Juluca",
          "Biktarvy",
          "Trogarzo",
          "Symtuza",
          "Pifeltro",
          "Delstrigo",
          "Cimduo",
          "Symfi Lo",
          "Dovato",
          "Tenofovir Disoproxil",
          "Tivicay PD",
          "Rukobia",
          "Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Efavirenz & Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Cabenuva",
          "Symfi",
          "Etravirine",
          "Triumeq PD",
          "Lopinavir & Ritonavir",
          "Maraviroc",
          "Efavirenz & Lamivudine & Tenofovir Disoproxil Fumarate",
          "Efavirenz",
          "Fosamprenavir Calcium",
          "Isentress HD",
          "Abacavir",
          "Ritonavir",
          "Abacavir & Lamivudine",
          "Abacavir & Lamivudine & Zidovudine",
          "Emtricitabine",
          "Sunlenca",
          "Darunavir",
          "Edurant PED",
          "Epogen",
          "Procrit",
          "Syndros",
          "Mytesi",
          "Retacrit",
          "WinRho SDF",
          "Apretude"
        ]
      },
      {
        "ProgramID": 30860,
        "ProgramName": "PAF Co-Pay Relief: HIV, AIDS and Prevention Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "HIV Infection",
          "HIV/AIDS - Supportive",
          "HIV-1 Integrase Strand Transfer Inhibitor (INSTI)",
          "HIV-1 Pre-Exposure Prophylaxis (PrEP)"
        ],
        "Drugs": [
          "Atripla",
          "Complera",
          "Edurant",
          "Egrifta SV",
          "Emtriva",
          "Epivir",
          "Evotaz",
          "Fuzeon",
          "Intelence",
          "Isentress",
          "Kaletra",
          "Norvir",
          "Prezcobix",
          "Prezista",
          "Retrovir",
          "Reyataz",
          "Selzentry",
          "Serostim",
          "Stribild",
          "Tivicay",
          "Triumeq",
          "Truvada",
          "Tybost",
          "Viracept",
          "Viread",
          "Ziagen",
          "Aptivus",
          "Lamivudine & Zidovudine",
          "Didanosine",
          "Lamivudine",
          "Nevirapine",
          "Nevirapine ER",
          "Stavudine",
          "Zidovudine",
          "Genvoya",
          "Odefsey",
          "Descovy",
          "Juluca",
          "Biktarvy",
          "Trogarzo",
          "Symtuza",
          "Pifeltro",
          "Delstrigo",
          "Cimduo",
          "Symfi Lo",
          "Dovato",
          "Tenofovir Disoproxil",
          "Tivicay PD",
          "Rukobia",
          "Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Efavirenz & Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Cabenuva",
          "Symfi",
          "Etravirine",
          "Triumeq PD",
          "Lopinavir & Ritonavir",
          "Maraviroc",
          "Efavirenz & Lamivudine & Tenofovir Disoproxil Fumarate",
          "Efavirenz",
          "Fosamprenavir Calcium",
          "Isentress HD",
          "Abacavir",
          "Ritonavir",
          "Abacavir & Lamivudine",
          "Abacavir & Lamivudine & Zidovudine",
          "Emtricitabine",
          "Sunlenca",
          "Darunavir",
          "Edurant PED",
          "Epogen",
          "Procrit",
          "Syndros",
          "Mytesi",
          "Retacrit",
          "WinRho SDF",
          "Apretude"
        ]
      },
      {
        "ProgramID": 30302,
        "ProgramName": "PAF Co-Pay Relief: Homozygous Familial Hypercholesterolemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hypercholesterolemia",
          "Homozygous Familial Hypercholesterolemia (HoFH)"
        ],
        "Drugs": [
          "Juxtapid",
          "Repatha",
          "Praluent",
          "Evkeeza",
          "Leqvio",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30960,
        "ProgramName": "PAF Co-Pay Relief: Huntington’s Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Huntington's Disease"
        ],
        "Drugs": [
          "Xenazine",
          "Austedo",
          "Ingrezza",
          "Tetrabenazine",
          "Valbenazine Tosylate",
          "Austedo XR",
          "Ingrezza Sprinkle"
        ]
      },
      {
        "ProgramID": 30959,
        "ProgramName": "PAF Co-Pay Relief: Hyperlipidemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hypercholesterolemia",
          "Homozygous Familial Hypercholesterolemia (HoFH)",
          "Heterozygous Familial Hypercholesterolemia (HeFH)",
          "Hyperlipidemia"
        ],
        "Drugs": [
          "Juxtapid",
          "Repatha",
          "Praluent",
          "Evkeeza",
          "Leqvio",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30873,
        "ProgramName": "PAF Co-Pay Relief: Hyperlipidemia Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hypercholesterolemia",
          "Homozygous Familial Hypercholesterolemia (HoFH)",
          "Heterozygous Familial Hypercholesterolemia (HeFH)",
          "Hyperlipidemia"
        ],
        "Drugs": [
          "Juxtapid",
          "Repatha",
          "Praluent",
          "Evkeeza",
          "Leqvio",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30922,
        "ProgramName": "PAF Co-Pay Relief: Hyperparathyroidism",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hyperparathyroidism"
        ],
        "Drugs": [
          "Sensipar",
          "Rayaldee",
          "Parsabiv",
          "Cinacalcet"
        ]
      },
      {
        "ProgramID": 30923,
        "ProgramName": "PAF Co-Pay Relief: Idiopathic Thrombocytopenic Purpura",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Immune Thrombocytopenic Purpura (ITP)",
          "Thrombocytopenia",
          "Acquired / Immune-Mediated Thrombotic Thrombocytopenic Purpura (aTTP / iTTP)",
          "Chronic Immune Thrombocytopenia (CITP)",
          "Congenital Thrombotic Thrombocytopenic Purpura (cTTP)"
        ],
        "Drugs": [
          "Gamunex-C",
          "Nplate",
          "Promacta",
          "Rayos",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Gammaked",
          "Cyclophosphamide",
          "Gammaplex",
          "Rhophylac",
          "Tavalisse",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "WinRho SDF",
          "Vidaza",
          "Nipent",
          "Cladribine",
          "Azacitidine",
          "Doptelet",
          "Mulpleta",
          "Cablivi",
          "Reblozyl",
          "Adzynma",
          "Alvaiz"
        ]
      },
      {
        "ProgramID": 31015,
        "ProgramName": "PAF Co-Pay Relief: IgA Nephropathy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Primary Immunoglobulin A Nephropathy (IgAN)",
          "IgA Nephropathy"
        ],
        "Drugs": [
          "Rayos",
          "Tarpeyo",
          "Filspari",
          "Fabhalta",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Jardiance"
        ]
      },
      {
        "ProgramID": 30303,
        "ProgramName": "PAF Co-Pay Relief: Inherited or Acquired Lipodystrophy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Lipodystrophy",
          "Progeria and Progeroid Laminopathies"
        ],
        "Drugs": [
          "Egrifta SV",
          "Myalept",
          "Zokinvy"
        ]
      },
      {
        "ProgramID": 30924,
        "ProgramName": "PAF Co-Pay Relief: Juvenile Idiopathic Systemic Arthritis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Juvenile Idiopathic Arthritis",
          "Systemic Juvenile Idiopathic Arthritis (SJIA)"
        ],
        "Drugs": [
          "Actemra",
          "Enbrel",
          "Acthar Gel",
          "Humira",
          "Ilaris",
          "Orencia",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Trexall",
          "Adalimumab-afzb",
          "Cyltezo",
          "Hyrimoz",
          "Rinvoq",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Actemra Actpen",
          "Hadlima",
          "Etanercept",
          "Orencia Clickject",
          "Jylamvo",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Simlandi",
          "Tyenne",
          "Adalimumab-ryvk",
          "Rinvoq LQ",
          "Acthar Selfject",
          "Tofidence"
        ]
      },
      {
        "ProgramID": 30843,
        "ProgramName": "PAF Co-Pay Relief: Lupus",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Systemic Lupus Erythematosus",
          "Pediatric Systemic Lupus Erythematosus"
        ],
        "Drugs": [
          "Benlysta",
          "Acthar Gel",
          "Rayos",
          "Cyclophosphamide",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Saphnelo",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 31048,
        "ProgramName": "PAF Co-Pay Relief: Lupus Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Systemic Lupus Erythematosus",
          "Pediatric Systemic Lupus Erythematosus"
        ],
        "Drugs": [
          "Benlysta",
          "Acthar Gel",
          "Rayos",
          "Cyclophosphamide",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Saphnelo",
          "Purified Cortrophin Gel",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30925,
        "ProgramName": "PAF Co-Pay Relief: Macular Degeneration",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD"
        ],
        "Drugs": [
          "Visudyne",
          "Eylea",
          "Beovu",
          "Byooviz",
          "Susvimo",
          "Vabysmo",
          "Cimerli",
          "Syfovre",
          "Izervay",
          "Yesafili",
          "Opuviz",
          "Ahzantive",
          "Enzeevu",
          "Pavblu",
          "Lucentis",
          "Eylea HD"
        ]
      },
      {
        "ProgramID": 30926,
        "ProgramName": "PAF Co-Pay Relief: Mast Cell Activation Disorders",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Aggressive Systemic Mastocytosis (ASM)",
          "Symptomatic Mast Cell Disease",
          "Oncology - Indolent Systemic Mastocytosis (ISM)"
        ],
        "Drugs": [
          "Gleevec",
          "Cyclophosphamide",
          "Gastrocrom",
          "Imatinib",
          "Rydapt",
          "Ayvakit",
          "Imkeldi"
        ]
      },
      {
        "ProgramID": 30927,
        "ProgramName": "PAF Co-Pay Relief: Melanoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Melanoma",
          "Oncology - Metastatic Uveal Melanoma (mUM)"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Proleukin",
          "Tafinlar",
          "Yervoy",
          "Zelboraf",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Vemurafenib",
          "Braftovi",
          "Mektovi",
          "Enhertu",
          "Opdivo & Yervoy",
          "Jemperli",
          "Kimmtrak",
          "Braftovi & Mektovi",
          "Opdualag",
          "Tafinlar & Mekinist",
          "Amtagvi",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30928,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Bladder Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bladder"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Vinblastine Sulfate",
          "Valstar",
          "Yondelis",
          "Cyclophosphamide",
          "Mutamycin",
          "Tecentriq",
          "Bavencio",
          "Tepadina",
          "Thiotepa",
          "Vitrakvi",
          "Balversa",
          "Padcev",
          "Enhertu",
          "Jelmyto",
          "Retevmo",
          "Jemperli",
          "Pemazyre",
          "Valrubicin",
          "Tafinlar & Mekinist",
          "Adstiladrin",
          "Kemoplat",
          "Augtyro",
          "Anktiva",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30571,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Breast Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Perjeta",
          "Prolia",
          "Tafinlar",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Trexall",
          "Methotrexate",
          "Yondelis",
          "Fluorouracil",
          "Docetaxel",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Everolimus",
          "Afinitor Disperz",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Tepadina",
          "Thiotepa",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Retevmo",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Jemperli",
          "Fulvestrant",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Trastuzumab & Hyaluronidase-oysk",
          "Orserdu",
          "Augtyro",
          "Truqap",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Jubbonti",
          "Hercessi",
          "Docivyx",
          "Tepylute",
          "Torpenz",
          "Itovebi",
          "Eribulin Mesylate",
          "Palbociclib"
        ]
      },
      {
        "ProgramID": 30996,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Breast Cancer Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Perjeta",
          "Prolia",
          "Tafinlar",
          "Taxotere",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Trexall",
          "Methotrexate",
          "Yondelis",
          "Fluorouracil",
          "Docetaxel",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Everolimus",
          "Afinitor Disperz",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Verzenio",
          "Ogivri",
          "Tepadina",
          "Thiotepa",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Retevmo",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Jemperli",
          "Fulvestrant",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Trastuzumab & Hyaluronidase-oysk",
          "Orserdu",
          "Augtyro",
          "Truqap",
          "Trastuzumab-dttb",
          "Trastuzumab-pkrb",
          "Jubbonti",
          "Hercessi",
          "Docivyx",
          "Tepylute",
          "Torpenz",
          "Itovebi",
          "Eribulin Mesylate",
          "Palbociclib"
        ]
      },
      {
        "ProgramID": 30304,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Colorectal Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Mismatch Repair-Deficient Colorectal Cancer (CRC)",
          "Oncology - Metastatic Colorectal Cancer (mCRC)"
        ],
        "Drugs": [
          "Avastin",
          "Camptosar",
          "Cyramza",
          "Erbitux",
          "Keytruda",
          "Opdivo",
          "Stivarga",
          "Vectibix",
          "Xeloda",
          "Yervoy",
          "Zaltrap",
          "Lonsurf",
          "Capecitabine",
          "Yondelis",
          "Fluorouracil",
          "Irinotecan",
          "Cyclophosphamide",
          "Mutamycin",
          "Mvasi",
          "Bevacizumab",
          "Braftovi",
          "Khapzory",
          "Vitrakvi",
          "Zirabev",
          "Enhertu",
          "Tukysa",
          "Retevmo",
          "Jemperli",
          "Alymsys",
          "Bevacizumab-awwb",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Krazati",
          "Fruzaqla",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Opdivo & Yervoy",
          "Levoleucovorin"
        ]
      },
      {
        "ProgramID": 30861,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Colorectal Cancer Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Mismatch Repair-Deficient Colorectal Cancer (CRC)",
          "Oncology - Metastatic Colorectal Cancer (mCRC)"
        ],
        "Drugs": [
          "Avastin",
          "Camptosar",
          "Cyramza",
          "Erbitux",
          "Keytruda",
          "Opdivo",
          "Stivarga",
          "Vectibix",
          "Xeloda",
          "Yervoy",
          "Zaltrap",
          "Lonsurf",
          "Capecitabine",
          "Yondelis",
          "Fluorouracil",
          "Irinotecan",
          "Cyclophosphamide",
          "Mutamycin",
          "Mvasi",
          "Bevacizumab",
          "Braftovi",
          "Khapzory",
          "Vitrakvi",
          "Zirabev",
          "Enhertu",
          "Tukysa",
          "Retevmo",
          "Jemperli",
          "Alymsys",
          "Bevacizumab-awwb",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Krazati",
          "Fruzaqla",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Opdivo & Yervoy",
          "Levoleucovorin"
        ]
      },
      {
        "ProgramID": 30305,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Gastric Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Gastric"
        ],
        "Drugs": [
          "Cyramza",
          "Herceptin",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Taxotere",
          "Xeloda",
          "Mitomycin",
          "Lonsurf",
          "Capecitabine",
          "Yondelis",
          "Fluorouracil",
          "Docetaxel",
          "Floxuridine",
          "Cyclophosphamide",
          "Ogivri",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Kanjinti",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Trastuzumab-anns",
          "Trastuzumab-dkst",
          "Trastuzumab-qyyp",
          "Trastuzumab",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Trastuzumab-dttb",
          "Hercessi",
          "Docivyx",
          "Vyloy"
        ]
      },
      {
        "ProgramID": 30806,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Melanoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Melanoma",
          "Oncology - Metastatic Uveal Melanoma (mUM)"
        ],
        "Drugs": [
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Proleukin",
          "Tafinlar",
          "Yervoy",
          "Zelboraf",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Vemurafenib",
          "Braftovi",
          "Mektovi",
          "Enhertu",
          "Opdivo & Yervoy",
          "Jemperli",
          "Kimmtrak",
          "Braftovi & Mektovi",
          "Opdualag",
          "Tafinlar & Mekinist",
          "Amtagvi",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30306,
        "ProgramName": "PAF Co-Pay Relief: Metastatic Prostate Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Castration-Sensitive Prostate Cancer",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
          "Oncology - Castration-Resistant Prostate Cancer"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Mekinist",
          "Nilandron",
          "Prolia",
          "Provenge",
          "Rayos",
          "Tafinlar",
          "Taxotere",
          "Trelstar",
          "Xofigo",
          "Xtandi",
          "Zoladex",
          "Zometa",
          "Zytiga",
          "Mitoxantrone",
          "Yondelis",
          "Zoledronic Acid",
          "Docetaxel",
          "Cyclophosphamide",
          "Mutamycin",
          "Leuprolide Acetate",
          "Rubraca",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Vitrakvi",
          "Abiraterone Acetate",
          "Nubeqa",
          "Enhertu",
          "Retevmo",
          "Orgovyx",
          "Jemperli",
          "Camcevi",
          "Pluvicto",
          "Tafinlar & Mekinist",
          "Akeega",
          "Augtyro",
          "Jubbonti",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30929,
        "ProgramName": "PAF Co-Pay Relief: Migraine",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Migraine Headaches"
        ],
        "Drugs": [
          "Botox",
          "Aimovig",
          "Ajovy",
          "Emgality",
          "Ubrelvy",
          "Vyepti",
          "Nurtec ODT",
          "Trudhesa",
          "Qulipta",
          "Zavzpret"
        ]
      },
      {
        "ProgramID": 30987,
        "ProgramName": "PAF Co-Pay Relief: Mucopolysaccharidosis Type I",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type I (MPS I: Hurler / Hurler-Scheie Syndrome)"
        ],
        "Drugs": [
          "Aldurazyme",
          "Rayos"
        ]
      },
      {
        "ProgramID": 30988,
        "ProgramName": "PAF Co-Pay Relief: Mucopolysaccharidosis Type II",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type II (MPS II: Hunter Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Elaprase"
        ]
      },
      {
        "ProgramID": 30989,
        "ProgramName": "PAF Co-Pay Relief: Mucopolysaccharidosis Type III",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type III (MPS III: Sanfilippo Syndrome)"
        ],
        "Drugs": [
          "Rayos"
        ]
      },
      {
        "ProgramID": 30990,
        "ProgramName": "PAF Co-Pay Relief: Mucopolysaccharidosis Type IV",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type IV (MPS IV: Morquio Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Vimizim"
        ]
      },
      {
        "ProgramID": 30991,
        "ProgramName": "PAF Co-Pay Relief: Mucopolysaccharidosis VI",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type VI (MPS VI: Maroteaux-Lamy Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Naglazyme"
        ]
      },
      {
        "ProgramID": 30992,
        "ProgramName": "PAF Co-Pay Relief: Mucopolysaccharidosis VII",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Enzyme Disorders - Mucopolysaccharidosis Type VII (MPS VII: Sly Syndrome)"
        ],
        "Drugs": [
          "Rayos",
          "Mepsevii"
        ]
      },
      {
        "ProgramID": 30307,
        "ProgramName": "PAF Co-Pay Relief: Multiple Myeloma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma"
        ],
        "Drugs": [
          "Doxil",
          "Kyprolis",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Thalomid",
          "Velcade",
          "Xgeva",
          "Zometa",
          "Cytarabine",
          "Mozobil",
          "Zoledronic Acid",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Mutamycin",
          "Empliciti",
          "Evomela",
          "Vincristine Sulfate",
          "Melphalan",
          "Xpovio",
          "Sarclisa",
          "Darzalex Faspro",
          "Blenrep",
          "Kyprolis & Darzalex",
          "Bortezomib",
          "Abecma",
          "Lenalidomide",
          "Carvykti",
          "Tecvayli",
          "Talvey",
          "Elrexfio",
          "Aphexda",
          "Wyost",
          "Boruzu"
        ]
      },
      {
        "ProgramID": 30874,
        "ProgramName": "PAF Co-Pay Relief: Multiple Myeloma Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma"
        ],
        "Drugs": [
          "Doxil",
          "Kyprolis",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Thalomid",
          "Velcade",
          "Xgeva",
          "Zometa",
          "Cytarabine",
          "Mozobil",
          "Zoledronic Acid",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Mutamycin",
          "Empliciti",
          "Evomela",
          "Vincristine Sulfate",
          "Melphalan",
          "Xpovio",
          "Sarclisa",
          "Darzalex Faspro",
          "Blenrep",
          "Kyprolis & Darzalex",
          "Bortezomib",
          "Abecma",
          "Lenalidomide",
          "Carvykti",
          "Tecvayli",
          "Talvey",
          "Elrexfio",
          "Aphexda",
          "Wyost",
          "Boruzu"
        ]
      },
      {
        "ProgramID": 30415,
        "ProgramName": "PAF Co-Pay Relief: Multiple Sclerosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Multiple Sclerosis (MS)"
        ],
        "Drugs": [
          "Ampyra",
          "Aubagio",
          "Avonex",
          "Betaseron",
          "Copaxone",
          "Gilenya",
          "Acthar Gel",
          "Lemtrada",
          "Plegridy",
          "Rayos",
          "Rebif",
          "Tecfidera",
          "Tysabri",
          "Mitoxantrone",
          "Glatopa",
          "Cyclophosphamide",
          "Cladribine",
          "Ocrevus",
          "Avonex Pen",
          "Glatiramer Acetate",
          "Rebif Rebidose",
          "Dalfampridine",
          "Mavenclad",
          "Mayzent",
          "Vumerity",
          "Zeposia",
          "Bafiertam",
          "Kesimpta",
          "Dimethyl Fumarate",
          "Ponvory",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Fleqsuvy",
          "Ozobax DS",
          "Purified Cortrophin Gel",
          "Tascenso ODT",
          "Fingolimod",
          "Dimethyl Fumarate DR",
          "Briumvi",
          "Teriflunomide",
          "Tyruko",
          "Peginterferon Beta-1A",
          "Acthar Selfject",
          "Ocrevus Zunovo"
        ]
      },
      {
        "ProgramID": 31050,
        "ProgramName": "PAF Co-Pay Relief: Multiple Sclerosis Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Multiple Sclerosis (MS)"
        ],
        "Drugs": [
          "Ampyra",
          "Aubagio",
          "Avonex",
          "Betaseron",
          "Copaxone",
          "Gilenya",
          "Acthar Gel",
          "Lemtrada",
          "Plegridy",
          "Rayos",
          "Rebif",
          "Tecfidera",
          "Tysabri",
          "Mitoxantrone",
          "Glatopa",
          "Cyclophosphamide",
          "Cladribine",
          "Ocrevus",
          "Avonex Pen",
          "Glatiramer Acetate",
          "Rebif Rebidose",
          "Dalfampridine",
          "Mavenclad",
          "Mayzent",
          "Vumerity",
          "Zeposia",
          "Bafiertam",
          "Kesimpta",
          "Dimethyl Fumarate",
          "Ponvory",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Fleqsuvy",
          "Ozobax DS",
          "Purified Cortrophin Gel",
          "Tascenso ODT",
          "Fingolimod",
          "Dimethyl Fumarate DR",
          "Briumvi",
          "Teriflunomide",
          "Tyruko",
          "Peginterferon Beta-1A",
          "Acthar Selfject",
          "Ocrevus Zunovo"
        ]
      },
      {
        "ProgramID": 30930,
        "ProgramName": "PAF Co-Pay Relief: Muscular Dystrophy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Duchenne Muscular Dystrophy (DMD)",
          "Muscular Dystrophy"
        ],
        "Drugs": [
          "Rayos",
          "Exondys 51",
          "Emflaza",
          "Vyondys 53",
          "Viltepso",
          "Amondys 45",
          "Elevidys",
          "Agamree",
          "Duvyzat"
        ]
      },
      {
        "ProgramID": 30931,
        "ProgramName": "PAF Co-Pay Relief: Myasthenia Gravis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Myasthenia Gravis"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Methotrexate",
          "Cyclophosphamide",
          "Ultomiris",
          "Vyvgart",
          "Mestinon",
          "Vyvgart Hytrulo",
          "Rystiggo",
          "Zilbrysq",
          "Ultomiris & Voydeya"
        ]
      },
      {
        "ProgramID": 30308,
        "ProgramName": "PAF Co-Pay Relief: Myelodysplastic Syndromes",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)"
        ],
        "Drugs": [
          "Gleevec",
          "Jakafi",
          "Neupogen",
          "Rayos",
          "Revlimid",
          "Vidaza",
          "Zarxio",
          "Dacogen",
          "Leukine",
          "Deferasirox",
          "Cyclophosphamide",
          "Atgam",
          "Decitabine",
          "Azacitidine",
          "Imatinib",
          "Vyxeos",
          "Fulphila",
          "Tibsovo",
          "Udenyca",
          "Reblozyl",
          "Inqovi",
          "Levoleucovorin",
          "Pemazyre",
          "Lenalidomide",
          "Udenyca Autoinjector",
          "Udenyca Onbody",
          "Rytelo",
          "Nypozi",
          "Imkeldi"
        ]
      },
      {
        "ProgramID": 30932,
        "ProgramName": "PAF Co-Pay Relief: Myeloproliferative Disorders",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myeloproliferative Neoplasms",
          "Oncology - Chronic Myeloid Leukemia (CML)",
          "Oncology - Myelofibrosis",
          "Hypereosinophilic Syndrome (HES)",
          "Oncology - Chronic Eosinophilic Leukemia (CEL)",
          "Polycythemia Vera",
          "Thrombocythemia",
          "Symptomatic Mast Cell Disease",
          "Oncology - Juvenile Myelomonocytic Leukemia (JMML)",
          "Oncology - Chronic Myelomonocytic Leukemia (CMMoL)",
          "Oncology - Chronic Neutrophilic Leukemia (CNL)",
          "Oncology - Philadelphia Chromosome Positive Chronic Myeloid  Leukemia (Ph+ CML)"
        ],
        "Drugs": [
          "Gleevec",
          "Jakafi",
          "Rayos",
          "Vidaza",
          "Dacogen",
          "Cyclophosphamide",
          "Alkeran",
          "Cotellic",
          "Azacitidine",
          "Inrebic",
          "Reblozyl",
          "Inqovi",
          "Levoleucovorin",
          "Pemazyre",
          "Vonjo",
          "Imkeldi",
          "Bosulif",
          "Iclusig",
          "Mekinist",
          "Sprycel",
          "Tasigna",
          "Cytarabine",
          "Busulfex",
          "Elitek",
          "Myleran",
          "Tabloid",
          "Scemblix",
          "Phyrago",
          "Danziten",
          "Ojjaara",
          "Nucala",
          "Imatinib",
          "Besremi",
          "Rydapt",
          "Vyxeos",
          "Decitabine",
          "Releuko"
        ]
      },
      {
        "ProgramID": 30933,
        "ProgramName": "PAF Co-Pay Relief: Narcolepsy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Narcolepsy"
        ],
        "Drugs": [
          "Xyrem",
          "Wakix",
          "Xywav",
          "Lumryz"
        ]
      },
      {
        "ProgramID": 30296,
        "ProgramName": "PAF Co-Pay Relief: Neoplasm Related Pain",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Supportive",
          "Oncology - Nausea & Vomiting Associated with Chemotherapy & Radiation",
          "Neuropathic Pain",
          "Pain Management"
        ],
        "Drugs": [
          "Adcetris",
          "Afinitor",
          "Aranesp",
          "Arranon",
          "Caprelsa",
          "Ellence",
          "Emend Capsules",
          "Emend for Injection",
          "Epogen",
          "Jevtana",
          "Lynparza",
          "Mekinist",
          "Neulasta",
          "Neupogen",
          "Procrit",
          "Prolia",
          "Rayos",
          "Sandostatin LAR Depot",
          "Tasigna",
          "Taxotere",
          "Temodar",
          "Torisel",
          "Trisenox",
          "Xgeva",
          "Zometa",
          "Purixan",
          "Soliris",
          "Mitoxantrone",
          "Vinblastine Sulfate",
          "Nipent",
          "Methotrexate",
          "Gammagard S/D",
          "Zarxio",
          "Dacogen",
          "Leukine",
          "Yondelis",
          "Matulane",
          "Fragmin",
          "Zolinza",
          "Cyclophosphamide",
          "Mutamycin",
          "Ethyol",
          "Vistogard",
          "Mylotarg",
          "Elitek",
          "Oncaspar",
          "Cladribine",
          "Azacitidine",
          "Myleran",
          "Vincristine Sulfate",
          "Syndros",
          "Sustol",
          "Emend for Oral Suspension",
          "Sandostatin",
          "Cinvanti",
          "Retacrit",
          "Nivestym",
          "Khapzory",
          "Nyvepria",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Neulasta Onpro",
          "Pegfilgrastim-bmez",
          "Filgrastim-sndz",
          "Releuko",
          "Pedmark",
          "Fylnetra",
          "Cosela",
          "Focinvez",
          "Akynzeo (Injection)",
          "Ryzneuta",
          "Iwilfin",
          "Xyosted",
          "Jubbonti",
          "Nypozi",
          "Posfrea",
          "Qutenza",
          "Ozobax DS",
          "Botox",
          "Lupron Depot",
          "Myobloc",
          "Prialt",
          "Sprix",
          "Hyalgan",
          "Dysport",
          "Supartz FX",
          "Omidria",
          "Gelsyn-3",
          "Hymovis",
          "Orilissa",
          "Gel-One",
          "Scenesse",
          "Relafen Ds",
          "Myfembree"
        ]
      },
      {
        "ProgramID": 30934,
        "ProgramName": "PAF Co-Pay Relief: Niemann-Pick Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Niemann-Pick Disease - Type C (NPC)",
          "Enzyme Disorders - Acid Sphingomyelinase Deficiency (ASMD)"
        ],
        "Drugs": [
          "Xenpozyme",
          "Miplyffa",
          "Aqneursa"
        ]
      },
      {
        "ProgramID": 31081,
        "ProgramName": "PAF Co-Pay Relief: Nonalcoholic Steatohepatitis (NASH)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Steatohepatitis"
        ],
        "Drugs": [
          "Rezdiffra"
        ]
      },
      {
        "ProgramID": 30158,
        "ProgramName": "PAF Co-Pay Relief: Non-Small Cell Lung Cancers",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Cyramza",
          "Gilotrif",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Tarceva",
          "Taxotere",
          "Xalkori",
          "Yervoy",
          "Zometa",
          "Zykadia",
          "Iressa",
          "Methotrexate",
          "Photofrin",
          "Docetaxel",
          "Cyclophosphamide",
          "Tagrisso",
          "Mutamycin",
          "Alecensa",
          "Portrazza",
          "Tecentriq",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Pemfexy",
          "Bevacizumab",
          "Braftovi",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Vitrakvi",
          "Mektovi",
          "Zirabev",
          "Rozlytrek",
          "Enhertu",
          "Tabrecta",
          "Retevmo",
          "Opdivo & Yervoy",
          "Gavreto",
          "Jemperli",
          "Rybrevant",
          "Lumakras",
          "Tepmetko",
          "Alymsys",
          "Bevacizumab-awwb",
          "Trastuzumab-anns",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Vegzelma",
          "Imjudo",
          "Krazati",
          "Imfinzi & Imjudo",
          "Gefitinib",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Pemrydi RTU",
          "Docivyx",
          "Lazcluze",
          "Lazcluze & Rybrevant",
          "Tecentriq Hybreza",
          "Bizengri"
        ]
      },
      {
        "ProgramID": 30875,
        "ProgramName": "PAF Co-Pay Relief: Non-Small Cell Lung Cancers Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Cyramza",
          "Gilotrif",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Tarceva",
          "Taxotere",
          "Xalkori",
          "Yervoy",
          "Zometa",
          "Zykadia",
          "Iressa",
          "Methotrexate",
          "Photofrin",
          "Docetaxel",
          "Cyclophosphamide",
          "Tagrisso",
          "Mutamycin",
          "Alecensa",
          "Portrazza",
          "Tecentriq",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Pemfexy",
          "Bevacizumab",
          "Braftovi",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Vitrakvi",
          "Mektovi",
          "Zirabev",
          "Rozlytrek",
          "Enhertu",
          "Tabrecta",
          "Retevmo",
          "Opdivo & Yervoy",
          "Gavreto",
          "Jemperli",
          "Rybrevant",
          "Lumakras",
          "Tepmetko",
          "Alymsys",
          "Bevacizumab-awwb",
          "Trastuzumab-anns",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Vegzelma",
          "Imjudo",
          "Krazati",
          "Imfinzi & Imjudo",
          "Gefitinib",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Pemrydi RTU",
          "Docivyx",
          "Lazcluze",
          "Lazcluze & Rybrevant",
          "Tecentriq Hybreza",
          "Bizengri"
        ]
      },
      {
        "ProgramID": 31075,
        "ProgramName": "PAF Co-Pay Relief: Obesity",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Obesity",
          "Chronic Weight Management"
        ],
        "Drugs": [
          "Imcivree",
          "Wegovy",
          "Zepbound"
        ]
      },
      {
        "ProgramID": 30310,
        "ProgramName": "PAF Co-Pay Relief: Osteoporosis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Osteoporosis"
        ],
        "Drugs": [
          "Forteo",
          "Prolia",
          "Xgeva",
          "Zometa",
          "Reclast",
          "Miacalcin",
          "Tymlos",
          "Evenity",
          "Teriparatide",
          "Romosozumab-aqqg",
          "Jubbonti"
        ]
      },
      {
        "ProgramID": 30311,
        "ProgramName": "PAF Co-Pay Relief: Ovarian Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Ovarian"
        ],
        "Drugs": [
          "Avastin",
          "Doxil",
          "Hycamtin Injection",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Tafinlar",
          "Paraplatin",
          "Methotrexate",
          "Yondelis",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Rubraca",
          "Gemcitabine",
          "Zejula",
          "Mvasi",
          "Bevacizumab",
          "Tepadina",
          "Thiotepa",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Elahere",
          "Kemoplat",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Tepylute"
        ]
      },
      {
        "ProgramID": 30876,
        "ProgramName": "PAF Co-Pay Relief: Ovarian Cancer Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Ovarian"
        ],
        "Drugs": [
          "Avastin",
          "Doxil",
          "Hycamtin Injection",
          "Keytruda",
          "Lynparza",
          "Mekinist",
          "Tafinlar",
          "Paraplatin",
          "Methotrexate",
          "Yondelis",
          "Cyclophosphamide",
          "Alkeran",
          "Mutamycin",
          "Rubraca",
          "Gemcitabine",
          "Zejula",
          "Mvasi",
          "Bevacizumab",
          "Tepadina",
          "Thiotepa",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Elahere",
          "Kemoplat",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Tepylute"
        ]
      },
      {
        "ProgramID": 30832,
        "ProgramName": "PAF Co-Pay Relief: Pancreatic Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Neuroendocrine Tumors of Pancreatic Origin (PNET)",
          "Oncology - Pancreatic",
          "Oncology - Gastroenteropancreatic Neuroendocrine Tumors"
        ],
        "Drugs": [
          "Afinitor",
          "Mekinist",
          "Sutent",
          "Tafinlar",
          "Cyclophosphamide",
          "Afinitor Disperz",
          "Lutathera",
          "Welireg",
          "Sunitinib Malate",
          "Tafinlar & Mekinist",
          "Augtyro",
          "Abraxane",
          "Keytruda",
          "Lynparza",
          "Tarceva",
          "Xeloda",
          "Zenpep",
          "Mitomycin",
          "Capecitabine",
          "Onivyde",
          "Yondelis",
          "Fluorouracil",
          "Mutamycin",
          "Gemcitabine",
          "Erlotinib Hydrochloride",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Lanreotide Acetate",
          "Paclitaxel Protein-Bound",
          "Bizengri",
          "Somatuline Depot",
          "Zortress"
        ]
      },
      {
        "ProgramID": 30935,
        "ProgramName": "PAF Co-Pay Relief: Paraganglioma & Pheochromocytoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Pheochromocytoma or Paraganglioma"
        ],
        "Drugs": [
          "Cyclophosphamide",
          "Vitrakvi",
          "Enhertu",
          "Demser",
          "Retevmo",
          "Jemperli",
          "Voranigo"
        ]
      },
      {
        "ProgramID": 30936,
        "ProgramName": "PAF Co-Pay Relief: Parkinson’s Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neurology - Parkinson's Disease",
          "Neurology - Dyskinesia (related to Parkinson's)"
        ],
        "Drugs": [
          "Apokyn",
          "Xeomin",
          "Zelapar",
          "Duopa",
          "Nuplazid",
          "Tasmar",
          "Gocovri",
          "Tolcapone",
          "Inbrija",
          "Nourianz",
          "Apomorphine",
          "Crexont",
          "Vyalev",
          "Austedo XR"
        ]
      },
      {
        "ProgramID": 31003,
        "ProgramName": "PAF Co-Pay Relief: Parkinson’s Disease Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Parkinson's Disease",
          "Neurology - Dyskinesia (related to Parkinson's)"
        ],
        "Drugs": [
          "Apokyn",
          "Xeomin",
          "Zelapar",
          "Duopa",
          "Nuplazid",
          "Tasmar",
          "Gocovri",
          "Tolcapone",
          "Inbrija",
          "Nourianz",
          "Apomorphine",
          "Crexont",
          "Vyalev",
          "Austedo XR"
        ]
      },
      {
        "ProgramID": 30439,
        "ProgramName": "PAF Co-Pay Relief: Periodic Paralysis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Primary Hyperkalemic Periodic Paralysis",
          "Primary Hypokalemic Periodic Paralysis"
        ],
        "Drugs": [
          "Keveyis",
          "Ormalvi"
        ]
      },
      {
        "ProgramID": 30937,
        "ProgramName": "PAF Co-Pay Relief: Peripheral Vascular Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Deep-Vein Thrombosis (DVT)",
          "Pulmonary Embolism (PE)",
          "Venous Thromboembolism",
          "Atherosclerotic Cardiovascular Disease (ASCVD)",
          "Peripheral Arterial Disease (PAD)"
        ],
        "Drugs": [
          "Xarelto",
          "Fragmin",
          "Arixtra",
          "Repatha",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30938,
        "ProgramName": "PAF Co-Pay Relief: Pompe Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Pompe Disease"
        ],
        "Drugs": [
          "Lumizyme",
          "Nexviazyme",
          "Opfolda & Pombiliti",
          "Opfolda",
          "Pombiliti"
        ]
      },
      {
        "ProgramID": 31080,
        "ProgramName": "PAF Co-Pay Relief: Primary Biliary Cholangitis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Primary Biliary Cholangitis (PBC)"
        ],
        "Drugs": [
          "Ocaliva",
          "Imfinzi",
          "Iqirvo",
          "Livdelzi"
        ]
      },
      {
        "ProgramID": 30939,
        "ProgramName": "PAF Co-Pay Relief: Primary Immunodeficiency",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Immunodeficiency",
          "Severe Combined Immunodeficiency Disease (SCID)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Hizentra",
          "Gamastan",
          "Flebogamma DIF",
          "HyQvia",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "Cuvitru",
          "Cutaquig",
          "Asceniv",
          "Xembify",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "HyperHEP B",
          "Joenja",
          "Alyglo",
          "Yimmugo",
          "Revcovi"
        ]
      },
      {
        "ProgramID": 30658,
        "ProgramName": "PAF Co-Pay Relief: Prostate Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Castration-Sensitive Prostate Cancer",
          "Oncology - Non-Metastatic Castration-Resistant Prostate Cancer",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
          "Oncology - Castration-Resistant Prostate Cancer"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Mekinist",
          "Nilandron",
          "Prolia",
          "Provenge",
          "Rayos",
          "Tafinlar",
          "Taxotere",
          "Trelstar",
          "Xofigo",
          "Xtandi",
          "Zoladex",
          "Zometa",
          "Zytiga",
          "Mitoxantrone",
          "Yondelis",
          "Zoledronic Acid",
          "Docetaxel",
          "Cyclophosphamide",
          "Mutamycin",
          "Leuprolide Acetate",
          "Rubraca",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Vitrakvi",
          "Abiraterone Acetate",
          "Nubeqa",
          "Enhertu",
          "Retevmo",
          "Orgovyx",
          "Jemperli",
          "Camcevi",
          "Pluvicto",
          "Tafinlar & Mekinist",
          "Akeega",
          "Augtyro",
          "Jubbonti",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30877,
        "ProgramName": "PAF Co-Pay Relief: Prostate Cancer Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Castration-Sensitive Prostate Cancer",
          "Oncology - Non-Metastatic Castration-Resistant Prostate Cancer",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
          "Oncology - Castration-Resistant Prostate Cancer"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Mekinist",
          "Nilandron",
          "Prolia",
          "Provenge",
          "Rayos",
          "Tafinlar",
          "Taxotere",
          "Trelstar",
          "Xofigo",
          "Xtandi",
          "Zoladex",
          "Zometa",
          "Zytiga",
          "Mitoxantrone",
          "Yondelis",
          "Zoledronic Acid",
          "Docetaxel",
          "Cyclophosphamide",
          "Mutamycin",
          "Leuprolide Acetate",
          "Rubraca",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Vitrakvi",
          "Abiraterone Acetate",
          "Nubeqa",
          "Enhertu",
          "Retevmo",
          "Orgovyx",
          "Jemperli",
          "Camcevi",
          "Pluvicto",
          "Tafinlar & Mekinist",
          "Akeega",
          "Augtyro",
          "Jubbonti",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30940,
        "ProgramName": "PAF Co-Pay Relief: Psoriatic Arthritis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Psoriatic Arthritis",
          "Juvenile Psoriatic Arthritis (JPsA)"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Acthar Gel",
          "Humira",
          "Orencia",
          "Otezla",
          "Rayos",
          "Remicade",
          "Simponi",
          "Simponi ARIA",
          "Stelara",
          "Xeljanz",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Taltz",
          "Inflectra",
          "Renflexis",
          "Tremfya",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Skyrizi",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Etanercept",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Orencia Clickject",
          "Purified Cortrophin Gel",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Bimzelx",
          "Wezlana",
          "Simlandi",
          "Adalimumab-ryvk",
          "Selarsdi",
          "Rinvoq LQ",
          "Pyzchiva",
          "Acthar Selfject",
          "Otulfi",
          "Imuldosa",
          "Yesintek"
        ]
      },
      {
        "ProgramID": 30770,
        "ProgramName": "PAF Co-Pay Relief: Pulmonary Fibrosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Idiopathic Pulmonary Fibrosis"
        ],
        "Drugs": [
          "Actemra",
          "Ofev",
          "Rayos",
          "Tyvaso",
          "Esbriet",
          "Pirfenidone",
          "Actemra Actpen",
          "Tyvaso DPI"
        ]
      },
      {
        "ProgramID": 30646,
        "ProgramName": "PAF Co-Pay Relief: Pulmonary Hypertension",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",
          "Hypertension",
          "Pulmonary Arterial Hypertension (PAH)"
        ],
        "Drugs": [
          "Adempas",
          "Wegovy",
          "Zepbound",
          "Tryvio",
          "Tezruly",
          "Adcirca",
          "Letairis",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tracleer",
          "Tyvaso",
          "Veletri",
          "Ventavis",
          "Flolan",
          "Sildenafil",
          "Uptravi",
          "Epoprostenol Sodium",
          "Tadalafil",
          "Ambrisentan",
          "Treprostinil",
          "Bosentan",
          "Treprostinil Diolamine",
          "Tyvaso DPI",
          "Tadliq",
          "Liqrev",
          "Opsynvi",
          "Winrevair",
          "Yutrepia"
        ]
      },
      {
        "ProgramID": 30312,
        "ProgramName": "PAF Co-Pay Relief: Renal Cell Carcinoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Renal Cell Carcinoma (Kidney Cancer) (RCC)"
        ],
        "Drugs": [
          "Afinitor",
          "Avastin",
          "Inlyta",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Nexavar",
          "Opdivo",
          "Proleukin",
          "Sutent",
          "Tafinlar",
          "Torisel",
          "Votrient",
          "Yervoy",
          "Cyclophosphamide",
          "Mutamycin",
          "Elitek",
          "Cabometyx",
          "Afinitor Disperz",
          "Bavencio",
          "Mvasi",
          "Sorafenib Tosylate",
          "Temsirolimus",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Enhertu",
          "Retevmo",
          "Opdivo & Yervoy",
          "Opdivo & Cabometyx",
          "Jemperli",
          "Keytruda & Lenvima",
          "Welireg",
          "Fotivda",
          "Alymsys",
          "Sunitinib Malate",
          "Bevacizumab-awwb",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Pazopanib",
          "Augtyro",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr"
        ]
      },
      {
        "ProgramID": 30737,
        "ProgramName": "PAF Co-Pay Relief: Rheumatoid Arthritis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Juvenile Rheumatoid Arthritis",
          "Rheumatoid Arthritis (RA)",
          "Polyarticular Juvenile Idiopathic Arthritis (pJIA)"
        ],
        "Drugs": [
          "Acthar Gel",
          "Orencia",
          "Rayos",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Cyltezo",
          "Hulio",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Orencia Clickject",
          "Purified Cortrophin Gel",
          "Jylamvo",
          "Adalimumab-aaty",
          "Coxanto",
          "Simlandi",
          "Adalimumab-ryvk",
          "Acthar Selfject",
          "Actemra",
          "Cimzia",
          "Enbrel",
          "Gengraf",
          "Humira",
          "Kineret",
          "Neoral",
          "Otrexup",
          "Rasuvo",
          "Remicade",
          "Rituxan",
          "Simponi",
          "Simponi ARIA",
          "Xeljanz",
          "Cyclophosphamide",
          "Cuprimine",
          "Depen",
          "Inflectra",
          "Renflexis",
          "Kevzara",
          "Infliximab",
          "Infliximab-dyyb",
          "Olumiant",
          "Hyrimoz",
          "Truxima",
          "Rinvoq",
          "Avsola",
          "Ruxience",
          "Riabni",
          "Abrilada",
          "Rituximab",
          "Xeljanz XR",
          "Relafen Ds",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Penicillamine",
          "Rituximab-pvvr",
          "Adalimumab-atto",
          "Actemra Actpen",
          "Hadlima",
          "Etanercept",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Tofidence",
          "Rituximab-abbs",
          "Rituximab-arrx",
          "Tyenne",
          "Rinvoq LQ"
        ]
      },
      {
        "ProgramID": 30941,
        "ProgramName": "PAF Co-Pay Relief: Sarcoma of the Bone",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bone"
        ],
        "Drugs": [
          "Mekinist",
          "Tafinlar",
          "Xgeva",
          "Xofigo",
          "Zometa",
          "Zoledronic Acid",
          "Cyclophosphamide",
          "Enhertu",
          "Tafinlar & Mekinist",
          "Wyost"
        ]
      },
      {
        "ProgramID": 30886,
        "ProgramName": "PAF Co-Pay Relief: Sickle Cell Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Sickle Cell Disease (SCD)"
        ],
        "Drugs": [
          "Ferriprox",
          "Adakveo",
          "Endari",
          "Siklos",
          "Casgevy",
          "Lyfgenia",
          "Xromi",
          "L-Glutamine"
        ]
      },
      {
        "ProgramID": 30885,
        "ProgramName": "PAF Co-Pay Relief: Sickle Cell Disease Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Sickle Cell Disease (SCD)"
        ],
        "Drugs": [
          "Ferriprox",
          "Adakveo",
          "Endari",
          "Siklos",
          "Casgevy",
          "Lyfgenia",
          "Xromi",
          "L-Glutamine"
        ]
      },
      {
        "ProgramID": 30738,
        "ProgramName": "PAF Co-Pay Relief: Skin Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Actinic Keratoses",
          "Oncology - Kaposi Sarcoma",
          "Oncology - Dermatofibrosarcoma Protuberans (DFSP)",
          "Oncology - Basal Cell Carcinoma (BCC)",
          "Oncology - Melanoma",
          "Oncology - Merkel Cell Carcinoma (MCC)",
          "Oncology - Cutaneous Squamous Cell Carcinoma (CSCC)"
        ],
        "Drugs": [
          "Carac",
          "Zyclara",
          "Fluorouracil",
          "Doxil",
          "Pomalyst",
          "Vinblastine Sulfate",
          "Methotrexate",
          "Cyclophosphamide",
          "Elitek",
          "Paclitaxel Protein-Bound",
          "Gleevec",
          "Imatinib",
          "Augtyro",
          "Imkeldi",
          "Erivedge",
          "Mekinist",
          "Tafinlar",
          "Odomzo",
          "Libtayo",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Tafinlar & Mekinist",
          "Keytruda",
          "Opdivo",
          "Proleukin",
          "Yervoy",
          "Zelboraf",
          "BiCNU",
          "Alkeran",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Vemurafenib",
          "Braftovi",
          "Mektovi",
          "Opdivo & Yervoy",
          "Kimmtrak",
          "Braftovi & Mektovi",
          "Opdualag",
          "Amtagvi",
          "Tecentriq Hybreza",
          "Bavencio",
          "Zynyz",
          "Taxotere",
          "Docetaxel",
          "Bleomycin"
        ]
      },
      {
        "ProgramID": 30942,
        "ProgramName": "PAF Co-Pay Relief: Small Cell Lung Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Small Cell Lung Cancer (SCLC)"
        ],
        "Drugs": [
          "Hycamtin",
          "Hycamtin Injection",
          "Keytruda",
          "Mekinist",
          "Tafinlar",
          "Methotrexate",
          "Cyclophosphamide",
          "Tecentriq",
          "Topotecan",
          "Etoposide Phosphate",
          "Imfinzi",
          "Zepzelca",
          "Jemperli",
          "Tafinlar & Mekinist",
          "Cosela",
          "Imdelltra",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30943,
        "ProgramName": "PAF Co-Pay Relief: Soft Tissue Sarcoma",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Kaposi Sarcoma",
          "Oncology - Dermatofibrosarcoma Protuberans (DFSP)",
          "Oncology - Astrocytoma",
          "Oncology - Gastrointestinal Stromal Tumor (GIST)",
          "Oncology - Glioblastoma",
          "Oncology - Soft Tissue Sarcoma (STS)",
          "Oncology - Tuberous Sclerosis-Related Subependymal Giant Cell Astrocytoma (SEGA)",
          "Oncology - Vasoactive Intestinal Polypeptide Secreting Tumor (VIPoma)",
          "Oncology - Renal Angiomyolipoma With Tuberous Sclerosis Complex",
          "Oncology - Metastatic Liposarcoma",
          "Oncology - Neuroblastoma",
          "Oncology - Pheochromocytoma or Paraganglioma",
          "Oncology - Hemophagocytic Lymphohistiocytosis (HLH)",
          "Oncology - Central Nervous System (CNS) Hemangioblastomas",
          "Oncology - Perivascular Epithelioid Cell Tumor (PEComa)",
          "Oncology - Leiomyosarcoma",
          "Oncology - Inflammatory Myofibroblastic Tumor (IMT)",
          "Oncology - Neurofibromatosis",
          "Oncology - Symptomatic Tenosynovial Giant Cell Tumor (TGCT)",
          "Oncology - Plexiform Neurofibromas (PN)",
          "Oncology - Alveolar Soft Part Sarcoma (ASPS)",
          "Oncology - Glioma",
          "Oncology - Desmoid Tumors",
          "Oncology - Synovial Sarcoma"
        ],
        "Drugs": [
          "Doxil",
          "Pomalyst",
          "Vinblastine Sulfate",
          "Methotrexate",
          "Cyclophosphamide",
          "Elitek",
          "Paclitaxel Protein-Bound",
          "Gleevec",
          "Imatinib",
          "Augtyro",
          "Imkeldi",
          "Afinitor",
          "Mekinist",
          "Tafinlar",
          "Temodar",
          "BiCNU",
          "Gleostine",
          "Everolimus",
          "Afinitor Disperz",
          "Temozolomide",
          "Mvasi",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Alymsys",
          "Tafinlar & Mekinist",
          "Voranigo",
          "Stivarga",
          "Sutent",
          "Vitrakvi",
          "Ayvakit",
          "Qinlock",
          "Sunitinib Malate",
          "Avastin",
          "Mutamycin",
          "Gliadel Wafer",
          "Bevacizumab",
          "Zirabev",
          "Bevacizumab-awwb",
          "Vegzelma",
          "Avzivi",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Votrient",
          "Yondelis",
          "Tazverik",
          "Pazopanib",
          "Torpenz",
          "Sandostatin LAR Depot",
          "Inlyta",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Rayos",
          "Yervoy",
          "Cabometyx",
          "Dactinomycin",
          "Vincristine Sulfate",
          "Bavencio",
          "Opdivo & Yervoy",
          "Opdivo & Cabometyx",
          "Keytruda & Lenvima",
          "Fotivda",
          "Halaven",
          "Eribulin Mesylate",
          "Vincasar PFS",
          "Danyelza",
          "Unituxin",
          "Iwilfin",
          "Demser",
          "Cotellic",
          "Gamifant",
          "Welireg",
          "Fyarro",
          "Xalkori",
          "Somavert",
          "Reclast",
          "Miacalcin",
          "Banzel",
          "Xcopri",
          "Skytrofa",
          "Romidepsin",
          "Koselugo",
          "Motpoly XR",
          "Coxanto",
          "Xgeva",
          "Turalio",
          "Tecentriq",
          "Tecentriq Hybreza",
          "Ojemda",
          "Ogsiveo",
          "Tecelra"
        ]
      },
      {
        "ProgramID": 30944,
        "ProgramName": "PAF Co-Pay Relief: Solid Organ Transplant Preservation and Rejection Prevention",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Transplant Rejection",
          "Organ Transplantation",
          "Kidney Transplant",
          "Post-Transplant Lymphoproliferative Disease (PTLD)"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Gengraf",
          "Myfortic",
          "Neoral",
          "Nulojix",
          "Prograf",
          "Rayos",
          "Sandimmune",
          "Zortress",
          "Thymoglobulin",
          "Simulect",
          "Atgam",
          "Envarsus XR",
          "Mycophenolate Mofetil",
          "Sirolimus",
          "Cyclosporine",
          "Tepadina",
          "Tacrolimus",
          "Myhibbin",
          "Cyclophosphamide",
          "Immune Globulin Intravenous (IGIV)",
          "Breyanzi",
          "Rituximab-arrx"
        ]
      },
      {
        "ProgramID": 30844,
        "ProgramName": "PAF Co-Pay Relief: Spinal Muscular Atrophy",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Spinal Muscular Atrophy (SMA)"
        ],
        "Drugs": [
          "Rayos",
          "Spinraza",
          "Zolgensma",
          "Evrysdi",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate"
        ]
      },
      {
        "ProgramID": 30883,
        "ProgramName": "PAF Co-Pay Relief: Spinal Muscular Atrophy Health Equity Fund",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Spinal Muscular Atrophy (SMA)"
        ],
        "Drugs": [
          "Rayos",
          "Spinraza",
          "Zolgensma",
          "Evrysdi",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate"
        ]
      },
      {
        "ProgramID": 30945,
        "ProgramName": "PAF Co-Pay Relief: Stroke",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Thrombotic Events (MI",
          "stroke",
          "etc.)"
        ],
        "Drugs": [
          "Xarelto",
          "Repatha",
          "Praluent",
          "Wegovy",
          "Repatha SureClick",
          "Tryvio",
          "Tezruly"
        ]
      },
      {
        "ProgramID": 30884,
        "ProgramName": "PAF Co-Pay Relief: Stroke Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Thrombotic Events (MI",
          "stroke",
          "etc.)"
        ],
        "Drugs": [
          "Xarelto",
          "Repatha",
          "Praluent",
          "Wegovy",
          "Repatha SureClick",
          "Tryvio",
          "Tezruly"
        ]
      },
      {
        "ProgramID": 30946,
        "ProgramName": "PAF Co-Pay Relief: Testicular Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Testicular Cancer"
        ],
        "Drugs": [
          "Mekinist",
          "Tafinlar",
          "Vinblastine Sulfate",
          "Cyclophosphamide",
          "Dactinomycin",
          "Bleomycin",
          "Etoposide Phosphate",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Tafinlar & Mekinist",
          "Kemoplat",
          "Augtyro"
        ]
      },
      {
        "ProgramID": 30947,
        "ProgramName": "PAF Co-Pay Relief: Thalassemia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Thalassemia"
        ],
        "Drugs": [
          "Exjade",
          "Jadenu",
          "Ferriprox",
          "Deferasirox",
          "Deferoxamine Mesylate",
          "Jadenu Sprinkle",
          "Reblozyl",
          "Deferiprone",
          "Zynteglo",
          "Casgevy"
        ]
      },
      {
        "ProgramID": 30948,
        "ProgramName": "PAF Co-Pay Relief: Thrombocytopenia",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Immune Thrombocytopenic Purpura (ITP)",
          "Thrombocytopenia",
          "Acquired / Immune-Mediated Thrombotic Thrombocytopenic Purpura (aTTP / iTTP)",
          "Chronic Immune Thrombocytopenia (CITP)",
          "Congenital Thrombotic Thrombocytopenic Purpura (cTTP)"
        ],
        "Drugs": [
          "Gamunex-C",
          "Nplate",
          "Promacta",
          "Rayos",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Gammaked",
          "Cyclophosphamide",
          "Gammaplex",
          "Rhophylac",
          "Tavalisse",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "WinRho SDF",
          "Vidaza",
          "Nipent",
          "Cladribine",
          "Azacitidine",
          "Doptelet",
          "Mulpleta",
          "Cablivi",
          "Reblozyl",
          "Adzynma",
          "Alvaiz"
        ]
      },
      {
        "ProgramID": 30949,
        "ProgramName": "PAF Co-Pay Relief: Thyroid Cancer",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Thyroid",
          "Oncology - Metastatic Differentiated Thyroid Cancer"
        ],
        "Drugs": [
          "Caprelsa",
          "Cometriq",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Nexavar",
          "Rayos",
          "Tafinlar",
          "Thyrogen",
          "Cyclophosphamide",
          "Cabometyx",
          "Sorafenib Tosylate",
          "Vitrakvi",
          "Enhertu",
          "Retevmo",
          "Gavreto",
          "Jemperli",
          "Tafinlar & Mekinist",
          "Augtyro"
        ]
      },
      {
        "ProgramID": 31016,
        "ProgramName": "PAF Co-Pay Relief: Thyroid Eye Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Thyroid Eye Disease (TED)"
        ],
        "Drugs": [
          "Rayos",
          "Tepezza",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Teprotumumab-trbw"
        ]
      },
      {
        "ProgramID": 30731,
        "ProgramName": "PAF Co-Pay Relief: Ulcerative Colitis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "IBD - Pediatric Ulcerative Colitis",
          "IBD - Ulcerative Colitis",
          "IBD - Ulcerative Proctitis"
        ],
        "Drugs": [
          "Humira",
          "Rayos",
          "Remicade",
          "Inflectra",
          "Renflexis",
          "Infliximab",
          "Infliximab-dyyb",
          "Avsola",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Infliximab-axxq",
          "Adalimumab",
          "Entyvio",
          "Simponi",
          "Stelara",
          "Xeljanz",
          "Adalimumab-afzb",
          "Dipentum",
          "Rowasa",
          "SF Rowasa",
          "Tremfya",
          "Cyltezo",
          "Hyrimoz",
          "Skyrizi",
          "Rinvoq",
          "Zeposia",
          "Hulio",
          "Abrilada",
          "Xeljanz XR",
          "Amjevita",
          "Ortikos ER",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Velsipity",
          "Zymfentra",
          "Omvoh",
          "Wezlana",
          "Simlandi",
          "Adalimumab-ryvk",
          "Entyvio Pen",
          "Rinvoq LQ",
          "Pyzchiva",
          "Otulfi",
          "Imuldosa",
          "Yesintek"
        ]
      },
      {
        "ProgramID": 30786,
        "ProgramName": "PAF Co-Pay Relief: Uterine Cancers",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Uterine/Endometrial Cancer",
          "Oncology - Perivascular Epithelioid Cell Tumor (PEComa)",
          "Oncology - Fallopian Tube Cancer"
        ],
        "Drugs": [
          "Avastin",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Tafinlar",
          "Paraplatin",
          "Methotrexate",
          "Yondelis",
          "Cyclophosphamide",
          "Elitek",
          "Bleomycin",
          "Zejula",
          "Imfinzi",
          "Mvasi",
          "Bevacizumab",
          "Tepadina",
          "Thiotepa",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Keytruda & Lenvima",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Augtyro",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Fyarro",
          "Lynparza",
          "Rubraca",
          "Zirabev",
          "Vegzelma",
          "Elahere",
          "Avzivi",
          "Bevacizumab-bvzr"
        ]
      },
      {
        "ProgramID": 31004,
        "ProgramName": "PAF Co-Pay Relief: Uterine Cancers Health Equity Fund",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Uterine/Endometrial Cancer",
          "Oncology - Perivascular Epithelioid Cell Tumor (PEComa)",
          "Oncology - Fallopian Tube Cancer"
        ],
        "Drugs": [
          "Avastin",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Tafinlar",
          "Paraplatin",
          "Methotrexate",
          "Yondelis",
          "Cyclophosphamide",
          "Elitek",
          "Bleomycin",
          "Zejula",
          "Imfinzi",
          "Mvasi",
          "Bevacizumab",
          "Tepadina",
          "Thiotepa",
          "Enhertu",
          "Retevmo",
          "Jemperli",
          "Keytruda & Lenvima",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Augtyro",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Fyarro",
          "Lynparza",
          "Rubraca",
          "Zirabev",
          "Vegzelma",
          "Elahere",
          "Avzivi",
          "Bevacizumab-bvzr"
        ]
      },
      {
        "ProgramID": 30950,
        "ProgramName": "PAF Co-Pay Relief: Uveitis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Uveitis"
        ],
        "Drugs": [
          "Acthar Gel",
          "Humira",
          "Ozurdex",
          "Rayos",
          "Triesence",
          "Retisert",
          "Adalimumab-afzb",
          "Cyltezo",
          "Yutiq",
          "Hyrimoz",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Amjevita",
          "Xipere",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Purified Cortrophin Gel",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Simlandi",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30993,
        "ProgramName": "PAF Co-Pay Relief: Von Willebrand Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Von Willebrand Disease"
        ],
        "Drugs": [
          "Alphanate",
          "Humate P",
          "Wilate",
          "Vonvendi"
        ]
      },
      {
        "ProgramID": 30951,
        "ProgramName": "PAF Co-Pay Relief: Wilson Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Wilson Disease"
        ],
        "Drugs": [
          "Syprine",
          "Cuprimine",
          "Depen",
          "Trientine",
          "Penicillamine",
          "Cuvrior"
        ]
      },
      {
        "ProgramID": 30247,
        "ProgramName": "PAN: Acromegaly (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Acromegaly"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Somavert",
          "Signifor",
          "Signifor LAR",
          "Octreotide Acetate",
          "Sandostatin",
          "Mycapssa",
          "Lanreotide Acetate"
        ]
      },
      {
        "ProgramID": 30510,
        "ProgramName": "PAN: Acute Myeloid Leukemia (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Acute Myeloid Leukemia (AML)",
          "Oncology - Acute Promyelocytic Leukemia (APL)"
        ],
        "Drugs": [
          "Neupogen",
          "Nexavar",
          "Otrexup",
          "Rasuvo",
          "Trisenox",
          "Vidaza",
          "Cytarabine",
          "Purixan",
          "Mitoxantrone",
          "Trexall",
          "Methotrexate",
          "Zarxio",
          "Dacogen",
          "Mylotarg",
          "Venclexta",
          "Decitabine",
          "Cladribine",
          "Azacitidine",
          "Clofarabine",
          "Clolar",
          "Etoposide Phosphate",
          "Rydapt",
          "IDHIFA",
          "Vyxeos",
          "Sorafenib Tosylate",
          "Fludarabine Phosphate",
          "Tibsovo",
          "Nivestym",
          "Daurismo",
          "Xospata",
          "Elzonris",
          "Tabloid",
          "Inqovi",
          "Onureg",
          "Venclexta Starting Pack",
          "Releuko",
          "Rezlidhia",
          "Nypozi",
          "Arsenic Trioxide"
        ]
      },
      {
        "ProgramID": 30686,
        "ProgramName": "PAN: Amyloidosis (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Amyloidosis"
        ],
        "Drugs": [
          "Actemra",
          "Astagraf XL",
          "Enbrel",
          "Humira",
          "Ilaris",
          "Kineret",
          "Kyprolis",
          "Orencia",
          "Otrexup",
          "Pomalyst",
          "Prograf",
          "Rasuvo",
          "Remicade",
          "Revlimid",
          "Thalomid",
          "Treanda",
          "Velcade",
          "Trexall",
          "Methotrexate",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Envarsus XR",
          "Bendeka",
          "Evomela",
          "Inflectra",
          "Venclexta",
          "Bendamustine",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Melphalan",
          "Onpattro",
          "Hyrimoz",
          "Vyndaqel",
          "Vyndamax",
          "Tacrolimus",
          "Belrapzo",
          "Avsola",
          "Darzalex Faspro",
          "Hulio",
          "Abrilada",
          "Bortezomib",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Adalimumab-adbm",
          "Actemra Actpen",
          "Amvuttra",
          "Hadlima",
          "Orencia Clickject",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Zymfentra",
          "Wainua",
          "Simlandi",
          "Adalimumab-ryvk"
        ]
      },
      {
        "ProgramID": 30249,
        "ProgramName": "PAN: Ankylosing Spondylitis (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ankylosing Spondylitis"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Humira",
          "Rayos",
          "Remicade",
          "Simponi",
          "Simponi ARIA",
          "Xeljanz",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Taltz",
          "Inflectra",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Hadlima",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Zymfentra",
          "Simlandi",
          "Adalimumab-ryvk",
          "Rinvoq LQ"
        ]
      },
      {
        "ProgramID": 30398,
        "ProgramName": "PAN: Asthma (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Asthma",
          "Severe Asthma",
          "Severe Eosinophilic Asthma"
        ],
        "Drugs": [
          "Rayos",
          "Xolair",
          "Nucala",
          "Cinqair",
          "Dupixent",
          "Fasenra",
          "Tezspire",
          "Zyflo",
          "Dupixent Pen",
          "Fasenra Pen",
          "Airsupra",
          "Eohilia"
        ]
      },
      {
        "ProgramID": 30802,
        "ProgramName": "PAN: Atopic Dermatitis (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Dermatology - Atopic Dermatitis"
        ],
        "Drugs": [
          "CellCept",
          "Gengraf",
          "Neoral",
          "Rayos",
          "Sandimmune",
          "Actimmune",
          "Trexall",
          "Methotrexate",
          "Mycophenolate Mofetil",
          "Dupixent",
          "Cyclosporine",
          "Tacrolimus",
          "Rinvoq",
          "Opzelura",
          "Adbry",
          "Cibinqo",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Fluovix Plus",
          "Dupixent Pen",
          "Zoryve",
          "Rinvoq LQ",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30252,
        "ProgramName": "PAN: Basal Cell Carcinoma",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Basal Cell Carcinoma (BCC)"
        ],
        "Drugs": [
          "Abraxane",
          "Erivedge",
          "Paraplatin",
          "Fluorouracil",
          "Odomzo",
          "Libtayo",
          "Paclitaxel Protein-Bound"
        ]
      },
      {
        "ProgramID": 30849,
        "ProgramName": "PAN: Biliary Tract Cancer (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Cholangiocarcinoma (Bile Duct Cancer)",
          "Oncology - Biliary Tract Cancer"
        ],
        "Drugs": [
          "Abraxane",
          "Keytruda",
          "Lenvima",
          "Mekinist",
          "Opdivo",
          "Perjeta",
          "Stivarga",
          "Tafinlar",
          "Xeloda",
          "Capecitabine",
          "Fluorouracil",
          "Gemcitabine",
          "Imfinzi",
          "Tibsovo",
          "Vitrakvi",
          "Rozlytrek",
          "Jemperli",
          "Levoleucovorin",
          "Pemazyre",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Lytgobi",
          "Herceptin",
          "Onivyde",
          "Gavreto",
          "Kemoplat"
        ]
      },
      {
        "ProgramID": 30823,
        "ProgramName": "PAN: Bipolar Disorder (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Behavioral Health - Bipolar Disorder"
        ],
        "Drugs": [
          "Invega Sustenna",
          "Risperdal Consta",
          "Aristada",
          "Vraylar",
          "Abilify Maintena",
          "Invega Trinza",
          "Perseris",
          "Aristada Initio",
          "Zyprexa Relprevv",
          "Aplenzin",
          "Zyprexa Zydis",
          "Caplyta",
          "Lybalvi",
          "Invega Hafyera",
          "Rykindo",
          "Uzedy",
          "Abilify Asimtufii",
          "Risperidone ER Injectable Suspension"
        ]
      },
      {
        "ProgramID": 30669,
        "ProgramName": "PAN: Bladder Cancer (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Bladder"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Doxil",
          "Ellence",
          "Keytruda",
          "Opdivo",
          "Xeloda",
          "Paraplatin",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Methotrexate",
          "Valstar",
          "Fluorouracil",
          "Docetaxel",
          "Mutamycin",
          "Tecentriq",
          "Bavencio",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Pemetrexed",
          "Pemfexy",
          "Tepadina",
          "Thiotepa",
          "Khapzory",
          "Balversa",
          "Padcev",
          "Trodelvy",
          "Valrubicin",
          "Paclitaxel Protein-Bound",
          "Adstiladrin",
          "Kemoplat",
          "Docivyx",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30014,
        "ProgramName": "PAN: Breast Cancer (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Breast",
          "Oncology - Hormone Receptor-Positive (HR+) Breast Cancer",
          "Oncology - Human Epidermal Growth Factor Receptor 2-negative (HER2-) Breast Cancer",
          "Oncology - Triple-Negative Breast Cancer (TNBC)"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Arimidex",
          "Avastin",
          "Doxil",
          "Eligard",
          "Ellence",
          "Fareston",
          "Faslodex",
          "Femara",
          "Halaven",
          "Herceptin",
          "Ibrance",
          "Ixempra",
          "Kadcyla",
          "Keytruda",
          "Lupron Depot",
          "Lupron Depot - PED",
          "Lynparza",
          "Perjeta",
          "Tykerb",
          "Xeloda",
          "Zoladex",
          "Letrozole",
          "Paraplatin",
          "Capecitabine",
          "Methotrexate",
          "Fluorouracil",
          "Zoledronic Acid",
          "Docetaxel",
          "Cyclophosphamide",
          "Leuprolide Acetate",
          "Tecentriq",
          "Everolimus",
          "Afinitor Disperz",
          "Vinorelbine Tartrate",
          "Kisqali",
          "Gemcitabine",
          "Kisqali Femara Co-Pack",
          "Nerlynx",
          "Mvasi",
          "Verzenio",
          "Ogivri",
          "Bevacizumab",
          "Tepadina",
          "Thiotepa",
          "Talzenna",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Piqray",
          "Kanjinti",
          "Zirabev",
          "Rozlytrek",
          "Herceptin Hylecta",
          "Enhertu",
          "Tukysa",
          "Trodelvy",
          "Phesgo",
          "Margenza",
          "Lapatinib Ditosylate",
          "Jemperli",
          "Fulvestrant",
          "Vijoice",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Orserdu",
          "Kemoplat",
          "Truqap",
          "Docivyx",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 31073,
        "ProgramName": "PAN: Chronic Inflammatory Demyelinating Polyneuropathy (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
        ],
        "Drugs": [
          "Gammagard Liquid",
          "Gamunex-C",
          "Gengraf",
          "Gilenya",
          "Hizentra",
          "Neoral",
          "Ozurdex",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "HyQvia",
          "Privigen",
          "Gammaked",
          "Cyclophosphamide",
          "Rituxan Hycela",
          "Truxima",
          "Ruxience",
          "Riabni",
          "Vyvgart",
          "Immune Globulin Intravenous (IGIV)",
          "Panzyga",
          "Vyvgart Hytrulo",
          "Rystiggo"
        ]
      },
      {
        "ProgramID": 30167,
        "ProgramName": "PAN: Chronic Lymphocytic Leukemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Chronic Lymphocytic Leukemia (CLL)",
          "Oncology - Small Lymphocytic Lymphoma (SLL)",
          "Oncology - B-Cell Prolymphocytic Leukemia (B-PLL)",
          "Oncology - T-Cell Prolymphocytic Leukemia (T-PLL)"
        ],
        "Drugs": [
          "Campath",
          "Gazyva",
          "Imbruvica",
          "Keytruda",
          "Opdivo",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Treanda",
          "Zydelig",
          "Leukeran",
          "Cytarabine",
          "Trexall",
          "Nipent",
          "Methotrexate",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Bendeka",
          "Venclexta",
          "Bendamustine",
          "Vincristine Sulfate",
          "Etoposide Phosphate",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Copiktra",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Imbruvica & Gazyva",
          "Jaypirca"
        ]
      },
      {
        "ProgramID": 30257,
        "ProgramName": "PAN: Colorectal Cancer (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Colorectal",
          "Oncology - Mismatch Repair-Deficient Colorectal Cancer (CRC)",
          "Oncology - Metastatic Colorectal Cancer (mCRC)"
        ],
        "Drugs": [
          "Avastin",
          "Camptosar",
          "Cyramza",
          "Erbitux",
          "Herceptin",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Perjeta",
          "Stivarga",
          "Tafinlar",
          "Tykerb",
          "Vectibix",
          "Xeloda",
          "Yervoy",
          "Zaltrap",
          "Zelboraf",
          "Lonsurf",
          "Capecitabine",
          "Fluorouracil",
          "Irinotecan",
          "Mvasi",
          "Ogivri",
          "Bevacizumab",
          "Braftovi",
          "Khapzory",
          "Vitrakvi",
          "Herzuma",
          "Ontruzant",
          "Trazimera",
          "Mektovi",
          "Kanjinti",
          "Zirabev",
          "Rozlytrek",
          "Tukysa",
          "Lapatinib Ditosylate",
          "Jemperli",
          "Levoleucovorin",
          "Braftovi & Mektovi",
          "Alymsys",
          "Bevacizumab-awwb",
          "Tafinlar & Mekinist",
          "Vegzelma",
          "Krazati",
          "Eylea HD",
          "Fruzaqla",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Pavblu",
          "Opdivo & Yervoy"
        ]
      },
      {
        "ProgramID": 30295,
        "ProgramName": "PAN: Cushing's Disease or Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Cushing’s Disease"
        ],
        "Drugs": [
          "Signifor",
          "Korlym",
          "Lysodren",
          "Metopirone",
          "Signifor LAR",
          "Isturisa",
          "Recorlev",
          "Mifepristone"
        ]
      },
      {
        "ProgramID": 30622,
        "ProgramName": "PAN: Diabetic Foot Ulcers (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Diabetic Foot Ulcers"
        ],
        "Drugs": [
          "Regranex",
          "Epifix",
          "Biovance",
          "Stravix"
        ]
      },
      {
        "ProgramID": 30977,
        "ProgramName": "PAN: Duchenne Muscular Dystrophy",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Duchenne Muscular Dystrophy (DMD)"
        ],
        "Drugs": [
          "Rayos",
          "Exondys 51",
          "Emflaza",
          "Vyondys 53",
          "Viltepso",
          "Amondys 45",
          "Elevidys",
          "Agamree",
          "Duvyzat"
        ]
      },
      {
        "ProgramID": 30700,
        "ProgramName": "PAN: Fabry Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 30712,
        "ProgramName": "PAN: Fabry Disease (Premium Assistance)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Fabry Disease"
        ],
        "Drugs": [
          "Fabrazyme",
          "Galafold",
          "Elfabrio"
        ]
      },
      {
        "ProgramID": 31051,
        "ProgramName": "PAN: Follicular Lymphoma (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Follicular Lymphoma"
        ],
        "Drugs": [
          "Gazyva",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Treanda",
          "Zevalin",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Bendeka",
          "Bendamustine",
          "Vincristine Sulfate",
          "Rituxan Hycela",
          "Kymriah",
          "Yescarta",
          "Copiktra",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Tazverik",
          "Riabni",
          "Rituximab",
          "Breyanzi",
          "Lenalidomide",
          "Rituximab-pvvr",
          "Vivimusta",
          "Lunsumio",
          "Epkinly",
          "Rituximab-abbs"
        ]
      },
      {
        "ProgramID": 31017,
        "ProgramName": "PAN: Gastrointestinal Stromal Tumors (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Gastrointestinal Stromal Tumor (GIST)"
        ],
        "Drugs": [
          "Afinitor",
          "Cometriq",
          "Gleevec",
          "Nexavar",
          "Sprycel",
          "Stivarga",
          "Sutent",
          "Tasigna",
          "Votrient",
          "Zortress",
          "Cabometyx",
          "Everolimus",
          "Afinitor Disperz",
          "Imatinib",
          "Sorafenib Tosylate",
          "Vitrakvi",
          "Rozlytrek",
          "Ayvakit",
          "Qinlock",
          "Sunitinib Malate",
          "Pazopanib"
        ]
      },
      {
        "ProgramID": 30258,
        "ProgramName": "PAN: Gaucher Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Gaucher Disease"
        ],
        "Drugs": [
          "Cerezyme",
          "Vpriv",
          "Zavesca",
          "Elelyso",
          "Cerdelga",
          "Miglustat",
          "Opfolda",
          "Yargesa"
        ]
      },
      {
        "ProgramID": 30633,
        "ProgramName": "PAN: Glioblastoma Multiforme",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Glioblastoma"
        ],
        "Drugs": [
          "Avastin",
          "Camptosar",
          "Mekinist",
          "Stivarga",
          "Tafinlar",
          "Temodar",
          "Zelboraf",
          "Paraplatin",
          "Matulane",
          "Irinotecan",
          "BiCNU",
          "Cyclophosphamide",
          "Cotellic",
          "Vincasar PFS",
          "Gliadel Wafer",
          "Gleostine",
          "Temozolomide",
          "Etoposide Phosphate",
          "Mvasi",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Rozlytrek",
          "Alymsys",
          "Vegzelma",
          "Kemoplat",
          "Voranigo"
        ]
      },
      {
        "ProgramID": 30846,
        "ProgramName": "PAN: Graft Vs Host Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Chronic Graft Versus Host Disease (cGVHD)",
          "Steroid-Refractory Acute Graft Versus Host Disease",
          "Acute Graft Versus Host Disease (aGvHD)",
          "Pediatric Chronic Graft-versus-Host Disease (PcGVHD)",
          "Pediatric Acute Graft-versus-Host Disease (PaGVHD)"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Enbrel",
          "Gengraf",
          "Imbruvica",
          "Jakafi",
          "Neoral",
          "Orencia",
          "Prograf",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Trexall",
          "Methotrexate",
          "Thymoglobulin",
          "Cyclophosphamide",
          "Envarsus XR",
          "Mycophenolate Mofetil",
          "Sirolimus",
          "Cyclosporine",
          "Truxima",
          "Tacrolimus",
          "Ruxience",
          "Riabni",
          "Rezurock",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Orencia Clickject",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30400,
        "ProgramName": "PAN: Heart Failure (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Congestive Heart Failure",
          "Heart Failure"
        ],
        "Drugs": [
          "Farxiga",
          "Jardiance",
          "Neffy"
        ]
      },
      {
        "ProgramID": 31057,
        "ProgramName": "PAN: Hemolytic Uremic Syndrome (Premium Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Atypical Hemolytic Uremic Syndrome (aHUS)",
          "Hemolytic Uremic Syndrome"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Cyclophosphamide",
          "Ultomiris",
          "CellCept",
          "Mycophenolate Mofetil",
          "Relafen Ds",
          "Coxanto"
        ]
      },
      {
        "ProgramID": 30878,
        "ProgramName": "PAN: Hemolytic Uremic Syndrome",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Atypical Hemolytic Uremic Syndrome (aHUS)",
          "Hemolytic Uremic Syndrome"
        ],
        "Drugs": [
          "Rayos",
          "Soliris",
          "Cyclophosphamide",
          "Ultomiris",
          "CellCept",
          "Mycophenolate Mofetil",
          "Relafen Ds",
          "Coxanto"
        ]
      },
      {
        "ProgramID": 30650,
        "ProgramName": "PAN: Hemophilia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hemophilia"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Tretten",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Andexxa",
          "Hemgenix",
          "Altuviiio"
        ]
      },
      {
        "ProgramID": 30634,
        "ProgramName": "PAN: Hemophilia (Premium Assistance)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hemophilia"
        ],
        "Drugs": [
          "Advate",
          "Alphanate",
          "AlphaNine SD",
          "Alprolix",
          "BeneFIX",
          "Eloctate",
          "Feiba",
          "Hemofil M",
          "Humate P",
          "Koate-DVI",
          "NovoEight",
          "NovoSeven RT",
          "Recombinate",
          "Rixubis",
          "Tretten",
          "Wilate",
          "Xyntha",
          "Profilnine",
          "Ixinity",
          "Adynovate",
          "Obizur",
          "Nuwiq",
          "Idelvion",
          "Kovaltry",
          "Afstyla",
          "Rebinyn",
          "Hemlibra",
          "Jivi",
          "SevenFact",
          "Esperoct",
          "Andexxa",
          "Hemgenix",
          "Altuviiio"
        ]
      },
      {
        "ProgramID": 30157,
        "ProgramName": "PAN: Hepatitis C",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hepatitis C"
        ],
        "Drugs": [
          "Harvoni",
          "Pegasys",
          "Sovaldi",
          "Ribavirin",
          "Zepatier",
          "Epclusa",
          "Vosevi",
          "Mavyret",
          "Sofosbuvir & Velpatasvir",
          "Ledipasvir & Sofosbuvir"
        ]
      },
      {
        "ProgramID": 30263,
        "ProgramName": "PAN: HIV Treatment and Prevention (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "HIV Infection",
          "HIV/AIDS - Supportive",
          "HIV-1 Integrase Strand Transfer Inhibitor (INSTI)",
          "HIV-1 Pre-Exposure Prophylaxis (PrEP)"
        ],
        "Drugs": [
          "Atripla",
          "Complera",
          "Edurant",
          "Emtriva",
          "Epivir",
          "Evotaz",
          "Fuzeon",
          "Intelence",
          "Isentress",
          "Kaletra",
          "Norvir",
          "Prezcobix",
          "Prezista",
          "Retrovir",
          "Reyataz",
          "Selzentry",
          "Stribild",
          "Tivicay",
          "Triumeq",
          "Truvada",
          "Tybost",
          "Viracept",
          "Viread",
          "Ziagen",
          "Aptivus",
          "Lamivudine & Zidovudine",
          "Didanosine",
          "Lamivudine",
          "Nevirapine",
          "Nevirapine ER",
          "Stavudine",
          "Zidovudine",
          "Genvoya",
          "Odefsey",
          "Descovy",
          "Juluca",
          "Biktarvy",
          "Trogarzo",
          "Symtuza",
          "Pifeltro",
          "Delstrigo",
          "Cimduo",
          "Symfi Lo",
          "Dovato",
          "Tenofovir Disoproxil",
          "Tivicay PD",
          "Rukobia",
          "Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Efavirenz & Emtricitabine & Tenofovir Disoproxil Fumarate",
          "Cabenuva",
          "Apretude",
          "Symfi",
          "Etravirine",
          "Triumeq PD",
          "Lopinavir & Ritonavir",
          "Maraviroc",
          "Efavirenz & Lamivudine & Tenofovir Disoproxil Fumarate",
          "Efavirenz",
          "Fosamprenavir Calcium",
          "Isentress HD",
          "Abacavir",
          "Ritonavir",
          "Abacavir & Lamivudine",
          "Abacavir & Lamivudine & Zidovudine",
          "Emtricitabine",
          "Sunlenca",
          "Darunavir"
        ]
      },
      {
        "ProgramID": 30264,
        "ProgramName": "PAN: Hypercholesterolemia (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hypercholesterolemia",
          "Homozygous Familial Hypercholesterolemia (HoFH)",
          "Heterozygous Familial Hypercholesterolemia (HeFH)"
        ],
        "Drugs": [
          "Juxtapid",
          "Repatha",
          "Praluent",
          "Evkeeza",
          "Leqvio",
          "Repatha SureClick"
        ]
      },
      {
        "ProgramID": 30406,
        "ProgramName": "PAN: Hyperkalemia (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Hyperkalemia"
        ],
        "Drugs": [
          "Veltassa",
          "Lokelma"
        ]
      },
      {
        "ProgramID": 31091,
        "ProgramName": "PAN: Hypophosphatasia (Premium Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypophosphatasia (HPP)"
        ],
        "Drugs": [
          "Strensiq",
          "Xphozah",
          "Coxanto"
        ]
      },
      {
        "ProgramID": 31090,
        "ProgramName": "PAN: Hypophosphatasia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Hypophosphatasia (HPP)"
        ],
        "Drugs": [
          "Strensiq",
          "Xphozah",
          "Coxanto"
        ]
      },
      {
        "ProgramID": 30325,
        "ProgramName": "PAN: Immune Thrombocytopenic Purpura (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Immune Thrombocytopenic Purpura (ITP)",
          "Thrombocytopenia",
          "Acquired / Immune-Mediated Thrombotic Thrombocytopenic Purpura (aTTP / iTTP)",
          "Chronic Immune Thrombocytopenia (CITP)",
          "Congenital Thrombotic Thrombocytopenic Purpura (cTTP)"
        ],
        "Drugs": [
          "CellCept",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gengraf",
          "Hizentra",
          "Myfortic",
          "Neoral",
          "Nplate",
          "Promacta",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Gamastan",
          "Flebogamma DIF",
          "Privigen",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Gammaplex",
          "RhoGAM Ultra-Filtered PLUS",
          "Mycophenolate Mofetil",
          "Cuvitru",
          "Cyclosporine",
          "Rhophylac",
          "Tavalisse",
          "Doptelet",
          "Mulpleta",
          "Truxima",
          "Cablivi",
          "Ruxience",
          "Cutaquig",
          "Riabni",
          "Rituximab",
          "HyperRHO S/D",
          "Panzyga",
          "WinRho SDF",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30266,
        "ProgramName": "PAN: Inflammatory Bowel Disease (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "IBD - Crohn's Disease",
          "Inflammatory Bowel Disease (IBD)",
          "IBD - Ulcerative Colitis",
          "IBD - Ulcerative Proctitis"
        ],
        "Drugs": [
          "Astagraf XL",
          "Cimzia",
          "Entyvio",
          "Gengraf",
          "Humira",
          "Neoral",
          "Otrexup",
          "Prograf",
          "Rasuvo",
          "Rayos",
          "Remicade",
          "Sandimmune",
          "Simponi",
          "Stelara",
          "Tysabri",
          "Xeljanz",
          "Xifaxan",
          "Purixan",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Dipentum",
          "Envarsus XR",
          "Rowasa",
          "SF Rowasa",
          "Inflectra",
          "Cyclosporine",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Skyrizi",
          "Tacrolimus",
          "Rinvoq",
          "Avsola",
          "Zeposia",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Humira Pen",
          "Amjevita",
          "Ortikos ER",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Infliximab-abda",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Zymfentra",
          "Simlandi",
          "Adalimumab-ryvk",
          "Entyvio Pen",
          "Rinvoq LQ",
          "Eohilia",
          "Velsipity",
          "Omvoh"
        ]
      },
      {
        "ProgramID": 30636,
        "ProgramName": "PAN: Inherited Retinal Disease",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD",
          "Ophthalmic - Inherited Retinal Disease",
          "Ophthalmic - RPE65 Mutation-Associated Retinal Dystrophy",
          "Ophthalmic - Myopic Choroidal Neovascularization",
          "Ophthalmic - Retinopathy of Prematurity (ROP)"
        ],
        "Drugs": [
          "Avastin",
          "Lucentis",
          "Eylea",
          "Bevacizumab",
          "Luxturna",
          "Susvimo",
          "Alymsys",
          "Cimerli",
          "Vegzelma",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Pavblu",
          "Eylea HD"
        ]
      },
      {
        "ProgramID": 30637,
        "ProgramName": "PAN: Inherited Retinal Disease (Premium Assistance)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD",
          "Ophthalmic - Inherited Retinal Disease",
          "Ophthalmic - RPE65 Mutation-Associated Retinal Dystrophy",
          "Ophthalmic - Myopic Choroidal Neovascularization",
          "Ophthalmic - Retinopathy of Prematurity (ROP)"
        ],
        "Drugs": [
          "Avastin",
          "Lucentis",
          "Eylea",
          "Bevacizumab",
          "Luxturna",
          "Susvimo",
          "Alymsys",
          "Cimerli",
          "Vegzelma",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Pavblu",
          "Eylea HD"
        ]
      },
      {
        "ProgramID": 30833,
        "ProgramName": "PAN: Liver Cancer (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Liver",
          "Oncology - Hepatocellular Carcinoma (HCC)"
        ],
        "Drugs": [
          "Avastin",
          "Cyramza",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Stivarga",
          "Yervoy",
          "Cabometyx",
          "Tecentriq",
          "Imfinzi",
          "Mvasi",
          "Sorafenib Tosylate",
          "Bevacizumab",
          "Vitrakvi",
          "Zirabev",
          "Rozlytrek",
          "Retevmo",
          "Jemperli",
          "Keytruda & Lenvima",
          "Alymsys",
          "Vegzelma",
          "Imjudo",
          "Imfinzi & Imjudo",
          "Tecentriq Hybreza",
          "Opdivo & Yervoy",
          "Tecentriq & Avastin",
          "Bevacizumab-awwb"
        ]
      },
      {
        "ProgramID": 31055,
        "ProgramName": "PAN: Long-Chain Fatty Acid Oxidation Disorders",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Long-Chain Fatty Oxidation Disorders (LC-FAOD)"
        ],
        "Drugs": [
          "Emend Capsules",
          "Emend for Injection",
          "Syndros",
          "Sustol",
          "Mytesi",
          "Xermelo",
          "Emend for Oral Suspension",
          "Cinvanti",
          "Dojolvi",
          "Focinvez",
          "Akynzeo (Injection)"
        ]
      },
      {
        "ProgramID": 31011,
        "ProgramName": "PAN: Lysosomal Acid Lipase Deficiency",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lysosomal Storage Disorders: Lysosomal Acid Lipase Deficiency (LALD)"
        ],
        "Drugs": [
          "Kanuma"
        ]
      },
      {
        "ProgramID": 31056,
        "ProgramName": "PAN: Lysosomal Acid Lipase Deficiency (Premium Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Lysosomal Storage Disorders: Lysosomal Acid Lipase Deficiency (LALD)"
        ],
        "Drugs": [
          "Kanuma"
        ]
      },
      {
        "ProgramID": 30269,
        "ProgramName": "PAN: Macular Diseases (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Diabetic Macular Edema",
          "Ophthalmic - Diabetic Retinopathy",
          "Ophthalmic - Macular Degeneration",
          "Ophthalmic - Macular Degeneration / Wet AMD",
          "Ophthalmic - Macular Edema Following Retinal Vein Occlusion",
          "Ophthalmic - Vitreomacular Adhesion",
          "Ophthalmic - Macular Edema",
          "Ophthalmic - Myopic Choroidal Neovascularization",
          "Ophthalmic - Geographic Atrophy (GA)"
        ],
        "Drugs": [
          "Lucentis",
          "Ozurdex",
          "Iluvien",
          "Visudyne",
          "Eylea",
          "Beovu",
          "Byooviz",
          "Susvimo",
          "Vabysmo",
          "Xipere",
          "Cimerli",
          "Eylea HD",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Avastin",
          "Triesence",
          "Retisert",
          "Mvasi",
          "Bevacizumab",
          "Yutiq",
          "Zirabev",
          "Alymsys",
          "Bevacizumab-awwb",
          "Vegzelma",
          "Syfovre",
          "Izervay"
        ]
      },
      {
        "ProgramID": 30270,
        "ProgramName": "PAN: Mantle Cell Lymphoma (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Mantle Cell Lymphoma (MCL)"
        ],
        "Drugs": [
          "Imbruvica",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Treanda",
          "Velcade",
          "Paraplatin",
          "Leukeran",
          "Cytarabine",
          "Methotrexate",
          "Matulane",
          "Cyclophosphamide",
          "Alkeran",
          "Vincasar PFS",
          "Bendeka",
          "Venclexta",
          "Bendamustine",
          "Vincristine Sulfate",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Melphalan",
          "Truxima",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Tecartus",
          "Rituximab",
          "Bortezomib",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Rituximab-pvvr",
          "Jaypirca",
          "Kemoplat",
          "Rituximab-abbs",
          "Rituximab-arrx"
        ]
      },
      {
        "ProgramID": 30271,
        "ProgramName": "PAN: Melanoma (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Melanoma",
          "Oncology - Metastatic Uveal Melanoma (mUM)"
        ],
        "Drugs": [
          "Abraxane",
          "Gleevec",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Proleukin",
          "Tafinlar",
          "Temodar",
          "Yervoy",
          "Zelboraf",
          "Paraplatin",
          "Alkeran",
          "Imlygic",
          "Cotellic",
          "Tecentriq",
          "Imatinib",
          "Temozolomide",
          "Vemurafenib",
          "Melphalan",
          "Braftovi",
          "Vitrakvi",
          "Mektovi",
          "Rozlytrek",
          "Opdivo & Yervoy",
          "Kimmtrak",
          "Braftovi & Mektovi",
          "Opdualag",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Amtagvi",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30274,
        "ProgramName": "PAN: Multiple Myeloma (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Multiple Myeloma (MM)",
          "Oncology - Relapsed or Refractory Multiple Myeloma"
        ],
        "Drugs": [
          "Doxil",
          "Kyprolis",
          "Pomalyst",
          "Rayos",
          "Revlimid",
          "Thalomid",
          "Treanda",
          "Velcade",
          "BiCNU",
          "Cyclophosphamide",
          "Alkeran",
          "Darzalex",
          "Ninlaro",
          "Empliciti",
          "Bendeka",
          "Evomela",
          "Venclexta",
          "Bendamustine",
          "Etoposide Phosphate",
          "Melphalan",
          "Belrapzo",
          "Xpovio",
          "Sarclisa",
          "Darzalex Faspro",
          "Kyprolis & Darzalex",
          "Bortezomib",
          "Abecma",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Carvykti",
          "Tecvayli",
          "Talvey",
          "Elrexfio",
          "Aphexda",
          "Kemoplat"
        ]
      },
      {
        "ProgramID": 30273,
        "ProgramName": "PAN: Multiple Sclerosis (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Multiple Sclerosis (MS)"
        ],
        "Drugs": [
          "Aubagio",
          "Avonex",
          "Betaseron",
          "Copaxone",
          "Gilenya",
          "Acthar Gel",
          "Lemtrada",
          "Plegridy",
          "Rayos",
          "Rebif",
          "Rituxan",
          "Tecfidera",
          "Tysabri",
          "Mitoxantrone",
          "Glatopa",
          "Cyclophosphamide",
          "Cladribine",
          "Ocrevus",
          "Avonex Pen",
          "Rituxan Hycela",
          "Glatiramer Acetate",
          "Rebif Rebidose",
          "Mavenclad",
          "Mayzent",
          "Vumerity",
          "Zeposia",
          "Bafiertam",
          "Kesimpta",
          "Dimethyl Fumarate",
          "Ponvory",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "Purified Cortrophin Gel",
          "Tascenso ODT",
          "Fingolimod",
          "Dimethyl Fumarate DR",
          "Briumvi",
          "Teriflunomide",
          "Peginterferon Beta-1A",
          "Acthar Selfject",
          "Ocrevus Zunovo"
        ]
      },
      {
        "ProgramID": 30852,
        "ProgramName": "PAN: Myasthenia Gravis (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Myasthenia Gravis"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gengraf",
          "Hizentra",
          "Neoral",
          "Prograf",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Gamastan",
          "Flebogamma DIF",
          "HyQvia",
          "Soliris",
          "Privigen",
          "Trexall",
          "Methotrexate",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Cyclophosphamide",
          "Gammaplex",
          "Envarsus XR",
          "Mycophenolate Mofetil",
          "Cuvitru",
          "Cyclosporine",
          "Rituxan Hycela",
          "Truxima",
          "Ultomiris",
          "Tacrolimus",
          "Ruxience",
          "Cutaquig",
          "Riabni",
          "Vyvgart",
          "Asceniv",
          "Xembify",
          "Panzyga",
          "Mestinon",
          "Vyvgart Hytrulo",
          "Rystiggo",
          "Zilbrysq",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 31092,
        "ProgramName": "PAN: Myasthenia Gravis (Premium Assistance) (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Myasthenia Gravis"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gengraf",
          "Hizentra",
          "Neoral",
          "Prograf",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Gamastan",
          "Flebogamma DIF",
          "HyQvia",
          "Soliris",
          "Privigen",
          "Trexall",
          "Methotrexate",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Gammaked",
          "Cyclophosphamide",
          "Gammaplex",
          "Envarsus XR",
          "Mycophenolate Mofetil",
          "Cuvitru",
          "Cyclosporine",
          "Rituxan Hycela",
          "Truxima",
          "Ultomiris",
          "Tacrolimus",
          "Ruxience",
          "Cutaquig",
          "Riabni",
          "Vyvgart",
          "Asceniv",
          "Xembify",
          "Panzyga",
          "Mestinon",
          "Vyvgart Hytrulo",
          "Rystiggo",
          "Zilbrysq",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 31070,
        "ProgramName": "PAN: Myelodysplastic Syndromes (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Myelodysplastic Syndromes (MDS)",
          "Refractory Anemia (RA)"
        ],
        "Drugs": [
          "Nplate",
          "Promacta",
          "Revlimid",
          "Vidaza",
          "Deferoxamine Mesylate",
          "Desferal",
          "Venclexta",
          "Azacitidine",
          "Reblozyl",
          "Inqovi",
          "Onureg",
          "Lenalidomide",
          "Venclexta Starting Pack",
          "Rytelo"
        ]
      },
      {
        "ProgramID": 31052,
        "ProgramName": "PAN: Neurofibromatosis",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Neurofibromatosis"
        ],
        "Drugs": [
          "Beleodaq",
          "Egrifta SV",
          "Forteo",
          "Fycompa",
          "Genotropin",
          "Humatrope",
          "Omnitrope",
          "Onfi",
          "Prolia",
          "Sabril",
          "Serostim",
          "Somavert",
          "Sprix",
          "Xgeva",
          "Juxtapid",
          "Repatha",
          "Zomacton",
          "Reclast",
          "Istodax",
          "Praluent",
          "Zoledronic Acid",
          "Zolinza",
          "Miacalcin",
          "Genotropin Miniquick",
          "Nutropin AQ Nuspin",
          "Briviact",
          "Tymlos",
          "Banzel",
          "Vigabatrin",
          "Epidiolex",
          "Zulresso",
          "Evenity",
          "Vigadrone",
          "Spravato",
          "Xcopri",
          "Demser",
          "Fintepla",
          "Norditropin Flexpro",
          "Sogroya",
          "Evkeeza",
          "Skytrofa",
          "Teriparatide",
          "Leqvio",
          "Relafen Ds",
          "Romidepsin",
          "Aptiom",
          "Felbatol",
          "Diacomit",
          "Zonisade",
          "Koselugo",
          "Repatha SureClick",
          "Motpoly XR",
          "Ngenla",
          "Zurzuvae",
          "Coxanto",
          "Vigafyde"
        ]
      },
      {
        "ProgramID": 31093,
        "ProgramName": "PAN: Neurofibromatosis: (Premium Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Neurofibromatosis"
        ],
        "Drugs": [
          "Beleodaq",
          "Egrifta SV",
          "Forteo",
          "Fycompa",
          "Genotropin",
          "Humatrope",
          "Omnitrope",
          "Onfi",
          "Prolia",
          "Sabril",
          "Serostim",
          "Somavert",
          "Sprix",
          "Xgeva",
          "Juxtapid",
          "Repatha",
          "Zomacton",
          "Reclast",
          "Istodax",
          "Praluent",
          "Zoledronic Acid",
          "Zolinza",
          "Miacalcin",
          "Genotropin Miniquick",
          "Nutropin AQ Nuspin",
          "Briviact",
          "Tymlos",
          "Banzel",
          "Vigabatrin",
          "Epidiolex",
          "Zulresso",
          "Evenity",
          "Vigadrone",
          "Spravato",
          "Xcopri",
          "Demser",
          "Fintepla",
          "Norditropin Flexpro",
          "Sogroya",
          "Evkeeza",
          "Skytrofa",
          "Teriparatide",
          "Leqvio",
          "Relafen Ds",
          "Romidepsin",
          "Aptiom",
          "Felbatol",
          "Diacomit",
          "Zonisade",
          "Koselugo",
          "Repatha SureClick",
          "Motpoly XR",
          "Ngenla",
          "Zurzuvae",
          "Coxanto",
          "Vigafyde"
        ]
      },
      {
        "ProgramID": 30952,
        "ProgramName": "PAN: Neuromyelitis Optica Spectrum Disorder",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
        ],
        "Drugs": [
          "Actemra",
          "CellCept",
          "Gengraf",
          "Myfortic",
          "Neoral",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Soliris",
          "Mitoxantrone",
          "Trexall",
          "Methotrexate",
          "Cyclophosphamide",
          "Mycophenolate Mofetil",
          "Cyclosporine",
          "Truxima",
          "Uplizna",
          "Ruxience",
          "Enspryng",
          "Riabni",
          "Actemra Actpen",
          "Vevye",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30779,
        "ProgramName": "PAN: Neurotrophic Keratitis (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Ophthalmic - Neurotrophic Keratitis"
        ],
        "Drugs": [
          "Ozurdex",
          "Xeomin",
          "Iluvien",
          "Dysport",
          "Retisert",
          "Tobramycin",
          "Oxervate",
          "Yutiq"
        ]
      },
      {
        "ProgramID": 30276,
        "ProgramName": "PAN: Neutropenia (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Neutropenia"
        ],
        "Drugs": [
          "Neulasta",
          "Neupogen",
          "Granix",
          "Zarxio",
          "Leukine",
          "Fulphila",
          "Nivestym",
          "Udenyca",
          "Ziextenzo",
          "Nyvepria",
          "Neulasta Onpro",
          "Releuko",
          "Rolvedon",
          "Stimufend",
          "Fylnetra",
          "Udenyca Autoinjector",
          "Udenyca Onbody",
          "Nypozi"
        ]
      },
      {
        "ProgramID": 30277,
        "ProgramName": "PAN: Non-Hodgkin's Lymphoma (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Kaposi Sarcoma",
          "Oncology - Castleman Disease",
          "Oncology - Chronic Lymphocytic Leukemia (CLL)",
          "Oncology - Mantle Cell Lymphoma (MCL)",
          "Oncology - Non-Hodgkin’s Lymphoma",
          "Oncology - Small Lymphocytic Lymphoma (SLL)",
          "Oncology - Anaplastic Large Cell Lymphoma (ALCL)",
          "Oncology - T-Cell Lymphoma",
          "Oncology - Mycosis Fungoides",
          "Oncology - B-Cell Lymphoma",
          "Oncology - Marginal Zone Lymphoma",
          "Oncology - Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
          "Oncology - Hairy Cell Leukemia",
          "Oncology - Large Granular Lymphocyte Leukemia (LGLL)",
          "Oncology - Lymphomatoid Papulosis (LyP)",
          "Oncology - Follicular Lymphoma",
          "Post-Transplant Lymphoproliferative Disease (PTLD)",
          "Oncology - Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
          "Oncology - Extranodal NK/T-Cell Lymphoma",
          "Oncology - T-Cell Prolymphocytic Leukemia (T-PLL)",
          "Oncology - Diffuse Large B-cell  Lymphoma (DLBCL)"
        ],
        "Drugs": [
          "Doxil",
          "Cyclophosphamide",
          "Rayos",
          "Revlimid",
          "Rituxan",
          "Thalomid",
          "Velcade",
          "Alkeran",
          "Etoposide Phosphate",
          "Truxima",
          "Ruxience",
          "Riabni",
          "Rituximab",
          "Bortezomib",
          "Lenalidomide",
          "Rituximab-pvvr",
          "Rituximab-abbs",
          "Rituximab-arrx",
          "Adcetris",
          "Campath",
          "Folotyn",
          "Gazyva",
          "Imbruvica",
          "Keytruda",
          "Opdivo",
          "Targretin",
          "Temodar",
          "Treanda",
          "Trisenox",
          "Valchlor",
          "Zydelig",
          "Leukeran",
          "Cytarabine",
          "Mitoxantrone",
          "Trexall",
          "Nipent",
          "Methotrexate",
          "Matulane",
          "Zolinza",
          "Vincasar PFS",
          "Bendeka",
          "Oncaspar",
          "Venclexta",
          "Bendamustine",
          "Vincristine Sulfate",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Copiktra",
          "Belrapzo",
          "Brukinsa",
          "Bexarotene",
          "Breyanzi",
          "Venclexta Starting Pack",
          "Imbruvica & Gazyva",
          "Paraplatin",
          "BiCNU",
          "Gemcitabine",
          "Tecartus",
          "Kemoplat",
          "Beleodaq",
          "Gengraf",
          "Neoral",
          "Pegasys",
          "Retrovir",
          "Sandimmune",
          "Xalkori",
          "Zevalin",
          "Actimmune",
          "Istodax",
          "Zidovudine",
          "Vinorelbine Tartrate",
          "Alferon N",
          "Cyclosporine",
          "Temozolomide",
          "Kymriah",
          "Yescarta",
          "Poteligeo",
          "Polivy",
          "Xpovio",
          "Monjuvi",
          "Tazverik",
          "Rylaze",
          "Romidepsin",
          "Lunsumio",
          "Epkinly",
          "Zynlonta"
        ]
      },
      {
        "ProgramID": 30275,
        "ProgramName": "PAN: Non-Small Cell Lung Cancer (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Non-Small Cell Lung Cancer (NSCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Avastin",
          "Cometriq",
          "Cyramza",
          "Erbitux",
          "Gilotrif",
          "Herceptin",
          "Kadcyla",
          "Keytruda",
          "Mekinist",
          "Opdivo",
          "Tafinlar",
          "Tarceva",
          "Xalkori",
          "Yervoy",
          "Zelboraf",
          "Zykadia",
          "Iressa",
          "Paraplatin",
          "Vinblastine Sulfate",
          "Photofrin",
          "Docetaxel",
          "Tagrisso",
          "Alecensa",
          "Portrazza",
          "Cabometyx",
          "Tecentriq",
          "Vinorelbine Tartrate",
          "Gemcitabine",
          "Etoposide Phosphate",
          "Alunbrig",
          "Imfinzi",
          "Mvasi",
          "Pemetrexed",
          "Erlotinib Hydrochloride",
          "Pemfexy",
          "Bevacizumab",
          "Braftovi",
          "Vizimpro",
          "Libtayo",
          "Lorbrena",
          "Vitrakvi",
          "Mektovi",
          "Zirabev",
          "Rozlytrek",
          "Enhertu",
          "Tabrecta",
          "Retevmo",
          "Opdivo & Yervoy",
          "Gavreto",
          "Rybrevant",
          "Lumakras",
          "Braftovi & Mektovi",
          "Tepmetko",
          "Alymsys",
          "Bevacizumab-awwb",
          "Paclitaxel Protein-Bound",
          "Tafinlar & Mekinist",
          "Fam-Trastuzumab Deruxtecan-nxki",
          "Vegzelma",
          "Imjudo",
          "Krazati",
          "Imfinzi & Imjudo",
          "Gefitinib",
          "Kemoplat",
          "Augtyro",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr",
          "Docivyx",
          "Lazcluze",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30278,
        "ProgramName": "PAN: Ovarian Cancer (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Ovarian"
        ],
        "Drugs": [
          "Abraxane",
          "Alimta",
          "Arimidex",
          "Avastin",
          "Camptosar",
          "Doxil",
          "Eligard",
          "Faslodex",
          "Femara",
          "Hycamtin Injection",
          "Keytruda",
          "Lupron Depot",
          "Lupron Depot - PED",
          "Lynparza",
          "Mekinist",
          "Nexavar",
          "Votrient",
          "Xeloda",
          "Letrozole",
          "Paraplatin",
          "Capecitabine",
          "Vinblastine Sulfate",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Cyclophosphamide",
          "Alkeran",
          "Vincasar PFS",
          "Leuprolide Acetate",
          "Dactinomycin",
          "Bleomycin",
          "Vincristine Sulfate",
          "Vinorelbine Tartrate",
          "Topotecan",
          "Rubraca",
          "Gemcitabine",
          "Zejula",
          "Etoposide Phosphate",
          "Mvasi",
          "Pemetrexed",
          "Sorafenib Tosylate",
          "Bevacizumab",
          "Melphalan",
          "Tepadina",
          "Thiotepa",
          "Vitrakvi",
          "Mektovi",
          "Zirabev",
          "Rozlytrek",
          "Jemperli",
          "Fulvestrant",
          "Alymsys",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Elahere",
          "Pazopanib",
          "Kemoplat",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30822,
        "ProgramName": "PAN: Pancreatic Cancer (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Oncology - Pancreatic"
        ],
        "Drugs": [
          "Abraxane",
          "Afinitor",
          "Camptosar",
          "Creon",
          "Doxil",
          "Keytruda",
          "Lynparza",
          "Sandostatin LAR Depot",
          "Somatuline Depot",
          "Sutent",
          "Tarceva",
          "Temodar",
          "Xeloda",
          "Mitomycin",
          "Capecitabine",
          "Onivyde",
          "Fluorouracil",
          "Docetaxel",
          "Irinotecan",
          "Everolimus",
          "Afinitor Disperz",
          "Octreotide Acetate",
          "Gemcitabine",
          "Temozolomide",
          "Sandostatin",
          "Erlotinib Hydrochloride",
          "Lutathera",
          "Khapzory",
          "Vitrakvi",
          "Rozlytrek",
          "Lanreotide Acetate",
          "Levoleucovorin",
          "Sunitinib Malate",
          "Paclitaxel Protein-Bound",
          "Kemoplat",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30279,
        "ProgramName": "PAN: Parkinson's Disease (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Neurology - Parkinson's Disease"
        ],
        "Drugs": [
          "Apokyn",
          "Myobloc",
          "Northera",
          "Xeomin",
          "Zelapar",
          "Sildenafil",
          "Duopa",
          "Nuplazid",
          "Tasmar",
          "Gocovri",
          "Tolcapone",
          "Tadalafil",
          "Inbrija",
          "Tacrolimus",
          "Nourianz",
          "Droxidopa",
          "Fleqsuvy",
          "Ozobax DS",
          "Mestinon",
          "Apomorphine",
          "Liqrev",
          "Crexont"
        ]
      },
      {
        "ProgramID": 31094,
        "ProgramName": "PAN: Paroxysmal Nocturnal Hemoglobinuria (Premium Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
        ],
        "Drugs": [
          "Soliris",
          "Ultomiris",
          "Empaveli",
          "Fabhalta",
          "Voydeya",
          "PiaSky"
        ]
      },
      {
        "ProgramID": 30953,
        "ProgramName": "PAN: Paroxysmal Nocturnal Hemoglobinuria",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
        ],
        "Drugs": [
          "Soliris",
          "Ultomiris",
          "Empaveli",
          "Fabhalta",
          "Voydeya",
          "PiaSky"
        ]
      },
      {
        "ProgramID": 31001,
        "ProgramName": "PAN: Pemphigus Vulgaris (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Dermatology - Pemphigus Vulgaris"
        ],
        "Drugs": [
          "CellCept",
          "Gengraf",
          "Hizentra",
          "Neoral",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Flebogamma DIF",
          "Privigen",
          "Trexall",
          "Methotrexate",
          "Gammagard S/D",
          "Octagam",
          "Bivigam",
          "Cyclophosphamide",
          "Gammaplex",
          "Mycophenolate Mofetil",
          "Cyclosporine",
          "Truxima",
          "Ruxience",
          "Riabni",
          "Asceniv",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Rituximab",
          "Panzyga",
          "Rituximab-pvvr",
          "Rituximab-abbs",
          "Rituximab-arrx",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30664,
        "ProgramName": "PAN: Philadelphia Chromosome Negative Myeloproliferative Neoplasms",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Myeloproliferative Neoplasms",
          "Oncology - Chronic Myeloid Leukemia (CML)",
          "Oncology - Myelofibrosis",
          "Oncology - Chronic Eosinophilic Leukemia (CEL)",
          "Polycythemia Vera",
          "Thrombocythemia",
          "Oncology - Chronic Neutrophilic Leukemia (CNL)"
        ],
        "Drugs": [
          "Gleevec",
          "Iclusig",
          "Jakafi",
          "Pegasys",
          "Revlimid",
          "Alkeran",
          "Busulfex",
          "Cladribine",
          "Myleran",
          "Imatinib",
          "Melphalan",
          "Inrebic",
          "Reblozyl",
          "Inqovi",
          "Besremi",
          "Siklos",
          "Lenalidomide",
          "Vonjo",
          "Ojjaara"
        ]
      },
      {
        "ProgramID": 30169,
        "ProgramName": "PAN: Plaque Psoriasis (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Dermatology - Psoriasis / Plaque Psoriasis",
          "Dermatology - Pediatric Psoriasis / Plaque Psoriasis"
        ],
        "Drugs": [
          "Astagraf XL",
          "CellCept",
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Gengraf",
          "Humira",
          "Myfortic",
          "Neoral",
          "Otezla",
          "Otrexup",
          "Prograf",
          "Rasuvo",
          "Remicade",
          "Sandimmune",
          "Stelara",
          "Xeljanz",
          "Trexall",
          "Methotrexate",
          "Enstilar",
          "Adalimumab-afzb",
          "Envarsus XR",
          "Taltz",
          "Inflectra",
          "Mycophenolate Mofetil",
          "Siliq",
          "Cyclosporine",
          "Renflexis",
          "Tremfya",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Ilumya",
          "Hyrimoz",
          "Skyrizi",
          "Tacrolimus",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Fluovix Plus",
          "Amjevita",
          "Siklos",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Vtama",
          "Hadlima",
          "Etanercept",
          "Infliximab-abda",
          "Sotyktu",
          "Zoryve",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Bimzelx",
          "Zymfentra",
          "Calsodore",
          "Calsodore Kit",
          "Simlandi",
          "Adalimumab-ryvk",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30890,
        "ProgramName": "PAN: Pompe Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pompe Disease"
        ],
        "Drugs": [
          "Lumizyme",
          "Nexviazyme",
          "Opfolda",
          "Pombiliti"
        ]
      },
      {
        "ProgramID": 31058,
        "ProgramName": "PAN: Pompe Disease (Premium Assistance)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pompe Disease"
        ],
        "Drugs": [
          "Lumizyme",
          "Nexviazyme",
          "Opfolda & Pombiliti",
          "Opfolda",
          "Pombiliti"
        ]
      },
      {
        "ProgramID": 30281,
        "ProgramName": "PAN: Postmenopausal Osteoporosis (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Osteoporosis"
        ],
        "Drugs": [
          "Forteo",
          "Prolia",
          "Reclast",
          "Zoledronic Acid",
          "Miacalcin",
          "Tymlos",
          "Evenity",
          "Teriparatide"
        ]
      },
      {
        "ProgramID": 30160,
        "ProgramName": "PAN: Prostate Cancer (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Prostate",
          "Oncology - Castration-Sensitive Prostate Cancer",
          "Oncology - Non-Metastatic Castration-Resistant Prostate Cancer",
          "Oncology - Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
          "Oncology - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
          "Oncology - Castration-Resistant Prostate Cancer"
        ],
        "Drugs": [
          "Casodex",
          "Eligard",
          "Firmagon",
          "Jevtana",
          "Keytruda",
          "Lupron Depot",
          "Lynparza",
          "Nilandron",
          "Provenge",
          "Rayos",
          "Supprelin LA",
          "Trelstar",
          "Xofigo",
          "Xtandi",
          "Zoladex",
          "Zytiga",
          "Paraplatin",
          "Mitoxantrone",
          "Docetaxel",
          "Leuprolide Acetate",
          "Rubraca",
          "Etoposide Phosphate",
          "Triptodur",
          "Erleada",
          "Nilutamide",
          "Yonsa",
          "Talzenna",
          "Abiraterone Acetate",
          "Nubeqa",
          "Orgovyx",
          "Camcevi",
          "Pluvicto",
          "Akeega",
          "Kemoplat",
          "Docivyx"
        ]
      },
      {
        "ProgramID": 30250,
        "ProgramName": "PAN: Psoriatic Arthritis (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Psoriatic Arthritis"
        ],
        "Drugs": [
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Gengraf",
          "Acthar Gel",
          "Humira",
          "Neoral",
          "Orencia",
          "Otezla",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Remicade",
          "Sandimmune",
          "Simponi",
          "Simponi ARIA",
          "Stelara",
          "Xeljanz",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Taltz",
          "Inflectra",
          "Siliq",
          "Cyclosporine",
          "Renflexis",
          "Tremfya",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Hyrimoz",
          "Skyrizi",
          "Rinvoq",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Xeljanz XR",
          "Cosentyx Pen",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Amjevita",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Etanercept",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Orencia Clickject",
          "Purified Cortrophin Gel",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Bimzelx",
          "Zymfentra",
          "Coxanto",
          "Simlandi",
          "Adalimumab-ryvk",
          "Rinvoq LQ",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30649,
        "ProgramName": "PAN: Pulmonary Hypertension",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Pulmonary Arterial Hypertension (PAH)"
        ],
        "Drugs": [
          "Adcirca",
          "Adempas",
          "Letairis",
          "Opsumit",
          "Orenitram",
          "Remodulin",
          "Revatio",
          "Tracleer",
          "Tyvaso",
          "Veletri",
          "Ventavis",
          "Flolan",
          "Sildenafil",
          "Uptravi",
          "Epoprostenol Sodium",
          "Tadalafil",
          "Ambrisentan",
          "Treprostinil",
          "Bosentan",
          "Treprostinil Diolamine",
          "Tyvaso DPI",
          "Liqrev",
          "Opsynvi",
          "Winrevair"
        ]
      },
      {
        "ProgramID": 30282,
        "ProgramName": "PAN: Renal Cell Carcinoma (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Renal Cell Carcinoma (Kidney Cancer) (RCC)"
        ],
        "Drugs": [
          "Afinitor",
          "Avastin",
          "Inlyta",
          "Keytruda",
          "Lenvima",
          "Nexavar",
          "Opdivo",
          "Pegasys",
          "Proleukin",
          "Sutent",
          "Tarceva",
          "Torisel",
          "Votrient",
          "Yervoy",
          "Paraplatin",
          "Cabometyx",
          "Everolimus",
          "Afinitor Disperz",
          "Bavencio",
          "Gemcitabine",
          "Mvasi",
          "Sorafenib Tosylate",
          "Temsirolimus",
          "Erlotinib Hydrochloride",
          "Bevacizumab",
          "Zirabev",
          "Welireg",
          "Fotivda",
          "Alymsys",
          "Sunitinib Malate",
          "Paclitaxel Protein-Bound",
          "Vegzelma",
          "Pazopanib",
          "Kemoplat"
        ]
      },
      {
        "ProgramID": 30284,
        "ProgramName": "PAN: Retinal Vein Occlusion (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Retinal Vein Occlusion"
        ],
        "Drugs": [
          "Avastin",
          "Lucentis",
          "Ozurdex",
          "Triesence",
          "Iluvien",
          "Retisert",
          "Eylea",
          "Mvasi",
          "Bevacizumab",
          "Yutiq",
          "Zirabev",
          "Byooviz",
          "Susvimo",
          "Vabysmo",
          "Alymsys",
          "Bevacizumab-awwb",
          "Cimerli",
          "Vegzelma",
          "Bevacizumab-maly",
          "Bevacizumab-adcd",
          "Bevacizumab-bvzr"
        ]
      },
      {
        "ProgramID": 31033,
        "ProgramName": "PAN: Rett Syndrome",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Rett Syndrome"
        ],
        "Drugs": [
          "Relafen Ds",
          "Daybue"
        ]
      },
      {
        "ProgramID": 30251,
        "ProgramName": "PAN: Rheumatoid Arthritis (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Osteoarthritis",
          "Rheumatoid Arthritis (RA)"
        ],
        "Drugs": [
          "Acthar Gel",
          "Rayos",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Relafen Ds",
          "Amjevita",
          "Coxanto",
          "Acthar Selfject",
          "Actemra",
          "Cimzia",
          "Cosentyx",
          "Enbrel",
          "Gengraf",
          "Humira",
          "Kineret",
          "Neoral",
          "Orencia",
          "Otrexup",
          "Rasuvo",
          "Remicade",
          "Rituxan",
          "Sandimmune",
          "Simponi",
          "Simponi ARIA",
          "Xeljanz",
          "Trexall",
          "Methotrexate",
          "Adalimumab-afzb",
          "Inflectra",
          "Cyclosporine",
          "Renflexis",
          "Kevzara",
          "Cyltezo",
          "Infliximab",
          "Infliximab-dyyb",
          "Olumiant",
          "Hyrimoz",
          "Truxima",
          "Rinvoq",
          "Avsola",
          "Ruxience",
          "Hulio",
          "Riabni",
          "Abrilada",
          "Xeljanz XR",
          "Enbrel Mini",
          "Enbrel Sureclick",
          "Humira Pen",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Actemra Actpen",
          "Hadlima",
          "Infliximab-abda",
          "Infliximab-qbtx",
          "Orencia Clickject",
          "Infliximab-axxq",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Vevye",
          "Adalimumab-fkjp",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Zymfentra",
          "Simlandi",
          "Adalimumab-ryvk",
          "Rinvoq LQ"
        ]
      },
      {
        "ProgramID": 30847,
        "ProgramName": "PAN: Schizophrenia (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Behavioral Health - Schizophrenia"
        ],
        "Drugs": [
          "Invega Sustenna",
          "Risperdal Consta",
          "Rexulti",
          "Aristada",
          "Vraylar",
          "Abilify Maintena",
          "Invega Trinza",
          "Perseris",
          "Secuado",
          "Aristada Initio",
          "Zyprexa Relprevv",
          "Zyprexa Zydis",
          "Caplyta",
          "Lybalvi",
          "Invega Hafyera",
          "Rykindo",
          "Uzedy",
          "Abilify Asimtufii",
          "Risperidone ER Injectable Suspension",
          "Erzofri",
          "Cobenfy"
        ]
      },
      {
        "ProgramID": 30288,
        "ProgramName": "PAN: Short Bowel Syndrome (Premium Assistance)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Short Bowel Syndrome"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Gattex",
          "Octreotide Acetate",
          "Sandostatin",
          "Mycapssa"
        ]
      },
      {
        "ProgramID": 30287,
        "ProgramName": "PAN: Short Bowel Syndrome",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Short Bowel Syndrome"
        ],
        "Drugs": [
          "Sandostatin LAR Depot",
          "Gattex",
          "Octreotide Acetate",
          "Sandostatin",
          "Mycapssa"
        ]
      },
      {
        "ProgramID": 30807,
        "ProgramName": "PAN: Sickle Cell Disease (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Sickle Cell Disease (SCD)"
        ],
        "Drugs": [
          "Adakveo",
          "Endari",
          "Relafen Ds",
          "Siklos",
          "Casgevy",
          "Lyfgenia",
          "Coxanto",
          "L-Glutamine"
        ]
      },
      {
        "ProgramID": 30828,
        "ProgramName": "PAN: Small Cell Lung Cancer (Medicare)",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Small Cell Lung Cancer (SCLC)"
        ],
        "Drugs": [
          "Abraxane",
          "Camptosar",
          "Doxil",
          "Hycamtin",
          "Hycamtin Injection",
          "Keytruda",
          "Opdivo",
          "Temodar",
          "Treanda",
          "Paraplatin",
          "Onivyde",
          "Docetaxel",
          "Irinotecan",
          "Cyclophosphamide",
          "Vincasar PFS",
          "Bendeka",
          "Tecentriq",
          "Bendamustine",
          "Vincristine Sulfate",
          "Vinorelbine Tartrate",
          "Topotecan",
          "Gemcitabine",
          "Temozolomide",
          "Etoposide Phosphate",
          "Imfinzi",
          "Belrapzo",
          "Zepzelca",
          "Paclitaxel Protein-Bound",
          "Kemoplat",
          "Docivyx",
          "Imdelltra",
          "Tecentriq Hybreza"
        ]
      },
      {
        "ProgramID": 30825,
        "ProgramName": "PAN: Spinal Muscular Atrophy",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Spinal Muscular Atrophy (SMA)"
        ],
        "Drugs": [
          "Rayos",
          "Spinraza",
          "Emflaza",
          "Zolgensma",
          "Evrysdi",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 31037,
        "ProgramName": "PAN: Systemic Lupus Erythematosus",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Systemic Lupus Erythematosus",
          "Pediatric Systemic Lupus Erythematosus"
        ],
        "Drugs": [
          "Benlysta",
          "CellCept",
          "Gammagard Liquid",
          "Gamunex-C",
          "Gengraf",
          "Neoral",
          "Otrexup",
          "Rasuvo",
          "Rayos",
          "Rituxan",
          "Sandimmune",
          "Flebogamma DIF",
          "Trexall",
          "Methotrexate",
          "Gammagard S/D",
          "Bivigam",
          "Gammaked",
          "Cyclophosphamide",
          "Mycophenolate Mofetil",
          "Cuvitru",
          "Cyclosporine",
          "Truxima",
          "Ruxience",
          "Riabni",
          "Lupkynis",
          "Saphnelo",
          "Vevye",
          "Myhibbin"
        ]
      },
      {
        "ProgramID": 30292,
        "ProgramName": "PAN: Uveitis",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Ophthalmic - Uveitis"
        ],
        "Drugs": [
          "Astagraf XL",
          "Campath",
          "CellCept",
          "Gengraf",
          "Acthar Gel",
          "Humira",
          "Kineret",
          "Lemtrada",
          "Neoral",
          "Otrexup",
          "Ozurdex",
          "Pegasys",
          "Prograf",
          "Rasuvo",
          "Rayos",
          "Remicade",
          "Sandimmune",
          "Triesence",
          "Leukeran",
          "Iluvien",
          "Trexall",
          "Methotrexate",
          "Retisert",
          "Adalimumab-afzb",
          "Cyclophosphamide",
          "Envarsus XR",
          "Inflectra",
          "Mycophenolate Mofetil",
          "Alferon N",
          "Sirolimus",
          "Cyclosporine",
          "Renflexis",
          "Cyltezo",
          "Infliximab",
          "Yutiq",
          "Hyrimoz",
          "Tacrolimus",
          "Avsola",
          "Hulio",
          "Abrilada",
          "Betamethasone Sodium Phosphate & Betamethasone Acetate",
          "Humira Pen",
          "Amjevita",
          "Xipere",
          "Adalimumab-adbm",
          "Adalimumab-atto",
          "Hadlima",
          "Purified Cortrophin Gel",
          "Idacio",
          "Yusimry",
          "Yuflyma",
          "Adalimumab-fkjp",
          "Xdemvy",
          "Adalimumab-bwwd",
          "Adalimumab-adaz",
          "Adalimumab-aacf",
          "Adalimumab-aaty",
          "Adalimumab-aqvh",
          "Adalimumab",
          "Zymfentra",
          "Simlandi",
          "Adalimumab-ryvk",
          "Myhibbin",
          "Acthar Selfject"
        ]
      },
      {
        "ProgramID": 30955,
        "ProgramName": "PAN: Venous Leg Ulcers (Medicare)",
        "FoundationFundLevels": [
          "Empty"
        ],
        "TherapAreas": [
          "Venous Leg Ulcers"
        ],
        "Drugs": [
          "Epifix",
          "Biovance",
          "Stravix"
        ]
      },
      {
        "ProgramID": 30956,
        "ProgramName": "PAN: Von Willebrand Disease",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Von Willebrand Disease"
        ],
        "Drugs": [
          "Alphanate",
          "Humate P",
          "Koate-DVI",
          "Wilate",
          "Vonvendi",
          "Andexxa"
        ]
      },
      {
        "ProgramID": 30747,
        "ProgramName": "PAN: Waldenstrom Macroglobulinemia",
        "FoundationFundLevels": [
          "Normal"
        ],
        "TherapAreas": [
          "Oncology - Waldenstrom’s Macroglobulinemia"
        ],
        "Drugs": [
          "Afinitor",
          "Imbruvica",
          "Kyprolis",
          "Rayos",
          "Rituxan",
          "Thalomid",
          "Treanda",
          "Velcade",
          "Leukeran",
          "Cyclophosphamide",
          "Ninlaro",
          "Vincasar PFS",
          "Bendeka",
          "Venclexta",
          "Cladribine",
          "Everolimus",
          "Bendamustine",
          "Vincristine Sulfate",
          "Afinitor Disperz",
          "Rituxan Hycela",
          "Calquence",
          "Fludarabine Phosphate",
          "Truxima",
          "Mavenclad",
          "Belrapzo",
          "Brukinsa",
          "Ruxience",
          "Riabni",
          "Bortezomib",
          "Venclexta Starting Pack"
        ]
      }
    ]
  }